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 Acute infection is one of the most common problems of children 
attending primary care and represents an important proportion of a 
general practitioner’s workload.[3] Febrile illness accounts for 20% of all 
visits to the paediatric emergency department.[4] 
 
In contrast, serious infections are rare in children in developed countries, 
but associated with considerable morbidity and mortality.[5] In a primary 
care setting, less than 1% of children will have a serious infection.[1, 6]  
The incidence of serious infections in children is assumed to be 5 to 10 
times higher at the paediatric emergency department, as seen in one of 
our recent studies.[6] In Flanders, infectious diseases are responsible for 
13.8% of all deaths in children under the age of one year, and for 4.6% 
of deaths in children aged 1 to 14 years,[7] comparable to death rates 
previously reported in the UK.[8]  
 
Serious infections in children are usually defined as sepsis (including 
bacteraemia), meningitis, pneumonia, complicated urinary tract infection, 
bacterial gastroenteritis with dehydration, osteomyelitis, and cellulitis.[5] 
Their consequences can be severe; the mortality of meningococcal 
disease can be as high as 14%,[9-12] and approximately 7% of children 
who survive bacterial meningitis suffer from hearing loss.[13]  
 
These serious infections need to be distinguished from the vast majority 
of non-serious infections in children, which can be challenging especially 
in primary care. Those few children with a serious infection can present 
at an early stage when the severity of the infection is not yet apparent.[5] 
At that point, their symptoms tend to mimic those of children with a non-
serious viral infection. This could cause a diagnosis to be missed at first 
contact, sometimes with serious consequences, due to the rapid 
deterioration of the illness.  
 
Clinical prediction rules and guidelines may assist in the early 
recognition of serious infections, especially in low prevalence settings 
where a high sensitivity is essential to effectively rule out serious 
infection.[5] Clinical prediction rules can be constructed to achieve 
maximum sensitivity (in contrast to red flags that can rule in serious 
infection). There is a widely accepted methodology for the development 
of clinical prediction rules.[14-16]  
The derivation of a clinical prediction rule is the first of three steps 
required before it can be disseminated and used in practice. This is 
followed by internal and external validation before finally testing the 
impact of its use on clinical outcomes.[2] (Figure I)  
These steps require cumulative levels of evidence and the adoption of 
several types of study designs to answer the relevant research and 
clinical questions. 
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The increasing number of clinical prediction rules reported in the 
literature have a tendency to focus on the derivation stage with only a 
minority progressing to validation and very few undergoing impact 
analysis.[17, 18] 
This framework should be considered as a cyclical rather than linear 
process, allowing you to retrace your steps and add new predictors to 
the model to increase diagnostic performance (e.g. adding C-reactive 
protein test results if external validation (Chapter 1 & 3) demonstrates 
low positive predictive value). (Figure I, Step B; Chapter 5) 
 
Over the last decade our research team has studied the value of clinical 
signs for the diagnosis of serious infections in acutely ill children in 
primary care,[1, 19] resulting in a systematic review of clinical features to 
identify serious infection in children in developed countries.[5] (Figure I, 
Step A) 
Our research group conducted the largest study on the diagnosis of 
serious infections in children in primary care so far, in which over 4000 
children were included prospectively to construct a decision tree based 
on signs and symptoms.[1] (Figure I, Step B) The decision tree had a 
sensitivity of nearly 100%. The probability, however, of having a serious 
infection in children testing positive, was approximately 6%. (Figure II) 
Figure I: Framework for study designs from theory to implementation of clinical 
prediction rules[2] 
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 This decision tree was identified by a systematic review as the only one 
developed in primary care, demonstrating best performance at ruling out 
for the composite outcome of serious infections.[5] It is easy to interpret 
as compared to other multivariable models, such as logistic regression-
based models, making it more practical in a clinical setting.[1] 
In this thesis, I aim to validate this decision tree in a new population 
(Figure I, Step C & D) and explore the added value of technological 
tests, such as point-of-care (POC) tests in diagnosing serious infection 
in acutely ill children in primary care. (Figure I, Step B & D) 
 
POC tests are defined as laboratory and other services provided to 
patients at the bedside. The physician has an immediate result and 
management can be adjusted accordingly. This makes them especially 
attractive in situations where a fast decision is warranted, such as 
urgent-access primary care. They are minimally invasive, and thus 
relevant in paediatric care. 
 
Members of our research team performed a systematic review of the 
literature in all relevant databases to identify the laboratory tests used to 
detect serious infections in febrile children in ambulatory care 
settings.[20]  
 
The most probable candidates for this purpose are C-reactive protein 
(CRP) and procalcitonin (PCT). CRP has been shown to decrease 
antibiotic prescriptions and predict bacterial aetiology of community-
acquired pneumonia.[21, 22] PCT has been shown to correlate with 
severity of urinary tract infections and sepsis and of community acquired 
pneumonia in children.[23, 24]  
Despite these promising results, evidence is not yet conclusive because 
most studies were performed in secondary care settings and other tests 
may be valuable as well. In addition, their use was limited because they 
required a normal blood sample to be sent off to the laboratory and 
results would become available too late to influence clinical 
management. 
At present, there is only one POC test for procalcitonin, which takes 30 
minutes to produce a result and requires blood centrifugation, making it 
unsuitable for use in acute ambulatory care, especially in general 
practice where consultations last between 10-15 minutes. On the other 
hand, a fast and accurate POC test for CRP is available that produces a 
result within 4 minutes. 
 
If the decision tree proves to be useful after external validation (retro- 
and prospectively), a point-of-care CRP test might be able to increase 
the diagnostic accuracy by reducing the number of children testing false 
positive on this decision tree. 
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The research question of this thesis can be formulated as follows: 
“In addition to measuring clinical signs and symptoms, can new or 
existing technology improve the early identification of seriously ill 
children in primary care?” More specifically, after applying the decision 
tree, can I further reduce the number of false positives (and thus 
increase the specificity) and maintain the same level of sensitivity? 
 
To study this research question, I aim to: 
- identify and validate the clinical features used for diagnosing serious 
infections in acutely ill children (Part 1) 
- determine the analytical and diagnostic accuracy, and the added 
value of a carefully selected point-of-care test (Part 2) 
 
In Chapter 1, I focus on the clinical prediction rules based on vital signs 
and symptoms, recently identified by a systematic review for use in 
ambulatory care populations (Figure I, Step A) and attempt to validate 
these rules in seven urgent-access datasets shared as part of an 
international network, and compare these results to recent findings in 
other studies. (Figure I, Step D) 
 
Clinical prediction rules tend to perform worse when validated in a new 
setting. I attempt to validate hospital-centred clinical prediction rules 
based on vital signs to detect serious infection in children admitted to an 
inpatient paediatric ward in Chapter 2. (Figure I, Step D) 
 
Chapter 3 describes the results of a prospective temporal & geographic 
validation of the best-performing decision tree in chapter 1 & 2 (in terms 
of ruling out value) based on signs and symptoms in a new but similar 
population in Flanders. (Figure I, Step C & D) 
 
Chapter 4 sets the scene for a large prospective trial with a feasibility 
study on the use of the point-of-care test in the intended setting, namely 
ambulatory primary care. I examine the analytical accuracy and user-
friendliness of a selected point-of-care test after careful selection of a 
device that meets all our preliminary requirements. 
 
Chapter 5 describes the results of the prospective diagnostic accuracy 
study, aiming to explore the added value of the selected point-of-care 
test in primary care, updating the clinical prediction rule with a new test. 
(Figure I, Step D)  I focus on the clinical utility of this point-of-care test in 
three different ambulatory care settings: general practice, outpatient 
paediatric clinic, and the emergency department.  
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The final discussion ties all the chapters together and discusses the 
findings of each chapter in relation to the incidence of serious infections, 
the development of clinical prediction rules, and the use of safety netting 
advice and offers a perspective for future developments in the field of 
point-of-care testing in serious infections in paediatric primary care. 
 
A PhD student from UGent, Marieke Lemiengre (Department of Family 
Practice and Primary Health Care, UGent) collaborates with this project. 
She examines the effect of the POC CRP test, a minimal intervention or 
both in comparison with usual care on antibiotic prescribing rate, the use 
of diagnostic tests and medical services, and parent’s satisfaction. 
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PART 1: CLINICAL FEATURES 
 
 
 
 
Aim 
to identify vital signs and clinical prediction rules used for diagnosing 
serious infections in acutely ill children and assess their value in 
diagnostic triage. 
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Chapter 1. 
 
 
 
 
 
 
 
 
 
 
Research question 
How well do clinical prediction rules perform in identifying serious 
infections in acutely ill children across different ambulatory care 
settings? 
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RETROSPECTIVE VALIDATION OF CLINICAL PREDICTION RULES 
FOR IDENTIFYING SERIOUS INFECTIONS IN ACUTELY ILL 
CHILDREN ACROSS AN INTERNATIONAL NETWORK OF 
AMBULATORY CARE DATASETS.  
 
ABSTRACT 
 
Background: Diagnosing serious infections in children is challenging 
because of the low incidence of such infections and their non-specific 
early presentation. Prediction rules are promoted as a means to improve 
recognition of serious infections. A recent systematic review identified 
seven clinical prediction rules, of which only one had been prospectively 
validated, calling into question their appropriateness for clinical practice. 
We aimed to examine the diagnostic accuracy of these rules in multiple 
ambulatory care populations in Europe.  
Methods: Four clinical prediction rules and two national guidelines, 
based on signs and symptoms, were validated retrospectively in seven 
individual patient datasets from primary care and emergency 
departments, comprising 11023 children from the UK, the Netherlands, 
and Belgium. The accuracy of each rule was tested, with pre-test and 
post-test probabilities displayed using dumbbell plots, with serious 
infection settings stratified as low prevalence (LP; <5%), intermediate 
prevalence (IP; 5 to 20%), and high prevalence (HP; >20%). Sensitivity 
analyses of the selected clinical prediction rules were performed to avoid 
spectrum bias. 
Results: In LP settings, the 4-step decision tree had highest sensitivity 
of 90% (95% CI 68-99%) at a specificity of 44% (95% CI 39-48%). The 
prediction rule with the second best sensitivity was the pneumonia rule, 
which had sensitivities above 92% for ruling out serious infections with 
specificities ranging from 41 to 45%. The UK NICE traffic light system 
and Dutch guideline achieved sensitivities between 81 and 100% and 
specificities between 1 and 85% in low or intermediate prevalence 
settings. 
Conclusions: None of the clinical prediction rules examined in this 
study provided adequate diagnostic accuracy. In LP or IP settings, 
prediction rules and evidence-based guidelines had high sensitivity, 
providing promising rule-out value for serious infections in these 
datasets, although all had a percentage of residual uncertainty. 
Additional clinical assessment or testing such as point-of-care laboratory 
tests may be needed to increase clinical certainty. None of the prediction 
rules identified seemed to be valuable for HP settings such as 
emergency departments.  
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BACKGROUND 
 
Acute infection is the most common presentation in children attending 
settings of ambulatory care (AC).[1, 2] Although most infections are self-
limiting, they remain an important cause of morbidity and mortality in 
children in economically developed countries.[3-5] In the UK, infections 
account for 20% of childhood deaths, especially in children under 5 
years of age.[6]  
Serious infections in children are usually defined as sepsis (including 
bacteraemia), meningitis, pneumonia, bacterial gastro-enteritis with 
dehydration, osteomyelitis, cellulitis, and complicated urinary-tract 
infection (UTI; positive urine culture combined with systemic features 
such as fever).[3] As a result of immunization against Haemophilus 
influenzae and Streptococcus pneumoniae, the incidence of these 
diseases has decreased steadily over recent decades, and they are now 
estimated to account for less than 1% of all acute childhood infections in 
primary care (PC).[2, 7]  
 
The combination of low incidence, non-specific initial clinical 
presentation, and potential for rapid deterioration makes the assessment 
of acutely ill children difficult.[8, 9] Clinical prediction rules and guidelines 
may assist in the early recognition of serious infections.[3] In a previous 
systematic review, we identified all available clinical prediction rules 
(seven in total), based on signs and symptoms, for identifying any 
serious infection (two rules), pneumonia (two), meningitis (two), and 
dehydration from bacterial gastroenteritis (one rule) in AC settings.[3] 
(Table 1.1) 
 
 
Four of these seven clinical prediction rules were derived for use in 
emergency-care settings and their applicability in PC and AC settings 
has not been confirmed. 
a) Identified clinical prediction rules by systematic review: 
1. Yale Observation Scale 
2. 4-step Decision Tree 
3. Pneumonia Rule I 
4. Pneumonia Rule II 
5. Meningitis Rule I 
6. Meningitis Rule II 
7. Gastro-enteritis Rule I 
b) Identified clinical guidelines: 
1. NICE Guideline on Feverish Ilness in Children 
2. Dutch College of General Practitioners Guideline 
c) Identified clinical prediction rules by focused literature search: 
1. Clinical Diagnostic Model for pneumonia, UTI, bacteraemia 
 
Table 1.1: Identified clinical prediction rules and guidelines 
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Only one rule, the Yale Observation Scale (YOS)[10] has been 
prospectively assessed in four studies,[11-14] of which only two 
assessed the YOS in the intended age group of 3 to 36 months.[12, 14]  
 
We also identified two national guidelines for the assessment of feverish 
children (Guideline on Feverish Illness in Children by the National 
Institute for Health and Clinical Excellence (NICE)[15] and the guidelines 
from the Dutch College of General Practitioners (NHG)).[16] The NICE 
traffic light system distinguishes between red features that require 
immediate referral to paediatric specialist care and amber features that 
can either require providing parents with a safety net or referral to 
paediatrics for further assessment.  
 
A focused literature search identified an additional clinical prediction rule 
published after this review: an emergency-department (ED) rule[17] to 
diagnose pneumonia, UTI, or bacteraemia (Table 1.2a-b).  
 
Although some of these guidelines (NICE guidelines, NHG alarm 
symptoms) are often used in clinical practice, very little external 
validation to support their use in practice has been performed in new 
and independent populations.[18] This raises questions about the 
robustness of the rules and their generalizability.  
 
The aim of this study was to examine the diagnostic accuracy both of the 
clinical prediction rules identified by the systematic review and of the 
evidence-based guidelines, using retrospective external validations on 
individual patient datasets from ambulatory paediatric settings including 
PC and ED settings from three European countries.  
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METHODS 
 
Identification of datasets  
We included datasets from studies identified in the systematic review,[3] 
which had been published within the past 10 years, and from expert 
contacts. The criteria used to select datasets (Table 1.3), were design 
(cohort studies that enrolled children consecutively), sample size (>500 
children), participants (children aged 0 to 18 years or subgroups of 
these), setting (AC defined as general or family practice, paediatric 
outpatient clinics, paediatric assessment units, or EDs in developed 
countries), outcome (serious infection), and data availability (agreement 
to share data) (Figure 1.1).  
30 studies identified 
by the systematic 
review 
11 studies 
4 datasets 
 [7, 18, 24-25] 
data sharing 
agreement could 
not be reached [17] 
Result:  
7 datasets [7, 18, 21-25] 
update June 2010: 
  4 new datasets  
[17, 21-23] 
non-consecutive 
inclusions: 
4 studies 
<500 cases: 
3 studies 
studies older than 10 
years (published 
before 2003): 
19 studies 
Figure 1.1: Flowchart of dataset inclusion 
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Ethics approval  
This research conformed to the Helsinki Declaration and to local 
legislation. The study authors, agreeing to share data, obtained ethics 
approval from their regional ethical review boards before the study for 
the initial data collection of the included datasets. 
 
Processing of included datasets  
Direct access to the raw data of each dataset was granted and key 
characteristics of each of the datasets were extracted (Table 1.4). The 
variables used in each dataset were translated to English if necessary, 
and the translation, coding, and definition of variables were clarified with 
the authors of the relevant study.  
 
We used the following criteria to determine which dataset could be used 
to validate each clinical prediction rule and guideline, and which 
diagnoses should be included in the composite outcome of serious 
infection.  
 Datasets used to derive a clinical prediction rule were not 
used to validate the same rule.  
 When variables were not entirely identical with the variables 
of the original clinical prediction rule, we identified proxies 
where possible. For example, the variable ‘dyspnoea’ of the 
4-step decision tree (4-sSDT) and the pneumonia rule was 
not recorded in three datasets; we therefore used either 
‘respiratory distress’ or ‘chest flaring’ as a proxy (Table 1.5 
and 1.6)  
 Based on the number of required variables, whenever one-
third or more (fever guidelines), one or more (pneumonia 
rule, meningitis rule) or two or more (YOS, 4-sDT) of the 
required variables were not recorded, that dataset was not 
used for validation of that specific rule. We performed 
sensitivity analyses as described below.  
 Missing data on variables used in the validation were not 
imputed because the necessary missing-at-random 
assumption was likely to be incorrect because some of the 
datasets consisted of routinely collected data from medical 
records.  
 Apart from the approximations used (Table 1.5 and 1.6), no 
alterations of the original data were performed. We report the 
number of observations available for analysis of each 
prediction rule after applying these assumptions.  
 In contrast to the other dichotomous rules, the YOS 
generates a sum score. We defined an abnormal result using 
two pre-selected cut-offs (of 8 or 10). 
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 Serious infection was defined as sepsis (including 
bacteraemia), meningitis, pneumonia, osteomyelitis, 
cellulitis, or complicated UTI.[3] These diagnoses were 
available for all datasets, and assessment of the diagnoses 
to ensure comparability of outcomes was discussed with the 
authors of each study.  
 
The settings in the included datasets were stratified as having low 
prevalence (LP; 0 to 5%), intermediate prevalence (IP; 5 to 20%) or high 
prevalence (HP; >20%) of the serious infection(s) of interest (including 
all serious infections, pneumonia, meningitis) with the clinical 
assumption that diagnostic goals are different in each setting. In LP 
settings, clinical prediction rules should have high sensitivity in order to 
correctly rule out (at a negative likelihood ratio (NLR) of up to 0.2) the 
target disorder(s) at a reasonable cost in terms of referral or admission 
rates.[9, 19]  
 
The accuracy of the clinical prediction rules was assessed 
retrospectively in each of the available prospectively collected datasets 
by calculating sensitivity, specificity, predictive value, and likelihood ratio 
(LR). We used dumbbell plots to display the change from pre-test to 
post-test probabilities.[3] The NICE traffic light system was considered 
positive if any amber or red traffic light feature was present. 
 
To avoid the risk of influencing diagnostic accuracy by either an 
arbitrarily chosen number of required variables, or the age range 
available in each dataset compared with the intended age range of the 
rule, we performed the following sensitivity analyses after obtaining initial 
results with the different clinical prediction rules.  
 
Firstly, when a clinical prediction rule was specifically designed for a 
certain age group (for example, the YOS for children aged 3 to 36 
months and the NICE guidelines for children up to 5 years of age), we 
visually compared the 95% confidence intervals (CIs) of the diagnostic 
characteristics (sensitivity, specificity, LRs and area under the curve 
(AUC))[20] in the target age group with the entire age range of the 
dataset at hand, checking for overlap.  
 
Second, when one or more variables of the original prediction rule were 
missing, we examined those same diagnostic characteristics in the 
datasets with no missing variables, to avoid biasing results on the 
number of missing variables.  
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Whenever more than one (for the clinical prediction rules) or more than 
two (for the fever guidelines) original variables were missing, we did not 
perform sensitivity analysis, based on the rationale that missing two (or 
more) of a maximum of six variables (for the clinical prediction rules) or 
three (or more) of a maximum of eight original variables (for the fever 
guidelines) did not seem clinically sensible. This was discussed and 
confirmed by all study authors, contributing data to the current study.  
 
Meta-analysis of the pooled results of the multiple external validations 
was not possible because substantial clinical heterogeneity was found in 
these datasets, including differences in setting, inclusion criteria, 
immunization schedules, and definition of serious infection.  
 
Additionally, the small number of included studies would have led to a 
high level of uncertainty in the estimates of the variances of the random 
effects for both the bivariate and hierarchical summary receiver 
operating characteristic models, if heterogeneity were to be explored 
statistically. Inclusion or exclusion of a single study would affect the 
convergence of the model greatly.[20]  
 
The individual patient data were analysed in every dataset separately. 
The translation, re-coding, and data checking were performed by one 
author (JV), and the results of each step were discussed with all of the 
other authors.  
 
All analyses were performed with Stata software (version 11.2; Stata 
Corp., College Station, TX, USA).  
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N: Number of children in dataset; % n/N: Percentage of cases (n) out of all children (N) used for the 
external validation analysis; aDerivation study (italic); b‘Clinical sick impression’ used as proxy for 
‘physician's gut feeling that something is wrong’; c‘Respiratory distress’ used as proxy for ‘dyspnoea’; 
d‘Chest flaring’ used as proxy for ‘dyspnoea’; e‘Meningeal irritation’ used as proxy for ‘nuchal rigidity’; 
f‘Unconsciousness’ used as proxy for ‘coma’. 
         
used for validation prevalence N children % n/N
All serious infections
Yale Observation Scale (cutoff > 10)
quality of cry
reaction 
to parent 
stimulation
state 
Variation colour hydration
response 
to social 
overtures
Van den Bruel et al. [7] No (no proxies or variables recorded) Low 3981 - - - - - - -
Monteny et al.[21] Yes Low 506 95.3% + + + + + +
Brent et al.[22] Yes Intermediate 2777 99.6% + - + + + +
Roukema et al.[23] No (no proxies or variables recorded) Intermediate 1750 - - - - - - -
Bleeker et al.[24] No (no proxies or variables recorded) High 595 - - - - - - -
Thompson et al.[18] Yes High 700 94.7% + + + + + +
Oostenbrink et al.[25] No (no proxies or variables recorded) High 593 - - - - - - -
4-step Decision Tree dyspnoea temperature diarrhoea age
Van den Bruel et al.a [7] No (derivation dataset) Low 3981 - + + + +
Monteny et al.[21] Yes Low 506 100.0% + + + +
Brent et al.[22] Yes Intermediate 2777 99.5% +c + + +
Roukema et al.[23] Yes Intermediate 1750 100.0% +d + + +
Bleeker et al.[24] Yes High 595 100.0% +c + - +
Thompson et al.[18] Yes High 700 100.0% + + + +
Oostenbrink et al.[25] No (2 variables not recorded) High 593 - - + - +
Clinical Diagnostic Model (Craig et al.)
Van den Bruel et al. [7] No (11 variables not recorded) Low 3981 -
Monteny et al.[21] No (8 variables not recorded) Low 506 -
Brent et al.[22] No (9 variables not recorded) Intermediate 2777 -
Roukema et al.[23] No (16 variables not recorded) Intermediate 1750 -
Bleeker et al.[24] No (18 variables not recorded) High 595 -
Thompson et al.[18] No (13 variables not recorded) High 700 -
Oostenbrink et al.[25] No (16 variables not recorded) High 593 -
Pneumonia
Pneumonia Rule 1
Van den Bruel et al.a [7] No (derivation dataset) Low 3981 -
Monteny et al.[21] No (1 variable not recorded) Low 506 -
Brent et al.[22] No (1 variable not recorded) Intermediate 2777 -
Roukema et al.[23] No (1 variable not recorded) Intermediate 1750 -
Bleeker et al.[24] No (1 variable not recorded) Intermediate 595 -
Thompson et al.[18] No (1 variable not recorded) Intermediate 700 -
Oostenbrink et al.[25] No (2 variables not recorded) High 593 -
Pneumonia Rule 2
Van den Bruel et al.a [7] No (derivation dataset) Low 3981 -
Monteny et al.[22] Yes Low 506 100.0%
Brent et al.[23] Yes Intermediate 2777 78.6%
Roukema et al.[24] Yes Intermediate 1750 96.1%
Bleeker et al.[25] Yes Intermediate 595 100.0%
Thompson et al.[18] Yes Intermediate 700 100.0%
Oostenbrink et al.[26] No (1 variable not recorded) High 593 -
Meningitis
Meningitis Rule 1
Van den Bruel et al. [7] Yes Low 3981 100.0%
Monteny et al.[21] No (2 variables not recorded) Low 506 -
Thompson et al.[18] Yes Low 700 100.0%
Roukema et al.[23] No (2 variables not recorded) Low 1750 -
Bleeker et al.[24] No (3 variables not recorded) Low 595 -
Brent et al.[22] Yes Low 2777 78.2%
Oostenbrink et al.[25] Yes High 593 100.0%
Meningitis Rule 2
Van den Bruel et al. [7] No (1 variable not recorded) Low 3981 -
Monteny et al.[21] No (1 variable not recorded) Low 506 -
Thompson et al.[18] No (1 variable not recorded) Low 700 -
Roukema et al.[23] No (1 variable not recorded) Low 1750 -
Bleeker et al.[24] No (2 variables not recorded) Low 595 -
Brent et al.[22] No (1 variable not recorded) Low 2777 -
Oostenbrink et al.[25] No (1 variable not recorded) High 593 -
Gastroenteritis with dehydration
Gastroenteritis rule absent tears
ill 
appearance 
Van den Bruel et al. [7] No (2 variables not recorded) Low 3981 - - +
Monteny et al.[21] No (2 variables not recorded) Low 506 - - +
Brent et al.[22] No (2 variables not recorded) Intermediate 2777 - - +
Roukema et al.[23] No (2 variables not recorded) Intermediate 1750 - - +
Bleeker et al.[24] No (2 variables not recorded) High 595 - - +
Thompson et al.[18] No (2 variables not recorded) High 700 - - +
Oostenbrink et al.[25] No (2 variables not recorded) High 593 - - +
10/26
-
+e +f
- +
-
coma
15/26
18/26
17/26
10/26
8/26
13/26
+
+c
-
+
dry mucous membranes
+d
+c
-
+c
+
+
+
+
-
+
any abnormal neurological findings
-
poor peripheral
 circulation
+
+f
+f
nuchal rigidity
-
+ -
-
+
+
illness is different (parent) dyspnoea
- -
+ +
-
+
+d
dyspnoea
+
+
+c
+
-
variables used (original or proxy)
something is wrong
+
+b
-
+b
-
petechiae
+
+
-
+
+b
+b
+b
+b
+b
+b
+b
+b
26 items (clinical signs and symptoms)
-+
-
Clinical Prediction Rule
+b
+b
+
something is wrong
-
-
-
-
-
-
+
+
+
+
+ +e +f
-
sought care < 48 hrs
-
-
-
-
-
Table 1.5: Variables and proxies used for clinical prediction rules validation 
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RESULTS 
 
Included datasets 
We obtained seven datasets providing data on 11023 children: two LP 
datasets from general practice,[7, 21] two IP datasets from EDs [22, 23] 
and three HP datasets from EDs [24, 25] or paediatric assessment units 
[18] in the UK (n = 2), the Netherlands (n = 4) and Belgium (n = 1) 
(Figure 1.1, Table 1.3). Children were included based on presence of 
fever, [21, 23, 24] acute illness, [7, 22] or acute infection,[18] or on 
referral for meningeal signs.[25] Children with various comorbidities 
were excluded in six studies, and one study excluded children who 
required immediate resuscitation. The outcome in all studies included 
sepsis, meningitis, pneumonia, and complicated UTI as part of the 
outcome variables. Osteomyelitis and cellulitis were explicitly mentioned 
in five and three datasets, respectively. The mean age ranged from 0.94 
to 5.0 years, and prevalence of serious infection from 0.8 to 43.8%.  
 
Clinical predictors included in the datasets 
Most datasets included basic demographic characteristics such as age, 
duration, and severity of illness, as well as referral status. Temperature 
was recorded in all datasets (with missing data rates ranging from 0 to 
18%), heart rate in five datasets (missing in 2 to 48%), capillary refill 
time in five (missing in 2 to 48%), respiratory rate in four (missing in 15 
to 53%), and oxygen saturation in four (missing in 4 to 74%).  
 
Validation of the 4-sDT [7] was possible in five datasets,[18, 21-24] of 
which four had all variables present using ‘clinical sick impression’ as a 
proxy for ‘physician’s gut feeling that something is wrong’, and 
‘respiratory distress’ or ‘chest flaring’ as a proxy for ‘dyspnoea’ (Table 
1.5). Because the variable ‘diarrhoea’ was missing in one dataset,[25] 
we performed a sensitivity analysis comparing the results of the three 
remaining variables, as noted below.  
Five datasets [18, 21-24] were available for one pneumonia rule,[7] 
developed in PC settings, with ‘sick impression to clinician’ as a proxy 
for the ‘physician’s gut feeling that something is wrong’ and ‘nasal 
flaring’ for ‘dyspnoea’. A second pneumonia rule, derived in the same 
dataset,[7] which included ‘respiratory distress’ and ‘parental concern 
the illness is different’ could not be validated, as the latter variable was 
not recorded in any of the validation datasets.  
A meningitis rule, derived by Offringa et al. [26] for children in the ED, 
was validated in three datasets.[7, 18, 25] Because all items except 
‘nuchal rigidity’ were present in one additional dataset,[22] we performed 
a sensitivity analysis comparing the results of the two remaining 
variables, eventually excluding this dataset from the analysis, as noted 
below. A second meningitis rule could not be validated because of the 
absence of its key variables in these datasets.[27]  
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For the YOS,[10] developed in secondary care, three datasets had 
recorded variables used in the original Yale scoring [18, 21, 22] (Table 
1.5). Because the YOS item ‘reaction to parent stimulation’ was missing 
in one dataset,[22] we performed a sensitivity analysis comparing the 
results of the five remaining YOS items, as noted below. None of the 
datasets included sufficient variables to validate the prediction rule to 
identify gastro-enteritis with dehydration developed by Gorelick et al.,[28] 
or the prediction rule developed by Craig et al.[17]  
The NICE guideline for feverish illness in children and the NHG alarm 
symptoms [15, 16] were validated in four [18, 21, 22, 25] and five [7, 18, 
21, 22, 25] datasets, respectively.  
 
Validation results 
The characteristics of diagnostic accuracy, according to prevalence, are 
shown for all clinical prediction rules (Figure 1.2, Figure 1.3).  
 
Low-prevalence settings 
The 4-sDT had a sensitivity of 90% (95% CI 68 to 99%) and a specificity 
of 85% (95% CI 84 to 86%) in the single LP dataset available for 
validation, with false-positive test results (for example, no serious 
infection present) in 54% of all children examined.[21] The sensitivities 
of the pneumonia rule were 94% (95% CI 71 to 100%) and 92% (95% CI 
86 to 96%) in two datasets, with specificities of less than 45%, resulting 
in 54% and 56% false-positive test results.[21, 22] Validation of the 
meningitis rule in two LP datasets [7, 18] resulted in sensitivities ranging 
from 33% (PC dataset) to 100% (secondary care dataset with a LP for 
meningitis) with specificities ranging from 90 to 99%. The YOS, with cut-
offs of 8 and 10, provided sensitivities below 46% in one LP dataset,[21] 
but had a specificity greater than 84%. The NICE ‘traffic light’ system 
with any amber or red sign present, and the NHG alarm symptoms were 
extremely sensitive (100%) with specificity from 1 to 85%, testing as 
false positive in 90 to 95% of all children in one LP dataset.[21]  
 
Intermediate-prevalence settings 
The 4-sDT provided moderate sensitivities of 76% (95% CI 69 to 81%) 
and 88% (95% CI 82 to 93%), in two IP settings [22, 23] (with 
specificities below 40%). The pneumonia rule had sensitivities ranging 
from 66 to 82% in two datasets [23, 24] but in a third dataset [18] with 
the highest prevalence (11%) of pneumonia, sensitivity was only 27% 
(95% CI 17 to 39%) with a specificity of 89% (95% CI 86 to 91%). The 
YOS, with cut-off values of 8 and 10, provided sensitivities of less than 
41% in one IP dataset,[22] and a specificity greater than 84%. Finally, 
the NICE guideline and NHG alarm symptoms had high sensitivity (97 to 
100%) in one IP setting [22] with specificities below 27%.  
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High-prevalence settings 
In one HP setting,[24] the 4-sDT had a sensitivity of 89% (95% CI 83 to 
94%) with specificity of 32% (95% CI 28 to 37%). However, sensitivity 
was only 23% (95% CI 18 to 29%) with specificity of 86% (95% CI 83 to 
89%) in a paediatric assessment unit.[18] In one study [26] that included 
children with meningeal signs identified by the referring physician, the 
meningitis rule showed high sensitivity, at 96% (95% CI 92 to 98%) and 
specificity of 49% (95% CI 44 to 54%). The Yale score, with cut-offs of 8 
and 10, provided sensitivities of less than 30% in one HP dataset [18], 
and specificity above 81%. Finally, both NICE guideline and NHG alarm 
symptoms had sensitivities ranging from 87 to 99% in two HP datasets 
[18, 25] with specificities ranging from 2 to 29%.  
 
Sensitivity analyses 
Comparing the 95% CIs, we found similar results for the diagnostic 
characteristics of the YOS and the NICE guidelines in children of all 
ages as well as in children for whom the rules were originally designed 
(3 to 35 months and up to 5 years, respectively) (Table 1.7).  
Comparing the results of the datasets in which the complete prediction 
rule could be validated with those of the datasets with one or two 
missing variables (five items of the YOS, four items of the 4-sDT, and six 
items of the NHG alarm symptoms), all diagnostic characteristics were 
found to be similar through visual comparison of the 95% CIs (Table 
1.7).  
By contrast, dropping ‘nuchal rigidity’ from the meningitis rule resulted in 
a lower sensitivity (67% (95% CI 9 to 99%) versus 100% (95% CI 29 to 
100%) when all three variables were considered) in one dataset,[18] 
eliminating one additional dataset, which had only two out of three 
original variables available, for further use in the validation.[22]  
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DISCUSSION 
 
Main findings 
None of the clinical prediction rules examined in this study provided 
adequate diagnostic accuracy. The best performing clinical prediction 
rule for ruling out serious infection in an LP setting was the 4-sDT, which 
uses the physician’s gut feeling, the patient’s temperature, and presence 
of dyspnoea and diarrhoea in a specific age range.[7] Sensitivity was 
lower than that reported in the original study, possibly explained by our 
use of ‘clinical impression’ as a proxy for ‘physician’s gut feeling’ which 
has been reported to be of lower diagnostic value.[3]  
Both the NICE guideline and the NHG alarm symptoms had high 
sensitivity in both LP and IP settings, suggesting possible clinical value 
for ruling out serious infections in children presenting in these settings. 
However, large numbers of children were flagged as potentially having a 
serious infection. If the prediction rules were to be used in clinical 
practice, additional clinical assessment, additional testing, or review at a 
later stage would be necessary to avoid inappropriate referrals or 
hospital admissions.  
For the well-known YOS, all sensitivities were low, which is similar to the 
results of a previously reported pooled sensitivity based on the meta-
analysis of seven studies.[3]  
Other disease-specific rules (pneumonia and meningitis) had acceptable 
sensitivities only in the LP settings, indicating value as rule-out tests. 
However, the percentage of false positives was too high in all datasets, 
apart from one IP dataset, probably due to the higher prevalence of 
pneumonia in this dataset.[18]  
 
Limitations  
Despite the large number of datasets available, we were able to validate 
only four of the eight prediction rules plus both guidelines. The 
methodological challenges encountered in performing these 
retrospective validations in prospectively collected datasets limit the 
translation into clinical practice. Performance of prediction rules was 
generally lower than in their original derivation studies. Clinical prediction 
rules tend to perform worse when validated in a new setting.[29] Often 
clinical prediction rules are only internally validated through split-sample 
or cross-validation, simply assessing the precision of a clinical prediction 
rule within its derivation sample. Naturally, this leads to an optimistic 
estimate of performance.[30] Another possible explanation for this is the 
approximations that we used for variables measured and recorded in 
different ways (and different languages).  
To avoid potential bias from validating in datasets with missing variables, 
a sensitivity analyses was performed and, if findings were robust 
throughout the different datasets, validation was deemed suitable.  
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In addition to variation in recorded variables, multiple other sources of 
heterogeneity were found in the included databases, including 
differences in setting, inclusion criteria, immunization schedules, and 
definition of serious infection.  
 
 
Strengths  
Although the limitations may be substantial, this is the first study to 
externally validate existing clinical prediction rules in different types of 
clinical settings. We used individual patient data from a total of seven 
existing datasets comprising 11023 children presenting to PC or EDs in 
three European countries to validate existing prediction rules and 
national evidence-based guidelines. Previously, only a single prediction 
rule had been prospectively validated in external datasets.[11-14] Our 
study therefore presents the first robust attempt to simultaneously 
validate multiple current prediction rules and evidence-based guidelines 
for management of one of the most common clinical conditions in AC 
settings. We anticipate that our findings will be applicable to guideline 
developers worldwide.  
 
Comparison with other studies  
The YOS was initially developed to identify serious illness in febrile 
children aged 3 to 36 months, but was subsequently discarded based on 
three prospective validation studies (of which only one was carried out in 
the intended age group).[11, 13, 14] The rule was also used to stratify 
patients in five studies evaluating inflammatory markers (such as 
procalcitonin and C-reactive protein), with discouraging results.[31-35] 
Bang et al. reported a slightly better performance of the YOS in 
predicting bacteraemia in febrile children in an HP study (28%), which 
does not apply to most AC settings.[12] Although the YOS was not 
useful for ruling out a serious infection in our analysis, a score of greater 
than 10 (with a combination of the presence of abnormal colour or 
hydration status, failure to respond to parents, different cry, and 
abnormal sleepiness) did slightly increase the likelihood of a serious 
infection in these datasets. 
  
Clinical implications  
With decreasing incidence of serious infections, clinicians will 
increasingly rely on clinical prediction rules in practice, particularly in 
high-volume triage settings. In these settings, ‘generic’ rules, which 
apply to all serious infections, are more useful than disease-specific 
rules. Particularly in settings where diagnosis of serious illness in 
children is essential (for example, PC), the 4-sDT, the NICE guidelines, 
and the NHG alarm symptoms may be used to rule out serious infections 
in a large proportion of children.  
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We suggest that the 4-sDT, mainly consisting of the child’s breathing 
status and temperature and the clinician’s gut feeling that something is 
wrong, should be used for assessment of every acutely ill child. The 
meningitis rule, with absence of nuchal rigidity, petechial rash, and 
coma, indicate that meningitis is highly unlikely in LP settings.  
Clinicians should be aware that none of the clinical prediction rules 
provide perfect discrimination, and it is perhaps unrealistic to expect 
such rules to provide this. Residual uncertainty may be further improved 
by conducting more detailed clinical assessments, repeating the 
assessment after some time, using additional testing (for example, urine 
or blood tests), and in most cases, providing an appropriate safety 
netting advice for children sent home detailing instructions on when to 
seek further care.[36] 
 
Research implications  
Most clinical prediction rules never undergo further validation or are 
implemented, perhaps inappropriately, with insufficient external 
validation.[37, 38] Indeed very few clinical prediction rules for the 
identification of children with serious infection have undergone either 
extensive validation or formal impact analysis, limiting the ability to truly 
evaluate their performance and to balance benefits and harms.[9, 39] In 
general, clinical prediction rules perform worse when validated in new 
populations.[29]  
 
Our study presents the first multiple external validation of clinical 
prediction rules in this common clinical area, and identifies which of 
them offer the best diagnostic accuracy in different types of clinical 
settings. This illustrates the clear need to perform extensive prospective 
validation and impact analysis of clinical prediction rules prior to clinical 
implementation.[39, 40] The 4-sDT and the NICE guidelines for 
assessment of feverish children are potential candidates for future 
prospective validation studies examining their performance in new 
prospectively collected data on similar populations.  
 
We recognize the previously identified major mismatch,[3] between the 
clinical settings where the majority of children with acute infections seek 
help (that is, PC), and the number of studies performed in that setting 
(two studies) (Table 1.3). There is a pressing need for more studies 
conducted in PC or in LP ED settings to validate clinical prediction rules 
for serious infection, or the need for hospital referral/admission. Given 
the relative infrequency of serious infections, such studies need to 
include large cohorts of children.[7, 8]  
 
Clinical prediction rules are mostly designed to rule out serious 
infections, often at the expense of moderate to low ability for inclusion.  
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As no rule is perfect at ruling out infection, research on the most 
effective content and methods of delivery with appropriate safety netting 
advice in PC and EDs is essential.[8, 36, 41] Adding newer tests such as 
point-of-care inflammatory markers may improve the diagnostic value of 
these rules, but the performance of these markers in non-referred 
populations has to be tested.[42]  
 
 
CONCLUSIONS 
 
None of the clinical prediction rules examined in this study provided 
adequate diagnostic accuracy. In LP settings (for example, PC) or IP 
settings, prediction rules, such as the 4-sDT and evidence-based 
guidelines (NICE guideline and the NHG alarm symptoms) had high 
sensitivity, providing promising rule-out value for serious infections in 
these datasets, although all seemed to leave residual uncertainty. 
Additional clinical assessment or testing such as point-of-care 
inflammatory markers may be needed to increase clinical certainty. 
None of the prediction rules identified seemed to be valuable for HP 
settings (for example, EDs).  
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Chapter 1: Appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison with other studies:  
The NICE “traffic” light clinical decision tool: a frontline triage system 
across different health settings. 
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“TRAFFIC LIGHT” CLINICAL DECISION TOOL: A FRONTLINE 
TRIAGE SYSTEM ACROSS DIFFERENT HEALTH SETTINGS. 
 
De and colleagues present the validation results of the National Institute 
for Health and Care Excellence (NICE) “traffic light” system to detect 
serious bacterial infections in young children with fever.[43] Such 
research is welcome, because timely recognition of the small number of 
children with serious bacterial infections among the majority with self-
limiting infections is difficult and consumes considerable frontline 
healthcare resources.[44] 
 
We recently examined the diagnostic accuracy of several clinical 
prediction rules, including the NICE traffic light system with any amber or 
red feature present, in ambulatory care: two low prevalence (primary 
care) and five intermediate to high prevalence (emergency department) 
datasets from three different countries.[45] Similar to De and colleagues, 
we found moderate sensitivity for the high prevalence settings (87.1%, 
95% CI 82.5 to 90.9).[18]  
 
However, sensitivity was much higher in the low to intermediate 
prevalence settings, with all sensitivities above 97.3%, suggesting a role 
in ruling out serious infections. We excluded datasets with a third or 
more of the required variables missing. In De and colleagues’ study, 11 
of the 43 NICE traffic light variables were missing and 19 symptoms 
were used as approximations for other NICE traffic light items, which 
might explain the differences in accuracy. In addition, De and 
colleagues’ study included fewer meningitis cases, which limited the 
precision of their findings.  
 
It could be argued that including children with fever ≥38°C might 
decrease sensitivity, because such a temperature in children under 3 
months is considered a red traffic light. However, three of the four 
datasets that we used included children with fever but had no effect on 
the results. The unrestricted age range might also have limited our 
results. 
  
However, a sensitivity analysis that compared the confidence intervals of 
the diagnostic characteristics for children less than 5 years of age with 
those for all children found no discrepancies. 
  
Finally, De and colleagues noted that 77% of the data on urine analysis 
were missing. Furthermore, urinalysis was more common in children 
who were triaged in category one or two by the Australasian triage scale. 
Unsurprisingly, this increased sensitivity when added to the NICE traffic 
light system.  
  
46 
C
H
A
P
TE
R
 1
 
Further research is probably needed before urine analysis becomes part 
of the diagnostic triage of acutely ill children. Because urine analysis is 
the first step in managing children with fever of unknown source, its 
importance cannot be denied.  
 
However, the low specificity and number of false positives raises 
concerns and might reduce the NICE traffic light system, with or without 
urine analysis, to its initial intended use - a frontline triage system across 
different care settings. 
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Chapter 2. 
 
 
 
 
 
 
 
 
 
 
 
Research question 
How well do clinical signs, and their prediction rules perform in 
identifying sepsis and meningitis in acutely ill children admitted to 
hospital? 
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Thompson. Sepsis and meningitis in Hospitalized Children. Pediatr Emerg Care 
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RETROSPECTIVE VALIDATION OF HOSPITAL-BASED CLINICAL 
PREDICTION RULES AND VITAL SIGNS TO DETECT SEPSIS AND 
MENINGITIS IN CHILDREN ADMITTED TO HOSPITAL . 
 
 
 
ABSTRACT 
 
 
Objective: Feverish illness is a common presentation to acute paediatric 
services. Clinical staff faces the challenge of differentiating the few 
children with meningitis or sepsis from the majority with self-limiting 
illness. We aimed to determine the diagnostic value of clinical features 
and their prediction rules for identifying children with sepsis or meningitis 
among those children admitted to a District General Hospital with acute 
febrile illness. 
 
Methods: Acutely ill children admitted to a District General Hospital in 
England were included in this case-control study between 2000 and 
2005. We examined the diagnostic accuracy of individual clinical signs 
and 6 clinical prediction rules, of which the modified Yale Observation 
Scale and AVPU scale were scored prospectively at the time of 
admission and the other four were examined retrospectively, to 
determine clinical utility in identifying children with a diagnosis of sepsis 
or meningitis.  
Results: Loss of consciousness, prolonged capillary refill, decreased 
alertness, respiratory effort, and the physician’s illness assessment had 
high positive likelihood ratios (9-114), although with wide confidence 
intervals, to rule in sepsis or meningitis. The National Institute for Clinical 
Excellence traffic light system, the modified Yale Observation Scale, and 
the Paediatric Advanced Warning Score performed poorly with positive 
likelihood ratios ranging from 1 to 3.  
Conclusions: The paediatrician’s overall illness assessment was the 
most useful feature to rule in sepsis or meningitis in these acutely ill 
children admitted to hospital. Clinical prediction rules did not effectively 
rule in sepsis or meningitis. The modified Yale Observation Scale should 
be used with caution. Single clinical signs could complement these scores 
to rule in sepsis or meningitis. Further research is needed to validate 
these clinical prediction rules.  
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BACKGROUND 
 
Feverish illness, usually caused by infection, is one of the most common 
presentations of children to health care services.[1] In the United 
Kingdom, infections are a significant cause of childhood deaths (of which 
>26% are judged to be avoidable), especially in the age group of 1 to 4 
years.[1] Most children presenting with febrile illness have self-limiting 
infections, but 50% of admissions to hospital are associated with 
infection, and up to 30% of febrile children presenting to hospital have a 
serious infection.[2] The challenge faced by paediatricians is the need to 
identify the few children with serious bacterial infections (SBIs), such as 
bacterial meningitis, bacteraemia, and sepsis. 
The previously reported red flags for SBI in hospitalized children include 
toxic appearance; abnormal vital signs such as temperature and 
capillary refill time (CRT), and raised inflammatory markers.[3-5] 
However, the evidence base underlying many clinical features is limited 
because most studies have been small and based in tertiary hospitals 
where disease prevalence, case mix, clinical staffing, and diagnostic 
facilities differ markedly from District General Hospitals (DGHs). 
Because approximately 75% of all acute paediatric admissions in the 
United Kingdom involve care in DGH rather than tertiary academic 
centres, there is a major gap in the evidence to support assessment of 
acutely ill children in such settings. 
  
We therefore aimed to determine the diagnostic value of clinical features 
and clinical prediction rules for identifying children with sepsis or 
meningitis at the time of admission to a DGH with acute febrile illness. 
 
 
METHODS 
 
We identified all children, up to 16 years, hospitalized at Pinderfields 
Hospital (Wakefield, United Kingdom) between 2000 and 2005 after 
referral by a general practitioner or self-referred attendance at the 
emergency department in this case-control study. Pinderfields Hospital 
has 40 children’s beds serving a local population of approximately 
200000 children and an admission rate of 80 per 1000 (national rate, 89 
per 1000 child population per year).[6] 
 
On admission, each child underwent a structured clinical assessment by 
the admitting paediatrician, which included vital signs (temperature, 
heart and respiratory rates, CRT, and oxygen saturation (SpO2)), an 
overall assessment of ‘‘how ill does this child appear?”, a scale 
evaluating the child’s response to Alert, Voice, Pain, or Unresponsive 
(AVPU),[7] and clinical assessment of a modified version of the Yale 
Observation Scale (YOS; Figure 2.1).[8, 9]  
  
52 
C
H
A
P
TE
R
 2
 
Most children in our study underwent additional tests (full blood count, 
C-reactive protein, blood and urine culture, lumbar puncture, and chest 
X-ray) according to a standardized protocol. A consultant paediatrician 
recorded the final discharge diagnosis on a database with full knowledge 
of the clinical findings and laboratory and imaging results.  
 
 
 
 
 
 
  
 
 
Presenting problem – tick as 
many as apply: 
 
    
Breathing difficulty   Co-morbidity – known to have:  
Diarrhoea   Asthma  
Feverish   Cerebral palsy  
Rash   Developmental delay  
Febrile Fit / Loss of 
consciousness 
  Epilepsy  
Cough   Congenital heart problem  
Vomiting   Chronic illness or diagnosis - specify  
Colour changes    
 .......................................................................  Other   
  
How ill do you think the patient is? (please tick) 
Not ill ❏      Mildly ill ❏      Moderately ill  ❏         Severely ill  ❏            Life threatening  ❏ 
Temperature…/ Pulse …/ Respiratory Rate…./ Capillary Refill Time…/Oxygen saturation…. 
Scoring 1 3 5 
Colour Normal  Pale or Flushed or 
Mottled 
Cyanotic or Ashen 
Response to 
social 
overture 
Chats or smiles 
OR “alerts” 
(<2mo) 
Single words or briefly 
smiles OR “alerts” briefly 
(<2mo) 
No smile. Face anxious 
OR dull and 
expressionless or no 
“alertness” 
State  
variation 
If awake stays 
awake OR if 
asleep and 
stimulated wakes 
quickly 
Eyes close briefly and 
then awakens OR 
awakens after prolonged 
stimulation 
Falls asleep when 
examined OR will not 
rouse 
Hydration 
Skin normal, 
eyes normal and 
mucous 
membranes 
moist 
Skin/eyes normal and 
mouth slightly dry 
Skin doughy or tented 
and dry mucous 
membranes and/or 
sunken eyes 
Respiratory 
effort a No distress 
a 
Some distress e.g. 
recession a 
Laboured with grunt or 
nasal flare OR marked 
recession OR absent 
respiratory sounds a 
AVPU SCALE 
Alert / Responding to voice / Responding to pain / Unresponsive 
 
Figure 2.1: Admission sheet (with the modified YOS) of the 
Pinderfields Paediatric Department. 
aNelson modification of the YOS (the item ‘‘respiratory effort’’ replaces the original 
Yale item ‘‘quality of cry’’).  
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Two research assistants extracted the data from the case records. We 
identified all children with a discharge diagnosis of bacterial meningitis, 
bacteraemia, or sepsis, with pathogenic bacteria isolated from a 
normally sterile site (cerebrospinal fluid or blood culture). A control group 
consisted of a half random sample of all children (using Microsoft Excel’s 
random sample feature), with a final diagnosis of a self-limiting or mild 
infection, including tonsillitis, viral or upper respiratory tract infections, 
with negative sterile site microbiologic cultures. 
14134 admissions  
in 9678 children  
(2000-2005) 
 
 10767 admissions  
excluded due to discharge diagnosis of:  
asthma, gastro-enteritis, head injury, 
epilepsy, bronchiolitis, ingestion, overdose, 
abdominal pain, petechial rash (judged not 
to be serious), diabetes, fracture, injury 
3367 admissions  
eligible for inclusion 
 
50 admissions  
 
with a diagnosis of: 
- meningitis  
- bacteraemia 
- sepsis 
&  
a positive microbiological culture  
2307 admissions  
with a diagnosis of: 
viral infection; URTI; tonsillitis 
Cases Controls 
1100 admissions 
random sample 
807 admissions 
viral infection: 594  admissions 
URTI:  145  admissions 
tonsillitis:   68  admissions 
293 admissions:  
incomplete case notes 
1010 admissions for an infection other 
than URTI, tonsillitis, sepsis or 
meningitis (e.g. pneumonia or urinary 
tract infection)  
Figure 2.2: Ascertainment of cases and controls 
URTI: upper respiratory tract infections 
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Children were excluded if their clinical features clearly pointed to an 
alternative diagnosis, according to a consultant paediatrician’s review of 
the database, e.g. gastroenteritis, head injury or epilepsy (Figure 2.2).  
In accordance with the current NICE guidelines for feverish illness in 
children,[10] the following cut-offs were used: temperature (≥38.0°C), 
SpO2 (≤95%), and CRT (≥3 seconds), as well as additional cut-offs for 
temperature (≥39.0°C) and SpO2 (<98%), based on clinical consensus. 
The Advanced Paediatric Life Support (APLS)[11] cut-offs were used for 
heart and respiratory rate, in addition to heart rate centiles adjusted for 
temperature and age.[12]  
 
Clinical Prediction Rules  
Six clinical prediction rules (first 2 scored prospectively on admission, 4 
others examined retrospectively) were selected for the analysis:  
1. a modified YOS providing a sum score, with an abnormal result 
defined using 2 preselected cut-offs (>8 or 10; Figure 2.1)[1, 8]  
2. the AVPU scale (Figure 2.1) 
3. the Paediatric Advanced Warning Score (PAWS) using the red scores 
for temperature, heart and respiratory rate, SpO2, respiratory effort, 
the AVPU scale, and CRT[13]  
4. a score developed by the UK’s Royal College of Paediatrics and Child 
Health Recognising Acute Illness in Children working group on (RAIC 
score) scoring 8 clinical variables (developmental delay, risk factor for 
infection, state variation, temperature, CRT, hydration status, 
respiratory rate, and hypoxia).[14] The score was dichotomized in 2 
ways (≥8 designed to rule in and ≤5 to rule out sepsis or meningitis). 
5. the Oxford Vital Signs score consisting of the presence of 1 or more 
abnormal vital signs (temperature, ≥39.0°C; SpO2 ≤94%; tachycardia; 
and tachypnoea)[15] 
6. the NICE febrile illness guideline ‘‘traffic light system,’’ with either any 
red or any amber or red traffic light present (Table 2.1).[10]  
 
The diagnostic accuracy of clinical signs and clinical prediction rules was 
assessed by calculating sensitivity, specificity, and likelihood ratios with 
95% confidence intervals (CIs) for sepsis or meningitis.  
Symptoms or prediction rules were considered clinically useful at ruling in 
if, when positive, they substantially raised the probability of SBI, (positive 
likelihood ratio (LR+) > 5.0) and conversely good at ruling out SBI if, when 
negative, they substantially lowered the probability of SBI (negative 
likelihood ratio (LR-) < 0.2).[16] For example, at a prevalence of 5%, a 
LR+ of 5 or a LR- of 0.2 would result in a post-test probability of 21% and 
1%, respectively. When a rule was specifically designed for a certain age 
group (e.g., the YOS for children 3-36 months and the NICE guidelines for 
children up to 5 y), we visually compared the 95% CIs of their diagnostic 
characteristics (sensitivity, specificity, LR+, LR-). 
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RESULTS  
 
From August 2000 to July 2005, there were 14699 admissions in 9678 
children (average of 1.52 admissions per child). We excluded 10767 
children from the analysis, with symptoms clearly pointing to alternative 
diagnoses (Figure 2.2).  
 
We included all 50 children with a discharge diagnosis of bacterial 
meningitis, bacteraemia, or sepsis and a positive sterile site culture. The 
most frequent bacterial isolates were Streptococcus pneumoniae and 
Neisseria meningitidis (Table 2.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Out of 2307 children admitted over the study period with a discharge 
diagnosis of tonsillitis, upper respiratory tract infection, and other viral 
infection, we identified a random sample of 1100 children and obtained 
full data from 807 children.  
 
Of a total of 50 children with sepsis or meningitis, there were 27 boys 
and 23 girls (age, both ranging from 0 to 15 years; Table 2.3). The 
median age was not statistically significantly different between the group 
with sepsis or meningitis (15 months) and the control group (23 months) 
(p=0.006).  
 
 
 
        
 
Diagnosis n 
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meningitis 18 0 13 0 1 1 1 2 
bacteraemia 16 4 6 3 2 0 1 0 
sepsis 16 7 6 1 0 2 0 0 
total 50 11 25 4 3 3 2 2 
 
 
    
n. number of cases 
 
Table 2.2: Causative pathogens of included meningitis/bacteraemia/sepsis 
cases 
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Some individual symptoms (febrile fit or loss of consciousness), the 
clinician’s overall assessment of illness, and CRT greater than or equal 
to 3 seconds had high LR+ for sepsis or meningitis (LR+, 8.7 (95% CI, 
4.6 to 16.4) to 89.5 (95% CI 16.2 to 495)) although with wide CIs (Figure 
2.3) at sensitivities below 25% and specificities above 97%. 
 
A temperature of greater than or equal to 39°C, respiratory rate or heart 
rate exceeding the APLS cut-offs, heart rate-temperature centile above 
the 95th centile, and SpO2 of less than 95% all had more modest LR+, 
ranging between 1.1 (95% CI 1.0 to 1.2) and 3.8 (95% CI 1.3 to 10.7) 
with sensitivities below 70% and specificities ranging from 68 to 98%.  
 
A YOS score of above 8 resulted in a LR+ of 1.0 (95% CI 0.9 to 1.0) for 
sepsis or meningitis with a sensitivity of 98% (95% CI 89-100%), 
however at a specificity of 2% (95% CI 1-4%). Several individual 
features from the YOS (‘‘state variation’’ (decreased alertness) and 
‘‘respiratory effort’’) when scored as highly abnormal (score of 5) had a 
LR+ ranging from 16.7 (95% CI 2.4 to 116.0) to 114.0 (95% CI 5.97 to 
2174.0), again with wide CIs (Figure 2.3), and all specificities ranging 
from 73 to 100% at sensitivities all below 57%.  
 
  
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
Characteristics Cases (n=50) Controls (n=807) 
   
 
meningitis/ 
bacteraemia/ 
sepsis  
(n=50) 
tonsillitis,  
upper respiratory tract 
and other viral infection 
(n=807) 
Gender, n (%)     
male 27 (54.0) 453 (56.1) 
female 23 (46.0) 353 (43.7) 
Age, n (%)     
<1 month 1 (2.0) 23 (2.9) 
1-12 months 18 (36.0) 213 (26.4) 
13-36 months 23 (46.0) 271 (33.6) 
37-60 months 3 (6.0) 114 (14.1) 
61-144 months 4 (8.0) 162 (20.1) 
>145 months 1 (2.0) 24 (3.0) 
Age median (IQR) in months        15.3    (8.0-24.1)      23.3    (10.2-56.8) 
n. number of cases; IQR. interquartile range 
Table 2.3: Baseline characteristics of included children 
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The PAWS had a moderate LR+ (3.1) and LR- (0.5) at a sensitivity of 
58% (95% CI 43-72%) and a specificity of 81% (95% CI 78-84%). Both 
the AVPU scale (child responding only to pain stimuli or being 
unresponsive) and the RAIC score (≥8) had high LR+ of 83.2 to 284.0 
although with very wide CI for sepsis or meningitis with 100% specificity, 
however at sensitivities below 18%, and the Oxford Vital Signs score 
(with a sensitivity of 80%) had the lowest LR- of 0.4 (95% CI 0.2 to 0.7) 
at a specificity of 49% (95% CI 46-53%).  
 
We were able to validate 9 (pallor, response to social cues, wakes with 
prolonged stimulation, decreased activity, no smile, nasal flaring, 
tachypnoea, oxygen saturation, dry mucous membranes, and CRT) of 
the 17 ambers, and 11 (ashen colour, no response to social cues, 
appears ill, does not wake, grunting, tachypnoea, chest indrawing, 
reduced skin turgor, focal seizures, temperature, and age) of the 18 red 
NICE febrile illness traffic light features. The presence of any of the 7 
ambers or 11 red signs provided a sensitivity of 100% (95% CI 93 to 
100%) and specificity of only 0.1% (95% CI 0.0-0.7%) at a LR+ of 1.00 
(95% CI 0.97 to 1.02). (Figure 2.3) 
 
Comparing the 95% CIs, we found similar results for the diagnostic 
characteristics of the YOS and the NICE guidelines in children of all 
ages as well as in children for whom the rules were originally designed 
(3 to 36 months and up to 5 y, respectively) (Table 2.4). 
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 DISCUSSION 
 
The single clinical features, most useful for ruling in sepsis or meningitis 
in children hospitalized in DGH, were as follows: clinician’s overall 
assessment of severity of illness, decreased alertness (the YOS state 
variation item), respiratory effort, and loss of consciousness. There was 
limited evidence to support the use of clinical prediction rules in both 
ruling in and ruling out sepsis or meningitis in this setting with a probable 
high prevalence of serious infections. A high RAIC score or a child 
responding only to pain or being unresponsive on the AVPU score was 
useful to rule in meningitis, bacteraemia, or sepsis. We found that only 
the NICE traffic light system was clinically useful in ruling out sepsis or 
meningitis in febrile children admitted to hospital, with any amber or red 
signs considered providing sensitivities of 100%. 
 
This is the first study in children admitted to a UK DGH to evaluate 
clinical appearance and subjective rating of ‘‘how ill’’ a child is overall, 
together with several clinical prediction rules. Our findings are likely to 
be generalizable to other hospitals in Europe. There was a high rate of 
data capture during the period of 5 years, a systematic protocol for the 
management of febrile children, and a high rate of blood investigations 
and microbiologic cultures.  
 
Our study has a number of potential limitations. First, the selection of 
children may result in selection bias. However, although sampling within 
those groups was random, these analyses should be robust.[17]  
Since our analysis was performed on anonymized case notes without 
prior informed consent, we were not able to retrace which proportion of 
children were admitted more than once and accounted for more than 
one admission in our analyses. However, diagnoses requiring recurrent 
admissions, such as asthma, epilepsy, and diabetes were excluded 
beforehand, reducing the re-admission rate in these children. A case-
control design has been shown to be more vulnerable to inflation of 
diagnostic values. Although it is not always the case, its presence 
cannot be tested.[18] Although spectrum bias tends to be present in 
case-control studies, our results are very much comparable with prior 
research in secondary care.[1, 15]  
Second, the measurement of predictors might be inaccurate, although 
these were done according to normal ward protocols. Third, some of the 
clinical prediction rules were designed for certain age groups (e.g. the 
YOS at 3-36 months, the NICE for 0-5 years), settings (e.g. the Oxford 
Vital Signs score for the paediatric assessment unit, the PAWS for 
paediatric intensive care unit), and certain purposes (e.g. the Oxford 
Vital Signs score for SBI) and may not apply to our age range, setting, 
and outcome.  
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Finally, our study was performed in the period before immunization 
against Streptococcus pneumoniae, resulting in higher rates of sepsis or 
meningitis caused by this pathogen, compared with the post-
immunization period. However, this provided a unique opportunity to 
examine the accuracy of several individual features and prediction rules.  
 
Indeed, more recent and larger studies have had very limited ability to 
study sepsis and bacterial meningitis because of low numbers.[19]  
 
Although difficult to test in future studies, we do not feel that the 
subsequent decline in the prevalence of invasive bacterial pathogens 
reduces the clinical implications of our findings.  
 
Our study confirms the usefulness of a paediatrician’s overall illness 
assessment to rule in sepsis or meningitis, which has been documented 
in ambulatory care settings.[1] Although demonstrating high sensitivities, 
the modified YOS, applied without age restrictions, had no value at 
ruling in or ruling out sepsis or meningitis, which is similar to previous 
findings.[1, 20] The YOS was derived in a tertiary US hospital in the 
1980s and used methods now considered crude to identify and combine 
predictors.  
 
The NICE traffic light system performed similar as 2 other studies but the 
same limitations apply, concerning age range and the number of amber 
or red features, which had simply not been recorded in our database.[15, 
20, 21] Thompson et al[15] found similar sensitivities, examining the 
diagnostic value of vital signs and the NICE traffic light system for 
identifying children with serious infections in a paediatric assessment 
unit. In a previous study by Verbakel et al,[20] the NICE traffic light 
system was highly sensitive in low- and intermediate-prevalence 
settings, suggesting clinical value for ruling out serious infections in 
children. De et al found moderate sensitivities for the NICE traffic light 
system in a high-prevalence setting, however, with very few cases of 
sepsis and meningitis identified in their dataset.[22]  
 
We were unable to confirm the results of the only published study of the 
PAWS, demonstrating a sensitivity of 70% and a specificity of 90% in 
identifying children who needed admission to the intensive care unit.[13] 
These limitations highlight the need for validation of clinical prediction 
rules to prepare them for impact analysis, enabling clinicians to evaluate 
whether a prediction rule will be ‘‘fit for purpose’’ or not.[23-25]  
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An ill-appearing child with breathing difficulty, loss of consciousness, 
prolonged capillary refill, increased respiratory effort, and decreased 
alertness constitutes ‘‘red flags’’ for possible sepsis or meningitis in this 
setting and should prompt additional clinical assessment, monitoring, 
and where appropriate, laboratory testing. Our study shows that even 
‘‘one-off’’ measurements are helpful to rule in or rule out sepsis or 
meningitis on admission. We did not find one clinical prediction rule that 
could meet the needs of paediatric staff, but some individual clinical 
signs could be used.  
 
The paediatric admission rates of acutely ill children in the United 
Kingdom continue to rise.[26, 27] The impact on resource use can be 
substantial. This strongly supports the need for well-conducted research 
on common issues (such as febrile children) to support the evidence 
base in these settings. In particular, we need to focus on the value of 
structured sequential observations, refining these features to ensure 
their ability to rule in or rule out sepsis or meningitis and further 
validation of clinical prediction rules.  
 
We conclude that a physician’s overall illness assessment could be the 
most useful feature to rule in sepsis or meningitis in hospitalized 
children. In contrast, clinical prediction rules, such as the NICE traffic 
light system, do not effectively rule out sepsis or meningitis in a high-
prevalence setting. Single clinical feature could complement these 
scores to adequately rule in sepsis or meningitis in hospitalized children. 
However, further research is needed to validate the clinical prediction 
rules in this setting and their impact on the management of febrile 
children.  
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Chapter 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research question 
Can we validate a clinical prediction rule based on signs and symptoms 
in a new but similar population? 
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Buntinx. Validating a decision tree for serious infection in acutely ill children in 
ambulatory care. 
 
 
Protocol published as: 
 
Jan Y Verbakel, Marieke B Lemiengre, Tine De Burghgraeve, An De Sutter, 
Dominique M A Bullens, Bert Aertgeerts, Frank Buntinx, on behalf of the ERNIE 2 
collaboration. Diagnosing serious infections in acutely ill children in ambulatory 
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DIAGNOSING SERIOUS INFECTIONS IN ACUTELY ILL CHILDREN 
IN AMBULATORY CARE:  
PROSPECTIVE VALIDATION OF A CLINICAL DECISION TREE 
BASED ON SIGNS AND SYMPTOMS. 
 
 
ABSTRACT 
 
Background: Acute infection is the most common presentation of 
children in primary care with only few having a serious infection (e.g. 
sepsis, meningitis, pneumonia). To avoid complications or death, early 
recognition and adequate referral are essential. Clinical prediction rules 
have the potential to improve diagnostic decision making for rare but 
serious conditions. In this study, we aimed to validate a recently 
developed decision tree in a new but similar population. 
 
Methods: This is a diagnostic accuracy study validating a clinical 
prediction rule of clinical features for serious infections. Acutely ill 
children presenting to a general practitioner or paediatrician were 
included consecutively in Flanders, Belgium. Physicians were asked to 
score the 4-step decision tree, in addition to a thorough clinical 
assessment and their usual care. The outcome of interest was hospital 
admission for at least 24 hours with a serious infection within 5 days 
after initial presentation. We report the diagnostic accuracy of the 
decision tree in sensitivity, specificity, positive and negative likelihood 
ratios, and positive and negative predictive values. 
 
Results:  
In total, 8664 acute illness episodes were available for analysis of which 
283 lead to admission to hospital with a serious infection. Sensitivity of 
the decision tree was 100% (95% CI 71.5-100%) at a specificity of 
83.6% (95% CI 82.3-84.9%) in the GP setting with 17% of children 
testing positive. In the paediatric outpatient and ED setting, sensitivities 
were below 92.0%, with specificities below 44.8%. 
 
Conclusions: This clinical prediction rule for identifying children at risk 
of hospital admission for a serious infection has shown to be extremely 
sensitive in general practice in an independent validation cohort, making 
it suitable for ruling out. 
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BACKGROUND 
 
Acute infection is the most common reason for encounter of children 
attending ambulatory care.  
In a primary care setting, less than 1% of children assessed will 
ultimately be diagnosed with a serious infection.[1] The incidence of 
serious infections in children is assumed to be five to ten times higher at 
the paediatric emergency department (ED).[2] Febrile illness accounts 
for 20% of all paediatric ED visits.[3] 
Serious infections in children are usually defined as sepsis (including 
bacteraemia), meningitis, pneumonia, complicated urinary tract infection, 
bacterial gastroenteritis with dehydration, osteomyelitis, and cellulitis.[4] 
The mortality of meningococcal disease can be as high as 14%.[5] In 
addition, approximately 7% of children who survive bacterial meningitis 
suffer from hearing loss.[6] 
Serious infections are rare in children in developed countries, but 
associated with considerable morbidity and mortality.[7] In Flanders, 
infectious diseases are responsible for 13.8% of all deaths in children 
under the age of one year, and for 4.6% of deaths in children aged 1 to 
14 years.[8] These numbers are comparable to death rates previously 
reported in the UK.[9]  
Serious infections need to be distinguished from the vast majority of self-
limiting infections in children. Those few children with a serious infection 
can present at an early stage when the severity of the infection is not yet 
apparent.[7] At that point, their symptoms tend to mimic those of children 
with a non-serious infection. The rapid deterioration could cause a 
diagnosis to be missed at first contact, sometimes with severe 
consequences. Early recognition and adequate referral of serious 
infections are of vital importance to avoid complications. A faster and 
more accurate recognition of serious diseases could prevent 
unnecessary investigations, referrals, treatments and hospitalizations in 
children without serious infection, avoiding traumatic experiences for the 
child, parental concerns and health care expenditures. 
 
Assessment of serious infections 
Clinicians use signs and symptoms to assess the probability of a serious 
infection and to decide on further management. Clinical prediction rules 
and guidelines may assist in the early recognition of serious infections. 
To investigate the predictive value of these signs and symptoms, Van 
den Bruel et al. conducted a study, which prospectively included over 
4000 children, resulting in a 4-step decision tree.[10] This decision tree 
is easy to interpret, facilitating its use in clinical practice. Although it 
demonstrated high sensitivity after retrospective validation in another 
primary care dataset using approximations for gut feeling and dyspnoea, 
(Chapter 1) prospective validation had not been performed as yet. 
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As described in Table 1.1a this decision tree consists of 4 clinical 
features: the clinician’s gut feeling “something is wrong”, “dyspnoea”, 
“temperature above 39.95°C” and “diarrhoea in children between 1 and 
2.5 years of age”.  
If yes to any of these 4 sequential questions, the tree is considered 
positive, reaching a sensitivity and negative predictive value of nearly 
100% in the derivation study. The probability of having a serious 
infection in children testing positive and thus indicating referral for further 
testing, however, was approximately 6%. Nevertheless, this algorithm 
demonstrated the highest sensitivity after validation in another primary 
care dataset, as described in Chapter 1.  
 
In this study, we aim to validate this decision tree in a new population 
diagnosing serious infection in acutely ill children in ambulatory care.  
The results of adding results of a point-of-care C-reactive protein test will 
be reported in Chapter 5. 
 
 
METHODS 
 
Design 
This is a prospective diagnostic accuracy study in ambulatory care 
(defined as general practice, paediatric outpatient clinics or ED). 
 
Participants 
Children aged 1 month to 16 years, presenting to a general practitioner 
(GP) or paediatrician in Flanders, Belgium, with an acute illness were 
included consecutively from February 15th 2013 to February 28th 2014. 
Physicians were instructed to recruit children consecutively during the 
inclusion period. If a physician included less than five children over the 
study period, the assumption of consecutive inclusion was probably 
violated, and his or her results were subsequently excluded from the 
analysis. 
 
Illness episode 
Children were included with an acute illness for a maximum of 5 days. 
Children were excluded if the acute illness was caused by purely 
traumatic or neurological conditions, intoxication, psychiatric or 
behavioural problem, or an exacerbation of a known chronic condition. 
If a physician included the same child twice within 5 days, we considered 
the second registration a consequence of the same illness episode and 
discarded it from the analysis. 
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Index tests 
We asked physicians to perform a thorough clinical assessment of every 
child, registering items based on experience from previous research and 
clinical consensus of an international team of clinicians and 
researchers,[11] such as measurement of the NICE traffic light system, 
the Yale Observation Scale, the 4-step decision tree, and vital signs, 
such as a pulse oximetry.[11-13]  
In total, 76 clinical features were scored with 28 features from history 
taking, 38 from clinical examination and point-of-care testing (see 
Chapter 5) and 10 features from diagnosis and management. 
 
The clinician recorded the clinical features, preliminary diagnosis and 
planned actions (e.g. investigations, treatment or referral) on a case 
report form (CRF). We provided every physician with a codebook, 
explaining every feature to be scored on the CRF. A full list of all 
features can be found in Appendix 3.1. 
 
4-step Decision Tree 
We asked physicians to score the 4-step decision tree, as developed by 
Van den Bruel et al.[10].  
“Something is wrong” was defined as a subjective gut feeling of the 
physician that something is out of the ordinary. “Dyspnoea” was defined 
as difficult or laboured breathing. “Body temperature” was defined as the 
highest body temperature measured by parents or the physician during 
the illness episode. Before analysis 0.5°C was added to temperatures 
measured under the axilla, or with a tympanic thermometer.[14, 15] 
“Diarrhoea” was defined as loose or watery stools, increased in 
frequency and volume.[16]  
In addition to the clinical features included in the 4-step decision tree, 
parents were asked if their child’s illness was different from previous 
illnesses, and clinicians whether the child appeared seriously ill because 
both features have been shown to be of diagnostic value, similar to gut 
feeling something is wrong, in the derivation study.[10] 
All features were scored as “yes” when present, “no” when absent, and 
“?” when they could not be evaluated. 
 
Vital signs 
The vital signs: temperature (and the site of temperature taking), 
respiratory rate, heart rate, oxygen saturation and capillary refill time 
were measured, each according to their respective standardized 
method.[17] 
All general practitioners (GP) were asked to measure pulse oximetry by 
means of a paediatric finger pulse oximeter (CMS50QA, ContecTM 
Medical Systems, China), which was provided specifically for this study, 
measuring oxygen saturation and pulse rate.  
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A small-scale pilot study was performed to determine the appropriate 
age requirements for the device and agreement with a large-size pulse 
oximeter, showing that agreement was sufficient, except in children 
under the age of three. Accordingly, clinicians were advised not to use 
the device in this age group. Paediatricians were given the choice to 
either use the provided finger pulse oximeter, or rather use their own 
large-size pulse oximeter, appropriate for all age ranges. 
 
Target condition 
The target condition was hospital admission (for more than 24 hours) for 
a serious infection, which was any of the following: 
- sepsis (including bacteraemia) with pathogenic bacteria isolated 
from haemoculture as the reference standard 
- meningitis (viral or bacterial) with a positive lumbar puncture 
(pleocytosis in cerebrospinal fluid and identification of bacteria or a 
virus) as the reference standard  
- appendicitis with a histological diagnosis as the reference standard 
- pneumonia (viral or bacterial) with an infiltrate seen on chest X-ray 
as the reference standard 
- osteomyelitis (pathogens from bone aspirate as the reference 
standard, or if unavailable with a MRI or bone scan suggestive for 
osteomyelitis) 
- cellulitis (acute suppurative inflammation of the subcutaneous 
tissues) 
- bacterial gastro-enteritis with dehydration (pathogen isolated from 
stool culture) 
- complicated urinary tract infection (positive urine culture (>105/ml 
pathogens of a single species) and systemic effects such as fever) 
 
To avoid missing admissions in children with serious infection, the 
outcome was verified by three complementary methods:  
(I) a thorough search of the electronic medical records of all hospitals 
within the referral region of the participating physicians,  
(II) an interview with each participating GP  
(III) a diary completed by parents for children recruited in general 
practice, recording the date of recovery. 
 
If methods (II) and (III) showed evidence of a hospital admission initially 
not captured by method (I), attempts were made to obtain information of 
this additional hospital. Children were considered as not having a 
serious infection if hospital records showed no evidence for a serious 
infection. In cases when no definitive adjudication could be made based 
on the above criteria, a steering committee consisting of clinicians 
involved in teaching and training in acute paediatric care took the final 
decision, using all available information. 
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Sample size 
Sample size calculations were based on the assumption that prevalence 
and diagnostic value of the decision tree would be similar to those 
reported by Van den Bruel and colleagues. 
Assuming a prevalence of 0.9%, recruiting 6500 children would result in 
59 cases. This would provide us with a margin of error of 12% around 
our estimate of sensitivity. For an expected sensitivity of 97%, our 95% 
confidence interval (95% CI) would range from 85-100%.  
 
We aimed to include 6500 acute episodes in children (in 88 general 
practices and 12 paediatric units) over a period of 12 months. 
 
Informed consent 
Parents were informed through posters in the waiting room, as well as 
flyers, with a short comprehensive description of the background, aims 
and requirements to participate. Physicians informed every eligible child 
and their parent(s), delivering an information leaflet and requesting 
formal approval. Parents were asked to sign a written informed consent 
form, including permission to access the hospital medical record in case 
of a possible admission. We provided adjusted information leaflets and 
consent forms for minors below and above 12 years of age. Baseline 
characteristics of children (or their parents) declining to participate were 
recorded on a separate form by the GP to assess potential selection 
bias. 
 
Ethics 
The protocol of this study was approved by the Ethical Review Board of 
the University Hospitals/KU Leuven, under reference ML8601 as well as 
all participating institutions. All children’s parents were requested to 
provide written informed consent. As soon as all hospitals within the 
referral region of all participating GPs were known, these centres were 
submitted for formal ethical approval by the coordinating and local 
ethical review boards. 
 
Statistical Analysis 
 
I. Exploratory analysis 
First, the accuracy of each clinical feature to diagnose serious infections 
was analysed and reported in sensitivity, specificity, positive and 
negative likelihood ratios, and positive and negative predictive values 
with their 95% confidence intervals (CI) for both the GP and specialist 
setting (paediatric outpatient and ED setting combined). A correction of 
0.5 was added to every cell in case of an empty cell in a 2 x 2 table.  
  
74 
C
H
A
P
TE
R
 3
 
To evaluate the discriminative value of the continuous measures, we 
constructed Receiver-Operating-Characteristic (ROC) curves to assess 
their value in both the GP and specialist setting.  
In addition, continuous variables, such as vital signs, were dichotomized 
based on previous research and the NICE guideline “Feverish illness in 
children”.[7, 17] The scoring of capillary refill time in seconds was 
analysed as a categorical variable, since most physicians scored this 
above or below 2 seconds. 
 
II. Primary analysis: validation of the 4-step decision tree 
The diagnostic accuracy of the 4-step decision tree was validated in the 
entire group and in three pre-defined subgroups according to setting: 
general practice, outpatient paediatric care and the ED. In addition, we 
performed subgroup analyses for pneumonia, complicated urinary tract 
infections and a composite outcome of sepsis and meningitis. 
Instead of limiting our analyses to complete cases, reducing the total 
number of children available for analysis, the validation of the 4-step 
decision tree was performed in all children, applying the exact same 
missing value categorizations for every decision tree variable as 
provided by the classification and regression tree (CART) analysis in the 
derivation study.  
 
III. Secondary analysis 
Optimizing thresholds for current data 
We optimized the classification of the tree by recalibrating the thresholds 
of the features in the decision tree using CART analysis, keeping the 
structure of the tree constant. 
 
Pragmatic thresholds for current data 
To improve clinician compliance, a pragmatic approach was used to 
create a more comprehensive decision tree with easy-to-remember 
thresholds for temperature and age, relevant in clinical practice: 
- temperature of 40°C or 39.5°C (instead of 39.95°C or 39.2°C) 
- age below 3 years of age (instead of 3.3) 
 
Sensitivity analyses were performed, comparing the results of all illness 
episodes versus illness episodes based on the first inclusion of children 
during the study period to avoid clustering based on recurring 
admissions in the same children. 
 
All analyses were performed with Excel (Microsoft Corporation, 
Redmond, USA), Stata software (version 11.2; Stata Corp., College 
Station, TX, USA), and JMP Statistical Discovery (version Pro 11.1.1; 
SAS Institute Inc., Cary, NC, USA). 
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RESULTS 
 
Baseline characteristics 
Children were recruited across Flanders at 92 GP surgeries, 6 outpatient 
paediatric clinics and 6 emergency departments. (Appendix 3.2) In total, 
276 physicians participated in this study of which 170 were GPs and 106 
were paediatricians: 33% were male, with a median of 13 years of 
clinical practice experience (range 0 – 40 years). 
We obtained 8962 inclusions between February 15th 2013 and February 
28th 2014. Appendix 3.3 illustrates children were included in the study at 
a constant rate throughout the year. 
Figure 3.1 shows the inclusion flow, resulting in 8664 inclusions 
available for analysis on 7355 unique children, with 88% of these 
children (n=6472) included only once during the study period. 
 
 
 
Figure 3.1: Flowchart of recruited children 
primary data:  
8962 inclusions 
8664 inclusions 
(7355 children) 
3147 inclusions at  
GP's office 
2895 inclusions at 
paediatrician's  
outpatient clinic 
2622 inclusions at 
emergency department 
  209 excluded (violation of protocol): 
  - 103 re-inclusions within 5 days 
  - 16 referred by their GP 
  - 89 non-consecutive (<5) inclusions 
  - 1 exceeded age range 
31 excluded:  
acute exacerbation  
of known chronic condition  
(e.g. asthma, cystic fibrosis) 
58 excluded:  
informed consent 
missing  
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Children had a median age of 2.1 years (IQR 1-4.4) and 3897 were boys 
(53.0%). (Table 3.1) Children for whom informed consent for recruitment 
was not obtained (n=77) had a median age of 4 years (interquartile 
range 5.6) with 56.6% boys. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical features 
Appendix 1 lists the clinical features and the number of missing data for 
every variable with a median of 3.9% (range 0.0 to 32.0%) with the 
highest numbers for the vital signs measurements. 
 
Outcome verification 
- hospital records of all recruited children were checked in all hospitals 
(60 in total), for participating GPs within their referral region and for 
paediatricians at the recruiting hospital (13144 records in total). 
- interviewing GPs yielded follow up data of 94% of children recruited in 
the GP setting. 
- 1450 (46%) diaries were collected for children recruited at the GP’s 
office.  
 
1025 children were admitted to hospital for more than 24 hours, of which 
283 had a serious infection according to our outcome definition.  
Baseline characteristics
inclusions in 
children with 
serious infection 
(n=283)
inclusions in 
children without 
serious infection 
(n=8381) 
median age in years (IQR) 1.8 (0.8-4.2) 2 (1-4.1)
sex, male (%) 150 (53.0) 4460 (53.3)
recruited at GP's office ( n=3147) 11 3136
recruited at paediatric outpatient clinic ( n=2895) 75 2820
recruited at emergency department ( n=2622) 197 2425
final outcome (admission >24h with)
sepsis 10 0
meningitis 17 0
appendicitis 15 0
pneumonia 163 0
osteomyelitis 0 0
cellulitis 3 0
bacterial gastro-enteritis with dehydration 21 0
complicated urinary tract infection 54 0
non-serious infection 0 8381
Table 3.1: Baseline characteristics for inclusions in children with or 
without a serious infection 
 
IQR: interquartile range; GP: general practitioner; h: hours 
 
  
77 
C
H
A
P
TE
R
 3
 
The remaining 742 children were admitted for either a non-serious viral 
infection (mostly dehydration as a result of pharyngitis, gastro-enteritis or 
hypoxia as a result of bronchiolitis) or an observation >24 hours in 
children suspected of a serious infection, but eventually diagnosed with 
a non-serious condition. No patient died during the study period. 
 
The prevalence of serious infections was 3.3% (95% CI 2.9 - 3.6%) for 
all inclusions in children, increasing from 0.3% in the GP setting over 
2.6% in the paediatric outpatient setting to 7.5% in the ED setting 
(confidence intervals not overlapping).  
 
We found only 11 cases of serious infection in the GP setting, of which 
eight had pneumonia, two a complicated urinary tract infection and one 
appendicitis. No sepsis or meningitis cases were identified in the GP 
setting, whereas 27 cases of sepsis and meningitis were identified in the 
specialist settings. 16 children with meningitis had a viral (mostly 
Enterovirus or Herpes simplex) and one had a bacterial (Group B 
Streptococcus) meningeal infection. Five out of the 10 children 
diagnosed with sepsis, had a positive blood culture for Streptococcus 
pneumoniae, one had Haemophilus influenzae type B (despite evidence 
of prior immunization), one Neisseria meningitidis, and three had 
uropathogenic bacteria (such as Escherichia coli). 
 
The age distribution of children with a serious infection and the total 
population is depicted in Figure 3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.2: Percentage age distribution of serious infections in 
comparison with total population (per cent) 
Dashed transparent black plot represents the percentage age distribution of all serious 
infections; grey plot represents the age distribution of the total population. 
 
Age in years 
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I. Exploratory analysis 
Overall the diagnostic accuracy of the presenting signs and symptoms in 
both the GP setting and specialist setting (paediatric outpatient clinic and 
ED combined) are listed in Appendix 3.4.  
 
In the GP setting, sensitivities were low: only gut feeling, fever of more 
than 1 day, eating or drinking less, and appearing less active, had 
sensitivities above 80%. Parental statement that the illness was different 
from previous illnesses identified 2 of the 11 cases of serious infection in 
the GP setting and only 5 of these 11 cases appeared seriously ill to 
their GP, although both features had specificities above 86%. The alarm 
signs: reduced consciousness, bloody diarrhoea, inconsistent speech, 
abnormal skin turgor and fontanel tension, petechial rash, meningeal 
irritation, nasal flaring, cyanosis, reduced peripheral circulation and 
peritoneal irritation all had specificities above 99%. 
 
In ambulatory paediatrics and the ED, overall sensitivities were even 
lower, with only fever duration >1 day and fever not reducing to normal 
temperatures with antipyretics having sensitivities above 80%. 
 
The ROC curves for the vital signs (temperature, breathing rate, heart 
rate and oxygen saturation) per setting are shown in Appendix 3.5.  
 
Overall the area under the curves for the vital signs measurements were 
low (0.58-0.69), except for breathing rate in the GP setting which had an 
AUC of 0.80, probably due to the high number of pneumonia cases in 
this setting. 
Due to the limitations of the provided pulse oximeter, only a limited 
number of oxygen saturation readings were available in the GP setting 
precluding any reliable analysis. 
 
II. Primary analysis: original validation for any serious infection 
Table 3.2 shows the validation results of the 4-step decision tree in all 
settings together and each setting separately. 
 
General practice 
The decision tree reached a sensitivity of 100% (95% CI 71.5-100%), 
with a specificity of 77.7% (95% CI 76.2-79.1%) in the GP setting. 
 
Paediatric outpatient clinic 
In the paediatric outpatient setting the validation of the 4-step decision 
tree resulted in a sensitivity of 82.7% (95% CI 72.2-90.4%) at a 
specificity of 60.5% (95% CI 58.7-62.3%).  
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Emergency department 
Validating the 4-step decision tree in the population seen at the 
emergency department resulted in a sensitivity of 69.5% (95% CI 62.6-
75.9%) and a specificity of 56.0% (95% CI 54.0-58.0%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2: Results of validation analysis of the 4-step decision tree 
for all serious infections 
sens 74.2 ( 68.7 - 79.2 ) 89.8 ( 85.6 - 93.0 ) 83.7 ( 78.9 - 87.8 )
spec 65.6 ( 64.6 - 66.6 ) 47.2 ( 46.1 - 48.2 ) 52.6 ( 51.6 - 53.7 )
LR+ 2.2 ( 2.0 - 2.3 ) 1.7 ( 1.6 - 1.8 ) 1.8 ( 1.7 - 1.9 )
LR- 0.4 ( 0.3 - 0.5 ) 0.2 ( 0.2 - 0.3 ) 0.3 ( 0.2 - 0.4 )
PPV 6.8 ( 5.9 - 7.7 ) 5.4 ( 4.8 - 6.1 ) 5.6 ( 5.0 - 6.4 )
NPV 98.7 ( 98.4 - 99.0 ) 99.3 ( 99.0 - 99.5 ) 99.0 ( 98.6 - 99.2 )
%pos 35.7 54.0 48.5
sens 100 ( 71.5 - 100 ) 100 ( 71.5 - 100 ) 100 ( 71.5 - 100 )
spec 77.7 ( 76.2 - 79.1 ) 85.4 ( 84.1 - 86.6 ) 83.6 ( 82.3 - 84.9 )
LR+ 4.3 ( 3.8 - 4.9 ) 6.6 ( 5.7 - 7.6 ) 5.9 ( 5.1 - 6.8 )
LR- 0.1 ( 0.0 - 0.8 ) 0.0 ( 0.0 - 0.7 ) 0.0 ( 0.0 - 0.8 )
PPV 1.6 ( 0.8 - 2.8 ) 2.4 ( 1.2 - 4.2 ) 2.1 ( 1.1 - 3.7 )
NPV 100 ( 99.8 - 100 ) 100 ( 99.9 - 100 ) 100 ( 99.9 - 100 )
%pos 23 15 17
sens 82.7 ( 72.2 - 90.4 ) 92.0 ( 83.4 - 97.0 ) 92.0 ( 83.4 - 97.0 )
spec 60.5 ( 58.7 - 62.3 ) 44.8 ( 43.0 - 46.7 ) 44.8 ( 43.0 - 46.7 )
LR+ 2.1 ( 1.9 - 2.3 ) 1.7 ( 1.6 - 1.8 ) 1.7 ( 1.6 - 1.8 )
LR- 0.3 ( 0.2 - 0.5 ) 0.2 ( 0.1 - 0.4 ) 0.2 ( 0.1 - 0.4 )
PPV 5.3 ( 4.0 - 13.2 ) 4.3 ( 3.3 - 5.3 ) 4.3 ( 3.3 - 5.3 )
NPV 99.2 ( 98.7 - 99.6 ) 99.5 ( 99.0 - 99.8 ) 99.5 ( 99.0 - 99.8 )
%pos 40.6 56.1 56.1
sens 69.5 ( 62.6 - 75.9 ) 87.8 ( 82.4 - 92.0 ) 80.2 ( 73.9 - 85.5 )
spec 56.0 ( 54.0 - 58.0 ) 33.1 ( 31.2 - 35.0 ) 37.0 ( 35.1 - 38.9 )
LR+ 1.6 ( 1.4 - 1.8 ) 1.3 ( 1.2 - 1.4 ) 1.3 ( 1.2 - 1.4 )
LR- 0.5 ( 0.4 - 0.7 ) 0.4 ( 0.3 - 0.5 ) 0.5 ( 0.4 - 0.7 )
PPV 11.4 ( 9.7 - 13.3 ) 9.6 ( 8.3 - 11.1 ) 9.4 ( 8.0 - 10.9 )
NPV 95.8 ( 94.6 - 96.8 ) 97.1 ( 95.7 - 98.1 ) 95.8 ( 94.3 - 97.0 )
%pos 45.9 68.5 64.3
all serious infectionssetting prevalence (%)
(n inclusions) validation optimal cut-offs pragmatic cut-offs
ED 7.5(2622 inclusions) 
all 3.3(8664 inclusions) 
GP 0.3(3147 inclusions) 
Paed 2.6(2895 inclusions) 
GP: general practice; Paed: paediatric outpatient clinic; ED: emergency department; 
prevalence: prevalence of serious infection; n inclusions: number of inclusions in each 
setting; sens: sensitivity; spec: specificity; LR+: positive likelihood ratio; LR-: negative 
likelihood ratio; PPV: positive predictive value; NPV: negative predictive value; %pos: 
percentage of children testing positive; all diagnostic characteristics are given with their 
respective 95% confidence intervals in brackets. 
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Subgroup-analyses for the three main diagnostic categories: pneumonia, 
complicated urinary tract infection and sepsis or meningitis, are shown in 
Table 3.3. 
For pneumonia, the diagnostic characteristics were almost identical to 
those for the composite outcome of serious infections, which is 
unsurprising since pneumonia cases make up 58% of all serious 
infections.  
Table 3.3: Results of validation analysis of the 4-step decision tree  
in the different outcome categories 
 
sens 80.4 ( 73.4 - 86.2 ) 66.7 ( 52.5 - 78.9 ) 74.1 ( 53.7 - 88.9 )
spec 64.8 ( 63.8 - 65.8 ) 64.1 ( 63.1 - 65.2 ) 54.2 ( 53.1 - 55.2 )
LR+ 2.3 ( 2.1 - 2.5 ) 1.9 ( 1.5 - 2.3 ) 1.6 ( 1.3 - 2.0 )
LR- 0.3 ( 0.2 - 0.4 ) 0.5 ( 0.4 - 0.5 ) 0.5 ( 0.3 - 0.9 )
PPV 4.2 ( 3.5 - 5.0 ) 1.2 ( 0.8 - 1.6 ) 0.5 ( 0.3 - 0.8 )
NPV 99.4 ( 99.2 - 99.6 ) 99.7 ( 99.5 - 99.8 ) 99.9 ( 99.7 - 99.9 )
sens 100 ( 63.1 - 100 ) 100 ( 15.8 - 100 )
spec 79.2 ( 77.7 - 80.6 ) 88.5 ( 87.3 - 89.5 )
LR+ 4.5 ( 3.8 - 5.4 ) 7.2 ( 4.3 - 12.1 )
LR- 0.1 ( 0.0 - 1.0 ) 0.2 ( 0.0 - 2.4 )
PPV 1.2 ( 0.5 - 2.3 ) 0.5 ( 0.1 - 2.0 )
NPV 100 ( 99.9 - 100 ) 100 ( 99.9 - 100 )
sens 84.3 ( 71.4 - 93.0 ) 73.3 ( 44.9 - 92.2 ) 100 ( 39.8 - 100 )
spec 59.9 ( 58.1 - 61.7 ) 59.3 ( 57.5 - 61.1 ) 63.2 ( 61.4 - 64.9 )
LR+ 2.1 ( 1.9 - 2.4 ) 1.8 ( 1.3 - 2.5 ) 2.4 ( 1.8 - 3.3 )
LR- 0.3 ( 0.1 - 0.5 ) 0.5 ( 0.2 - 1.0 ) 0.2 ( 0.0 - 2.2 )
PPV 3.6 ( 2.6 - 4.9 ) 0.9 ( 0.5 - 1.7 ) 0.4 ( 0.1 - 1.0 )
NPV 99.5 ( 99.1 - 99.8 ) 99.8 ( 99.4 - 99.9 ) 100 ( 99.8 - 100 )
sens 76.9 ( 67.6 - 84.6 ) 62.2 ( 44.8 - 77.5 ) 69.6 ( 47.1 - 86.8 )
spec 54.9 ( 53.0 - 56.9 ) 53.9 ( 51.9 - 55.8 ) 41.9 ( 40.0 - 43.9 )
LR+ 1.7 ( 1.5 - 1.9 ) 1.4 ( 1.0 - 1.7 ) 1.2 ( 0.9 - 1.6 )
LR- 0.4 ( 0.3 - 0.6 ) 0.7 ( 0.5 - 1.1 ) 0.7 ( 0.4 - 1.4 )
PPV 6.6 ( 5.3 - 8.1 ) 1.9 ( 1.2 - 2.8 ) 1.1 ( 0.6 - 1.7 )
NPV 98.3 ( 97.5 - 98.9 ) 99.0 ( 98.3 - 99.5 ) 99.4 ( 98.7 - 99.7 )
no cases
subgroups of serious infection
setting
pneumonia UTI sepsis/meningitis
ED
all
GP
Paed
GP: general practice; Paed: paediatric outpatient clinic; ED: emergency 
department; sens: sensitivity; spec: specificity; LR+: positive likelihood ratio; LR-: 
negative likelihood ratio; PPV: positive predictive value; NPV: negative predictive 
value; all diagnostic characteristics are given with their respective 95% 
confidence intervals in brackets; UTI: complicated urinary tract infections; 
sepsis/meningitis: composite group of sepsis and meningitis cases 
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The 4-step decision tree had an even higher specificity for complicated 
urinary tract infection (88.5% (95% CI 87.3-89.5%)) as compared to 
validation of the decision tree in the composite outcome of serious 
infection. 
 
In the paediatric outpatient clinic setting, the tree had a sensitivity of 
100% (95% CI 39.8-100%) at a specificity of 63.2% (95% CI 31.4-
64.9%) for sepsis and meningitis, although the limited numbers of cases 
(3 cases of sepsis and 1 case of meningitis) led to a wide confidence 
interval. The same high sensitivity was not seen in the ED setting, where 
23 cases of sepsis or meningitis were found, namely 69.6% (95% CI 
47.1-86.8%) at a specificity of 41.9% (95% CI 40.0-43.9%). 
 
 
II. Secondary analysis 
 
Optimizing thresholds for current data 
General practice 
If CART analysis was used to define the optimized thresholds for the 
variables included in the original decision tree, the threshold for 
“temperature” changed from 39.95°C to 40.7°C, and no threshold for 
diarrhoea (no serious infections left for this split) which increased the 
specificity from 77.7 to 85.4% (95% CI 84.1-86.6%). Other variables 
were left unchanged. 
 
Paediatric outpatient clinic 
In this setting changing the thresholds for three variables resulted in the 
optimal classification: 
- gut feeling now classified children as positive only when gut feeling is 
positive instead of “positive” and “not applicable” 
- temperature above 39.5°C (instead of 39.95°C) 
- diarrhoea in children <18 months (instead of 14-29 months)  
 
This resulted in a sensitivity of 92.0% (95% CI 83.4-97.0%), however at 
a lower specificity of 44.8% (95% CI 43.0-46.7%). 
 
Emergency department 
Similar to the decision tree at the paediatric outpatient clinic, three 
variables were changed: 
- gut feeling now classified children as positive only when gut feeling is 
positive instead of “positive” and “not applicable” 
- temperature above 39.2°C (instead of 39.95°C) 
- diarrhoea in children <39 months (instead of 14-29 months)  
A sensitivity of 87.8% (95% CI 82.4-92.0%) was found, however at a 
specificity of 33.1% (95% CI 31.2-35.0%).
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Pragmatic thresholds for current data 
General practice 
When the pragmatic threshold for temperature was used, sensitivity 
remained at 100% (95% CI 71.5-100%) but specificity was 83.6% (95% 
CI 82.3-84.9%) which is higher than the value obtained with the original 
tree but slightly lower than that obtained with the optimized thresholds 
for the current data. 
 
Paediatric outpatient clinic 
We did not perform any additional analysis here, as the optimized 
thresholds for the current data chosen by CART in the optimization 
process can be considered clinically sensible, and easy to apply. 
 
Emergency department 
Applying the pragmatic thresholds for temperature and age resulted in a 
sensitivity of 80.2% (95% CI 73.9-85.5%), still higher than the original 
tree, but a lower specificity of 37.0% (95% CI 35.1-38.9%). 
  
The sensitivity analyses revealed similar sensitivities and specificities 
with overlapping confidence intervals for all settings and chosen 
thresholds in the 7355 (84.9% of all episodes) acute illness episodes, 
excluding the recurring admissions in the same children. 
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DISCUSSION 
 
Main findings 
Validating the 4-step decision tree in a new but similar population nine 
years after the derivation study, demonstrated a perfect sensitivity and at 
a specificity of 84% in the GP setting, thus confirming its usefulness to 
rule out serious infections in general practice, what it was designed for. 
This perfect sensitivity compares favourably with current practice in 
which four of the 11 children that were ultimately admitted to hospital 
with a serious infection were initially not identified at first presentation.  
 
A clinical decision tree that is able to rule out serious infections is 
especially useful in low prevalence situations. We found only 11 cases of 
serious infections in the GP setting (0.3%), most of which were 
pneumonia (8 cases) and no sepsis or meningitis cases. In the 
derivation study by Van den Bruel et al. prevalence in the GP setting 
was a comparable 0.4%.[10] 
 
Validation in the paediatric outpatient clinic and ED settings did not 
provide useful rule out value, with sensitivities below 83%, however 
considerably rose to 92% if optimization of the threshold was applied in 
the paediatric outpatient clinic setting, which had an intermediate 
prevalence of 2.6% between the GP and ED setting. 
 
A pragmatic approach to the selected thresholds allowed us to enhance 
overall clarity and ease-of-use of this 4-step decision tree, even resulting 
in identical diagnostic characteristics in the GP and paediatric outpatient 
setting. 
 
Strengths and limitations 
This is a prospective multi-centre validation study of the 4-step decision 
tree in a large and similar population of children. Children were recruited 
consecutively in three different settings covering the whole spectrum of 
acutely ill children seen at first contact, enhancing the generalizability of 
these findings. 
 
We obtained almost 9000 inclusions, which makes this study one of the 
largest cohorts of children with acute illness.[18, 19]  
 
The only other validation study in seven datasets of the 4-step decision 
tree found similar sensitivities in the single low prevalence dataset, 
available for validation.[11] Very few studies have validated clinical 
prediction rules of vital signs and symptoms in acutely ill children in 
primary care.[7] Most research has been performed in secondary care, 
with varying results.[12, 18, 20, 21] 
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To ensure identification of all cases of serious infections, the outcome 
was measured through three different strategies. However verification of 
the outcome relied on the quality of hospital records and information 
obtained during follow-up. Although it is possible that not every child with 
a serious infection was identified, it is reasonable to assume that our 
strategies are robust and this was probably avoided.  
 
Measuring the presenting signs and symptoms as mentioned in this 
study, might have led to additional testing and potentially to a diagnosis 
of a serious infection (verification bias), further increasing the sensitivity 
and specificity.[22] Bias due to an inappropriate reference standard 
could have been present (e.g. normal initial chest X-ray in children with 
pneumonia), however our standardized follow-up period most likely dealt 
with this effectively. 
 
Appendicitis was also included in the composite outcome of serious 
infection. Evidence suggests a wait-and-see policy in certain cases can 
be beneficial, e.g. cooling down the infection with empirical antibiotic 
treatment. This shift in management and the relatively unspecific early 
presentation (stomach ache, fever) supports its inclusion in our 
composite outcome.[23] 
 
Implications for clinicians 
Signs and symptoms are the first available tests to support clinical 
decision making in primary care.[24] Clinician’s feeling that “something is 
wrong” (gut feeling) is an important predictor of a serious infection.[10] 
Other red flags, such as cyanosis, rapid breathing, poor peripheral 
circulation, meningeal irritation and petechial rash also increase the 
likelihood of a serious infection in ill children, but are rarely present.[7] 
 
We have demonstrated that the 4-step decision tree is both robust and 
sufficiently sensitive to allow implementation in general practice. 77% of 
children will safely test negative on the tree. However, it will still identify 
23% of acutely ill children (n=711 in our study) as potentially at risk of a 
serious infection with only 1.5% of these children having a serious 
infection. Consequently, appropriate additional strategies (point-of-care 
(POC) testing, safety netting procedures) need to be put in place to 
avoid unnecessary referrals and use of other medical services. 
 
We still believe that vital signs measurements are of value in evaluating 
acutely ill children. Physicians often choose not to measure vital signs, 
assuming them to be normal, however most recent guidelines advice to 
measure vital signs in acutely ill children,[17, 25] as they might act as a 
red flag for serious infection.  
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Future research 
Blood tests are only rarely performed in acutely ill children in primary 
care, due to the need to make management decisions prior to the 
availability of test results. Very little research has been performed in 
ambulatory care and none of it in primary care specifically. However, 
there might be a role for a C-reactive protein POC test to rule out serious 
infections.[26] POC tests enable physicians to adjust their management 
according to the immediate test results. They are minimally invasive, 
with great potential in paediatric care. 
Future research might be able to establish the exact role of such tests in 
the management of acutely ill children presenting to primary care. 
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Chapter 3: Appendix. 
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a) temperature b) breathing rate 
c) heart rate d) oxygen saturation 
Appendix 3.5: Receiver-Operating-Characteristic (ROC) curves for the 
vital signs measurements on a continuous scale per setting. 
GP: general practice; specialist setting: paediatric outpatient clinic and emergency 
department setting combined; circles and triangles: scatter plots in GP and specialist setting 
respectively; regression plot: regression plot using fractional polynomials (smooth function 
using flexible parameterization for continuous variables). The Area Under the Curves (AUC) 
values are shown for both settings (black: GP setting; grey: specialist setting) in every 
graph. For oxygen saturation the inverse of the absolute value was used, as lower values 
tend to correspond with more severe cases. 
AUC = 0.69 
AUC = 0.63 
AUC = 0.80 
AUC = 0.59 
AUC = 0.67 
AUC = 0.62 
AUC = 0.58 
AUC = 0.58 
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PART 2: POINT-OF-CARE TESTS 
 
 
 
 
 
 
 
 
Aim 
to determine the analytical accuracy of the selected POC test and its 
added value in diagnosing serious infections in acutely ill children. 
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Chapter 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research question 
What is the agreement of the selected point-of-care C-reactive protein 
test with a corresponding laboratory test in children and adults? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published as: 
 
Jan Y Verbakel, Bert Aertgeerts, Marieke Lemiengre, An De Sutter, Dominique M 
A Bullens, Frank Buntinx. Analytical accuracy and user-friendliness of the Afinion 
point-of-care test. J Clin Pathol 2014; 67(1):83-86. 
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ANALYTICAL ACCURACY AND USER-FRIENDLINESS OF A 
POINT-OF-CARE CRP TEST. 
 
 
ABSTRACT 
 
Background: Venous blood sampling can be difficult in children in 
ambulatory care. A point-of-care (POC) test, provided at the bedside, 
presents an immediate result from a droplet of blood and is especially 
useful in children. We aimed to determine the analytical accuracy and 
user-friendliness of the Afinion CRP test in children and adults. 
 
Methods: We performed POC CRP tests in children (1 month - 18 
years) at an inpatient paediatric unit and outpatient paediatric clinic, and 
in adults (18 - 65 years) attending a general practice surgery. The 
accuracy was assessed comparing the results between the Afinion CRP 
test and the venous sample immunoturbidimetric CRP test on a Roche 
Cobas c702. The correlation was analysed and plotted using the 
Passing-Bablok linear regression method and the differences and 
agreement according to the Bland-Altman method. The participating 
general practitioners evaluated user-friendliness. 
 
Results: In 100 children the agreement between the Afinion CRP test 
results and the Cobas CRP test results demonstrated a mean difference 
of 0.1% with 95% limits of agreement from -17.6% to 17.4%. A slope of 
1.01 (95% CI 1.00 to 1.05) was found with a strong correlation (y=1.01x - 
0.04) even at high CRP concentrations.  
In the 35 adults a mean difference of 1.3% with 95% limits of agreement 
from -15.4% to 12.8% was found.  
The GPs gave the POC CRP test median scores of 4 to 5 for all items. 
 
Conclusions: We were able to confirm the analytical accuracy of the 
Afinion POC CRP test in comparison with an immunoturbidimetric CRP 
test on a Cobas c702 device in children as well as in adults. Even at 
high CRP concentrations, the test demonstrated high agreement and 
precise measurements. All participating physicians and the principal 
investigators deemed the device user-friendly. 
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INTRODUCTION 
 
In children it is often essential to recognize serious infections at an early 
stage to reduce possible life-threatening complications.  
C-reactive protein (CRP) is an acute-phase protein, secreted in 
response to any infection or inflammation.[1] Venous blood sampling can 
be difficult in children in ambulatory care. A point-of-care (POC) test, 
provided at the bedside, presents an immediate result from a droplet of 
blood and is especially useful in children.  
Previous generations of POC CRP tests have shown good correlation 
with standard laboratory tests in studies in primary care and emergency 
departments.[1-3] Measuring CRP could contribute to clinical decision-
making in diagnosing serious infection.[4]  
We determined the analytical accuracy (closeness of the agreement 
between the measurement results and a reference value) and user-
friendliness of the Afinion CRP test (on the Afinion AS100 Analyzer, 
Alere, USA), in children and adults.  
 
 
METHODS 
 
To assess analytical accuracy, we performed POC CRP tests in children 
(aged 1 month-18 years) admitted to an inpatient paediatric unit or 
attending an outpatient paediatric clinic, and in adults (aged 18-65 
years) attending a general practice surgery. The participating general 
practitioners evaluated user-friendliness.  
This study was approved by the ethical review board of the KU Leuven, 
under reference ML8239.  
 
Afinion CRP test  
The Afinion CRP Test Cartridge consists of a 1.5 mL glass capillary and 
a reagent container. The result is available within 4 min and the 
measuring range for CRP is 5 to 200 mg/L. One physician (JYV) 
performed all POC CRP tests in children, executing every fingerstick in a 
similar fashion (lateral side of the index finger with a small 28 Gauge 
spring loaded needle). For internal quality control, a positive sample 
provided by the device manufacturer was measured regularly to confirm 
the efficacy and correct performance of the test.  
 
The accuracy was assessed comparing the results of the Afinion CRP 
test and the venous sample immunoturbidimetric CRP test with 
antibody-carrying latex particles tested performed on a Cobas c702 
(Roche Diagnostics, Switzerland), the available accredited reference 
standard test at the university hospital central laboratory.  
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The correlation was analysed and plotted using the Passing-Bablok 
linear regression method and the differences and agreement according 
to the Bland-Altman method.  
 
In three general practice surgeries, 10 physicians performed POC CRP 
tests. They were asked to fill out a questionnaire, consisting of a 5-point 
Likert scale, based on device start-up, handling of the capillary, filling of 
the capillary, placing the capillary in the cartridge, placing the test 
cartridge in the test device, duration of analysis and display of results.  
 
 
RESULTS 
 
From May to June 2012, 100 children (56% boys) at a median age of 9.9 
years (IQR 4.7-14.5) were tested and 35 adults (54% men) at a median 
age of 35.5 (IQR 29.3-45.6).  
 
In children aged 0-18 years  
Figure 4.1a illustrates the agreement on a Bland-Altman-plot in 100 
children between the CRP test results on the Afinion AS100 Analyzer 
and the CRP test results on the Cobas c702 with a mean difference of 
0.1% with 95% limits of agreement from -17.6% to 17.4% with all 
differences below ±23 mg/L. (Figure 4.2a) 
A slope of 1.01 (95% CI 1.00 to 1.05) was found with a regression 
equation of y=1.01x - 0.04, indicating a strong correlation even at high 
CRP concentrations. (Figure 4.3a) 
  
In adults aged 18-65 years 
Figure 4.1b shows a mean difference of 1.3% with 95% limits of 
agreement from -15.4% to 12.8% in the 35 adults with all differences 
below ±4 mg/L. (Figure 4.2b) 
A slope of 1.02 (95% CI 1.01 to 1.08) with a regression equation of 
y=1.02x - 0.10 was found. (Figure 4.3b) 
 
User-friendliness of the POC CRP device 
The results of the survey provided median scores of 4 to 5 for all items 
evaluated.  
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Figure 4.1: (a) Percentage difference plot of the agreement between the Afinion 
point-of-care (POC) CRP test results on an AS100 Analyzer and the CRP test 
results on a Roche Cobas c702 in 100 children. (b) Percentage difference plot 
of the agreement between the Afinion POC CRP test results on an AS100 
Analyzer and the CRP test results on a Roche Cobas c702 in 35 adults.  
CRP: C-reactive protein; dots: scatter; central line: mean agreement between both 
methods; outer lines: 95% limits of agreement; SD: standard deviation. 
 
Figure 4.1 a)  
Figure 4.1 b)  
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Figure 4.2: (a) Absolute difference plot of the agreement between the Afinion 
point-of-care (POC) CRP test results on an AS100 Analyzer and the CRP test 
results on a Roche Cobas c702 in 100 children. (b) Absolute difference plot of 
the agreement between the Afinion POC CRP test results on an AS100 
Analyzer and the CRP test results on a Roche Cobas c702 in 35 adults.  
CRP: C-reactive protein; dots: scatter; central line: mean agreement between both 
methods; outer lines: 95% limits of agreement; SD: standard deviation. 
 
Figure 4.2 a)  
Figure 4.2 b)  
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Figure 4.3: (a) scatter plots of the Afinion point-of-care (POC) CRP test 
results on an AS100 Analyzer and the CRP test results on a Roche Cobas 
c702 in 100 children, fitted with a regression line. (b) scatter plots of the 
Afinion POC CRP test results on an AS100 Analyzer and the CRP test results 
on a Roche Cobas c702 in 35 adults, fitted with a regression line. CRP: C-
reactive protein; dots: scatter; grey dashed line: 95% confidence intervals of 
regression; for comparison the line y=x is presented depicting perfect agreement. 
Figure 4.3 a)  
Figure 4.3 b)  
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DISCUSSION 
 
We were able to confirm the analytical accuracy of the Afinion POC CRP 
test in comparison with an immunoturbidimetric CRP test on a Cobas 
c702 device in children as well as in adults. Even at high CRP 
concentrations, the test demonstrated high agreement and precise 
measurements. The few differences between both methods in cases 
with high CRP levels were not found to be clinically significant, as they 
would not change decisions on further treatment or testing. All 
participating physicians and the principal investigators deemed the 
device user-friendly.  
 
This is the first study to examine the Afinion CRP test in children. We 
performed capillary blood CRP tests in a large sample of 100 children. A 
total of 100 of the 104 children (and their parents) eligible for inclusion 
were willing to participate, ensuring a representative sample of those 
children admitted to hospital or attending a paediatric clinic. Although we 
provided a sufficiently large sample of children, generalizability to other 
settings (e.g. primary care) and populations (e.g. neonates) cannot be 
guaranteed. 
  
As this is the first study to evaluate the Afinion CRP test, we can only 
compare these findings with those of the Nycocard, its predecessor. 
Previous studies have confirmed its use to be acceptable in children.[5-
8] It, however, required additional steps such as dilution of the sample, 
applying a conjugate, washing the sample and finally reading the test 
result. We believe the Afinion CRP Analyzer to be undeniably user-
friendlier as confirmed by our results. 
 
Diagnostic accuracy studies are needed to evaluate the added value of 
POC CRP tests in diagnosing serious infections in children. The 
selected device met primary requirements to assess an acutely ill child 
at risk of a serious infection. Further research is needed to support this 
assumption.  
 
 
CONCLUSION 
 
In this study, the Afinion AS100 Analyzer was accurate in children and 
should be considered reliable and user-friendly.  
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Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
Research question 
What is the diagnostic value of the selected point-of-care test together 
with vital signs and symptoms in diagnosing serious infections in acutely 
ill children in ambulatory care?  
 
 
 
 
 
 
 
 
Protocol published as: 
 
Jan Y Verbakel, Marieke B Lemiengre, Tine De Burghgraeve, An De Sutter, 
Dominique M A Bullens, Bert Aertgeerts, Frank Buntinx, on behalf of the ERNIE 2 
collaboration. Diagnosing serious infections in acutely ill children in ambulatory 
care (ERNIE 2 study protocol part A): diagnostic accuracy of a Clinical Decision 
Tree and added value of a Point-of-Care C-reactive protein Test and Oxygen 
Saturation. BMC Pediatr 2014, 14:207. 
 
and: 
 
Marieke B Lemiengre, Jan Y Verbakel, Tine De Burghgraeve, Bert Aertgeerts, 
Frans De Baets, Frank Buntinx, An De Sutter, on behalf of the ERNIE2 
collaboration. Optimizing antibiotic prescribing for acutely ill children in primary 
care (ERNIE2 study protocol, part B): a cluster randomized, factorial controlled 
trial evaluating the effect of a Point-of-Care C-reactive protein test and a brief 
intervention combined with written safety net advice. BMC Pediatr 2014, 14:246. 
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DIAGNOSING SERIOUS INFECTIONS IN ACUTELY ILL CHILDREN 
IN AMBULATORY CARE: ADDED VALUE OF A POINT-OF-CARE C-
REACTIVE PROTEIN TEST. 
 
 
ABSTRACT 
 
Background: Acute infection is the most common presentation of 
children to ambulatory care. In contrast, serious infections are rare and 
often present at an early stage. To avoid complications or death, early 
recognition and adequate referral are essential. In a recent large study 
children were included prospectively to construct a symptom-based 
decision tree with a sensitivity and negative predictive value of nearly 
100%. To reduce the number of false positives, point-of-care tests might 
be useful, providing an immediate result at the bedside. The most 
probable candidate is C-reactive protein. 
 
Methods: This is a diagnostic accuracy study of signs, symptoms and 
point-of-care tests for serious infections. Acutely ill children presenting to 
a general practitioner or paediatrician were included consecutively in 
Flanders, Belgium. Children testing positive on the decision tree 
received a point-of-care C-reactive protein test. The outcome of interest 
was hospital admission more than 24 hours with a serious infection 
within 5 days. We reported the diagnostic accuracy of the decision tree + 
the point-of-care C-reactive protein test result in sensitivity, specificity, 
likelihood ratios and predictive values. Considering suboptimal 
performance in specialist setting, we explored whether a new decision 
tree could be constructed, feeding only clinical features to the model that 
could be assessed by trained triage nurses and junior doctors. 
 
Results: Adding the results of the point-of-care C-reactive protein test to 
the decision tree increased the specificity from 83.6% (95% CI 82.3-
84.9%) to 89.5% (95%CI 88.3 - 90.5%) while maintaining a sensitivity of 
100% (95% CI 71.5 - 100%) in the GP setting. The newly developed 
multivariable model in the specialist setting achieved a sensitivity of 
97.1% (95% CI 94.3-98.7%) and a negative predictive value of 99.6% 
(95% CI 99.2-99.8%). 
 
Conclusions: Adding point-of-care C-reactive protein test results to a 
validated signs and symptoms-based decision tree aids identifying 
serious infections in the GP setting and can potentially reduce the 
number of investigations and admissions in children with non-serious 
infections. We propose a new multivariable model to be used as a triage 
instrument in specialist settings to safely rule out serious infections. 
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BACKGROUND 
 
The 4-step decision tree was able to identify all children with a serious 
infection in the GP setting. However, the specificity of 78% means that a 
substantial proportion of children (22%) will have a false positive result, 
potentially leading to an increase in onward referrals or additional 
testing.  
 
Adding a C-reactive protein (CRP) test may rule out a serious infection 
in those testing positive to the decision tree thus reducing false positive 
rates. In the paediatric outpatient and emergency department (ED) 
setting, where a considerable amount of first contact consultations in 
acutely ill children are assessed, adding CRP to the decision tree might 
increase its diagnostic performance both in terms of sensitivity and 
specificity. 
 
Moreover, a decision tree consisting of history features and a CRP, 
which is assessable by a trained triage nurse or junior doctor, could be a 
cost-effective way of managing acutely ill children in a specialist setting. 
 
Point-of-care (POC) tests are defined as laboratory and other tests 
performed at the patient’s bedside (or in the doctor’s surgery for 
ambulatory care). The physician obtains an immediate result and 
management can be adjusted accordingly. This makes them especially 
attractive in situations where a fast decision is warranted, such as 
urgent-access ambulatory care. Typically, POC tests are minimally 
invasive, and thus applicable in acute paediatric care.  
 
An earlier systematic review identified CRP and procalcitonin as the best 
performing laboratory tests to detect serious infections in febrile children 
in ambulatory settings.[1, 2] Despite these promising results, evidence is 
inconclusive because most studies were performed in secondary care 
settings. In addition, their use was limited because they required a 
normal blood sample to be sent off to the laboratory and results would 
become available too late to influence clinical management. At present, 
there is only one POC test for procalcitonin[3] which takes 30 minutes to 
produce a result and requires blood centrifugation, making it unsuitable 
for use in acute ambulatory care, especially in general practice where 
consultations last between 10-15 minutes. On the other hand, a fast and 
accurate POC test for CRP is available that produces a result within 4 
minutes. (see Chapter 4) 
 
In this study, we aim to explore the added value of a POC CRP test 
following a positive result on a 4-step decision tree in diagnosing serious 
infection in acutely ill children in ambulatory care. 
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METHODS 
 
Design  
This is a prospective diagnostic accuracy study in ambulatory care 
(defined as general practice, paediatric outpatient clinics or EDs) 
identifying the diagnostic value of a POC CRP test for serious infection. 
The main outcome measure was a serious infection for which a hospital 
admission for at least 24 hours was required within 5 days of first 
contact. 
 
Participants, Outcome measure & Sample Size calculation 
Details concerning the participants, outcome measure verification and 
sample size calculation are described in full detail in Chapter 3. In short, 
we recruited children aged 1 month to 16 years who presented with an 
acute illness to general practice, ambulatory paediatric care or ED. The 
target condition was hospital admission (for more than 24 hours) for a 
serious infection, defined as sepsis (including bacteraemia), meningitis, 
appendicitis, pneumonia, osteomyelitis, cellulitis, bacterial gastro-
enteritis with dehydration, complicated urinary tract infection, each 
verified by their corresponding reference standard test. 
 
Index tests 
4-step Decision Tree 
As part of a thorough clinical assessment, physicians were asked to 
score the 4-step decision tree, as developed by Van den Bruel et al.[4].  
Children testing positive on this tree then proceeded to a POC CRP test.  
 
POC CRP test (fingerstick) 
Based on sample volume, test duration, accuracy and user-friendliness, 
we selected the Afinion™ CRP Test Cartridge, which consists of a 1.5 
µL glass capillary to be filled with blood from a fingerstick and a reagent 
container. It requires no handling of the sample. The result is available 
within 4 minutes. The CRP measuring range is 5 - 200 mg/L. 
 
We trained all physicians on how to perform the POC CRP test, as they 
were not blinded from the final result. For internal quality control, a low 
and a high control positive sample was tested at regular intervals to 
confirm the efficacy and correct performance of the test according to the 
manufacturer’s instructions. The device distributor provided technical 
assistance in case of a device malfunction. 
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Statistical Analysis 
 
I. Exploratory analysis: bivariable diagnostic accuracy of POC CRP 
We constructed Receiver-Operating-Characteristic (ROC) curves to 
assess the value of CRP for general practice and for the specialist 
setting (paediatric outpatient and ED setting, combined) respectively.  
The accuracy of the CRP test results was analysed for our composite 
outcome of serious infections at different thresholds: 5 and 200 mg/L 
(lower and upper limit of the POC CRP test as measured with the Afinion 
CRP test) and 20 and 80 mg/L (identified by previous research as rule 
out and rule in threshold, respectively).[5] We reported the diagnostic 
accuracy in sensitivity, specificity, and positive and negative predictive 
values with their 95% confidence intervals (CI). A correction of 0.5 was 
added to every cell in case of an empty cell in a 2 by 2 table.  
 
II. Primary analysis: diagnostic accuracy of the 4-step decision tree 
and POC CRP 
For every child testing positive on the pragmatic version of the decision 
tree (see Chapter 3) with easy to remember thresholds, we added a 
POC CRP test to improve specificity by lowering the number of children 
testing false positive. We used classification and regression tree 
analysis (CART) to select the optimized threshold for the CRP test in this 
dataset. We tested whether this resulted in a statistically significant 
increase in sensitivity or specificity by comparing confidence intervals to 
those of the 4-step decision tree without CRP and in overall accuracy by 
testing for differences between areas under the receiver-operating 
characteristic (ROC) curves (AUC) using chi square (chi2) tests. 
Subgroup analyses were performed according to setting: GP, outpatient 
paediatric and emergency department, and according to diagnostic 
category: pneumonia, complicated urinary tract infections, and sepsis 
and meningitis. 
 
III. Secondary analysis: developing a new decision tree for triage in 
specialist settings 
Considering the suboptimal performance of the 4-step decision tree in 
ambulatory paediatric care and the ED, we explored whether a new 
decision tree could be constructed, deliberately only feeding clinical 
features to the model that could be assessed by trained triage nurses 
and junior doctors. As a result, analyses were limited to the POC CRP 
test, all items from history taking, all items from observation (including 
skin-related items), and none of the clinical examination items, except 
the vital signs measurements. (Appendix 3.1). This selection was based 
on expert opinion from a group of clinicians involved in teaching and 
training in acute paediatric care.  
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“Gut feeling something is wrong” and “clinical impression child is 
seriously ill” are less specific when assessed by inexperienced clinicians 
and are considered to be holistic features encompassing all available 
information obtained during a clinical examination,[6] which is why they 
were deemed unsuitable for this specific analysis.  
We used CART analyses to develop this decision tree, limiting the 
minimum split size to 20 and applying a weighing factor of 100 for 
misclassification of serious infection. This weight was chosen in a data-
driven way balancing maximum sensitivity with the complexity of the 
tree.  
To avoid over-fitting, we performed a 50-fold cross-validation.  
Sensitivity analyses were performed, comparing the results of all 
children versus (a) children included only once during the study period to 
avoid clustering based on children with a predisposition for abnormal 
clinical findings such as high temperature and (b) children up to 36 
months of age, in accordance with previous research.[7-9] 
 
Dealing with missing values 
The median number of missing data per variable was 3.9% (range 0.0 to 
32.0%) with the highest numbers for the vital signs measurements. 
(Appendix 3.1). There was 12.4% and 11.3% missing data for POC 
CRP in the GP and specialist setting, respectively. 
We used CART analysis (except for the bivariable analysis), which 
avoids limiting the analysis to complete cases, which would reduce the 
total number of subjects, but allows for missing value categorization for 
categorical predictors and informative treatment of missing values for 
continuous predictors. We again limited the minimum split size to 20 and 
applied a weighing factor of 100 for misclassification of serious infection. 
 
Whenever missing values were present for the key variables, they were 
treated as: 
- a separate level of the variable for categorical variables 
- a continuous predictor value at one of either sides of the sorted 
values for continuous variables, in which case the optimal split was 
determined by CART. 
 
If missing values for a continuous variable were categorized on one end 
of the optimal split, the significance of this categorization was evaluated 
on clinical grounds. For example, if missing values for temperature were 
categorized on the high end of the temperature values, a sensitivity 
analysis would have been performed comparing complete case analysis 
to the full data analysis base on this specific split, since missing values 
for temperature are more likely to be associated with lower values of 
temperature as clinicians tend to record abnormal findings more than 
normal findings. 
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All analyses were performed with Excel (Microsoft Corporation, USA), Stata 
software (version 11.2; Stata Corp., College Station, TX, USA), and JMP 
Statistical Discovery (version Pro 11.1.1; SAS Institute Inc., NC, USA). 
 
 
RESULTS  
  
Baseline characteristics and validation results of the decision tree are 
described in Chapter 3. We obtained 8962 inclusions between February 
15th 2013 and February 28th 2014. As shown in Figure 3.2, 8664 
inclusions (corresponding to 7355 unique children) were available for 
analysis: 3147 inclusions in the GP setting, 2895 inclusions in the 
paediatric outpatient clinic setting and 2622 inclusions in the ED setting. 
 
I. Exploratory analysis 
The area under the curve (AUC) value for CRP was 0.76 (95% CI 0.73-
0.79) in the specialist setting versus 0.70 (95% CI 0.57-0.84) in the GP 
setting, but the difference was not statistically significant. (chi2: 
p=0.4342) (Figure 5.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Receiver-Operating-Characteristic (ROC) curve for C-reactive 
protein test result (fingerstick) on a continuous scale per setting. 
GP: general practice; specialist setting: paediatric outpatient clinic and emergency department 
setting; circles and triangles: scatter plots in each setting; regression plot: regression plot using 
fractional polynomials (smooth function using flexible parameterization for continuous variables). 
The Area Under the Curves (AUC) values are shown for both settings (black: GP setting; grey: 
specialist setting) in every graph. 
AUC = 0.70 
AUC = 0.76 
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The diagnostic accuracy of the CRP test results at different thresholds in 
the general practice and specialist setting (paediatric outpatient clinic 
and ED setting combined) is shown in Appendix 5.1. As expected at a 
low threshold of 5 mg/L, sensitivities were above 86.8% for all settings, 
with a sensitivity of 100% (95% CI 71.5-100%) in the GP setting, at 
specificities ranging from 41.1% (95% CI 39.8-42.5%) in the specialist 
setting to 64.1% (95% CI 62.4-65.8) in the GP setting.  
At a higher threshold of 80 mg/L, sensitivities dropped below 33.5% but 
specificities were all above 95%. 
 
II. Primary Analysis: added value of POC CRP 
The diagnostic accuracy of the pragmatic version of the decision tree 
plus the POC CRP test is shown in Table 5.1, with subgroup analyses 
for the three pre-defined settings: GP, paediatric outpatient clinic and 
emergency department. 
 
 
 
 
 
 
 
 
pragmatic tree for all serious infections
sens 100 ( 71.5 - 100 ) 100 ( 71.5 - 100 )
spec 83.6 ( 82.3 - 84.9 ) 89.5 ( 88.3 - 90.5 )
LR+ 5.9 ( 5.1 - 6.8 ) 9.1 ( 7.8 - 10.6 )
LR- 0.0 ( 0.0 - 0.8 ) 0.0 ( 0.0 - 0.7 )
PPV 2.1 ( 1.1 - 3.7 ) 3.2 ( 1.6 - 5.7 )
NPV 100 ( 99.9 - 100 ) 100 ( 99.9 - 100 )
%pos 17 11
sens 93.9 ( 86.3 - 98.0 ) 68.3 ( 57.1 - 78.1 )
spec 43.9 ( 42.0 - 45.7 ) 76.9 ( 75.4 - 78.5 )
LR+ 1.7 ( 1.6 - 1.8 ) 3.0 ( 2.5 - 3.5 )
LR- 0.1 ( 0.1 - 0.3 ) 0.4 ( 0.3 - 0.6 )
PPV 4.6 ( 3.6 - 5.7 ) 7.8 ( 6.0 - 10.0 )
NPV 99.6 ( 99.1 - 99.9 ) 98.8 ( 98.3 - 99.2 )
%pos 57.2 24.3
sens 79.5 ( 73.0 - 85.0 ) 59.5 ( 52.1 - 66.5 )
spec 37.6 ( 35.7 - 39.6 ) 74.0 ( 72.2 - 75.8 )
LR+ 1.3 ( 1.2 - 1.4 ) 2.3 ( 2.0 - 2.6 )
LR- 0.6 ( 0.4 - 0.7 ) 0.6 ( 0.5 - 0.7 )
PPV 9.2 ( 7.9 - 10.7 ) 15.4 ( 12.9 - 18.3 )
NPV 95.8 ( 94.3 - 97.0 ) 95.8 ( 94.8 - 96.7 )
%pos 63.6 28.4
without CRP
setting prevalence (%)(n inclusions) with CRP
ED 7.3(2573 inclusions) 
GP 0.3(3147 inclusions) 
Paed 2.8(2944 inclusions) 
Table 5.1: Results of added value of POC CRP analysis in the 
three pre-defined settings 
 
GP: general practice; Paed: paediatric outpatient clinic; ED: emergency 
department; prevalence; prevalence of serious infection; n inclusions: number 
of inclusions in each setting; with CRP: decision tree plus pragmatic CRP-
thresholds; sens: sensitivity; spec: specificity; LR+: positive likelihood ratio; 
LR-: negative likelihood ratio; PPV: positive predictive value; NPV: negative 
predictive value; %pos: percentage of children testing positive; all diagnostic 
characteristics are given with their 95% confidence intervals. 
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point-of-care 
CRP test 
Figure 5.2: Results of adding the POC CRP results to  
the validated pragmatic decision tree in the GP setting 
GP: general practitioner; SI: serious infections; “?”: could not be evaluated 
temperature 
dyspnoea 
gut feeling 
something is 
wrong 
children recruited 
at GP's office 3147 children 
"No" 
2781 total: 
2 with SI 
"No" or "?" 
2691 total: 
1 with SI 
<40°C 
2622 total: 
0 with SI 
>40°C 
69 total: 
1 with SI 
 5 mg/L 
50 total: 
1 with SI 
< 5 mg/L 
19 total: 
0 with SI 
"Yes" 
90 total: 
1 with SI 
 5 mg/L 
48 total: 
1 with SI 
< 5 mg/L 
42 total: 
0 with SI 
"Yes" or "?" 
366 total: 
9 with SI 
 5 mg/L 
244 total: 
9 with SI 
< 5 mg/L 
122 total: 
0 with SI 
General practice 
Adding CRP at optimized thresholds in the current data of: 
(a) 5 mg/L in a child for which the doctor has a gut feeling something is 
wrong 
(b) 13 mg/L in a child with dyspnoea 
(c) 201 mg/L in a child with a temperature of >40°C 
resulted in a sensitivity of 100% (95% CI 71.5-100%) and specificity of 
91.5% (95% CI 90.5-92.5%). 
 
Since every child with a serious infection had a CRP level above 5 mg/L, 
using CRP thresholds of 5 mg/L after every positive result on the 
decision tree resulted in a specificity of 89.5% (95% CI 88.3-90.5%) 
(Figure 5.2), and increased the AUC of the pragmatic tree from 0.92 
(without CRP) to 0.95 (with CRP; chi2: p<0.0001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The false positive rate reduced by 52.7% from 700 to 331 children 
without a serious infection and still testing positive. This was equivalent 
to the 326 children receiving additional testing or a letter of referral from 
their GP. However, our decision tree identified all serious infections at 
first contact, while 4 of the 11 children with a serious infection were 
eventually not referred to hospital by their GP. 
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Paediatric outpatient clinic 
The optimized thresholds for CRP in the current data were: 
(a) 37 mg/L in a child for which the doctor has a gut feeling something 
is wrong 
(b) 11 mg/L in a child with dyspnoea 
(c) 23 mg/L in a child with a temperature of >39.5°C 
(d) 20 mg/L in child aged <18 months with diarrhoea 
This resulted in a sensitivity of 66.7% (95% CI 54.8-77.1%) and 
specificity of 79.4% (95% CI 77.9-80.9%). 
 
Levelling all CRP thresholds to a user-friendly 20 mg/L, brought the 
sensitivity to 69.3% (95% CI 57.6-78.7%) and specificity to 77.1% (95% 
CI 75.5-78.7%), increasing the AUC of the pragmatic tree from 0.77 
(without CRP) to 0.82 (with CRP; chi2: p=0.0069), with 23 out of 75 
children testing false negative. (Figure 5.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Results of adding the POC CRP results to the validated pragmatic  
4-step decision tree in the paediatric outpatient setting 
SI: serious infections; “?”: could not be evaluated 
 
 
point-of-care 
CRP test 
diarrhoea in children  
< 1.5 years 
temperature 
dyspnoea 
gut feeling  
something is wrong 
children recruited at 
paediatric outpatient 
clinic 
2895 
children 
"No" or "?" 
2553 total: 
43 with SI 
"No" or "?" 
2398 total: 
36 with SI 
<39.5°C 
1401 total: 
8 with SI 
"Yes" 
143 total: 
3 with SI 
≥ 20 mg/L 
28 total: 
3 with SI 
< 20 mg/L 
115 total: 
0 with SI 
"No" or "?" 
1258 total: 
5 with SI 
≥39.5°C 
997 total: 
28 with SI 
≥ 20 mg/L 
466 total: 
19 with SI 
< 20 mg/L 
531 total: 
9 with SI 
"Yes" 
155 total: 
7 with SI 
≥ 20 mg/L 
54 total: 
3 with SI 
< 20 mg/L 
101 total: 
4 with SI    
"Yes" 
342 total: 
32 with SI 
≥ 20 mg/L 
149 total: 
27 with SI      
< 20 mg/L 
193 total: 
5 with SI      
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Emergency department 
In the ED setting, the optimized thresholds for CRP in the current data 
were: 
(a) 36 mg/L in a child for which the doctor has a gut feeling something 
is wrong 
(b) 22 mg/L in a child with dyspnoea 
(c) 17 mg/L in a child with a temperature of >39.5°C 
(d) 23 mg/L in a child aged <36 months with diarrhoea 
leading to a sensitivity of 56.9% (95% CI 49.6-63.9%) and specificity of 
74.7% (95% CI 72.9-76.4%). 
 
When we used CRP-thresholds of 20 mg/L, this resulted in a sensitivity 
of 59.4% (95% CI 52.2-66.3%) and specificity of 73.8% (95% CI 72.0-
75.6%), increasing the AUC of the pragmatic tree from 0.69 (without 
CRP) to 0.73 (with CRP; chi2: p=0.0086), with 635 children testing false 
positive but more importantly 80 (40.6%) missed serious infections.  
(Figure 5.4) 
 
 
 
 
 
 
 
 
 
 
 
 
point-of-care 
CRP test 
diarrhoea in children  
< 3 years 
temperature 
dyspnoea 
gut feeling  
something is wrong 
children recruited at 
emergency 
department 
2622 
children 
"No" or "?" 
2198 total: 
118 with SI 
"No" or "?" 
2031 total: 
102 with SI 
<39.5°C 
1153 total: 
42 with SI 
"Yes" 
217 total: 
3 with SI 
≥ 20 mg/L 
76 total: 
3 with SI 
< 20 mg/L 
141 total: 
0 with SI 
"No" or "?" 
936 total: 
39 with SI 
≥39.5°C 
878 total: 
60 with SI 
≥ 20 mg/L 
416 total: 
42 with SI 
< 20 mg/L 
462 total: 
18 with SI 
"Yes" 
167 total: 
16 with SI 
≥ 20 mg/L 
46 total: 
11 with SI 
< 20 mg/L 
121 total: 
5 with SI    
"Yes" 
424 total: 
79 with SI 
≥ 20 mg/L 
214 total: 
61 with SI      
< 20 mg/L 
210 total: 
18 with SI      
 
^ 
Figure 5.4: Results of adding the POC CRP results to the validated pragmatic  
4-step decision tree in the emergency department setting 
SI: serious infections; “?”: could not be evaluated 
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Subgroup analyses for different outcome categories 
Table 5.2 shows the subgroup analyses for pneumonia, complicated 
urinary tract infection and sepsis or meningitis in the three pre-defined 
settings. 
For pneumonia, the diagnostic characteristics were almost identical to 
those for the composite outcome of serious infections. This is probably 
due to the high proportion of pneumonia cases (58% of all serious 
infections).  
Adding CRP at a threshold of 5 mg/L (GP) or 20 mg/L (specialist setting) 
to the 4-step decision tree increased specificity in the GP setting for 
complicated urinary tract infection from 88.5% to 92.3% (95% CI 91.3-
93.2%). For sepsis and meningitis, adding CRP increased specificity 
from 42.6% up to 73.5% (95% CI 71.8-75.1) in the specialist settings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sens 100 ( 63.1 - 100 ) 100 ( 15.8 - 100 )
spec 89.4 ( 88.2 - 90.4 ) 92.3 ( 91.3 - 93.2 )
LR+ 8.9 ( 7.4 - 10.7 ) 10.8 ( 6.4 - 18.2 )
LR- 0.1 ( 0.0 - 0.9 ) 0.2 ( 0.0 - 2.3 )
PPV 2.3 ( 1.0 - 4.6 ) 0.8 ( 0.1 - 2.9 )
NPV 100 ( 99.9 - 100 ) 100 ( 99.9 - 100 )
sens 64.7 ( 50.1 - 77.6 ) 80.0 ( 51.9 - 95.7 ) 75 ( 19.4 - 99.4 )
spec 76.7 ( 75.1 - 78.2 ) 72.7 ( 71.0 - 74.3 ) 73.5 ( 71.8 - 75.1 )
LR+ 2.8 ( 2.2 - 3.4 ) 2.9 ( 2.3 - 3.8 ) 2.8 ( 1.6 - 5.0 )
LR- 0.5 ( 0.3 - 0.7 ) 0.3 ( 0.1 - 0.8 ) 0.3 ( 0.1 - 1.9 )
PPV 4.7 ( 3.3 - 6.6 ) 1.5 ( 0.8 - 2.6 ) 0.4 ( 0.1 - 1.1 )
NPV 99.2 ( 98.7 - 99.5 ) 99.9 ( 99.6 - 100 ) 100 ( 99.7 - 100 )
sens 66.3 ( 56.4 - 75.3 ) 54.1 ( 36.9 - 70.5 ) 34.8 ( 16.4 - 57.3 )
spec 72.9 ( 71.1 - 74.6 ) 74.9 ( 73.2 - 76.6 ) 59.4 ( 57.5 - 61.3 )
LR+ 2.5 ( 2.1 - 2.8 ) 2.2 ( 1.6 - 2.9 ) 0.9 ( 0.5 - 1.5 )
LR- 0.5 ( 0.4 - 0.6 ) 0.6 ( 0.4 - 0.9 ) 1.1 ( 0.8 - 1.5 )
PPV 9.2 ( 7.2 - 11.5 ) 3.0 ( 1.8 - 4.6 ) 0.8 ( 0.3 - 1.5 )
NPV 98.1 ( 97.4 - 98.7 ) 99.1 ( 98.6 - 99.5 ) 99.0 ( 98.4 - 99.5 )
no cases
subgroups of serious infection
setting
pneumonia UTI sepsis/meningitis
ED
GP
Paed
Table 5.2: Results of added value of POC CRP in the 
different outcome categories  
 
GP: general practice; Paed: paediatric outpatient clinic; ED: emergency 
department; sens: sensitivity; spec: specificity; LR+: positive likelihood ratio; LR-
: negative likelihood ratio; PPV: positive predictive value; NPV: negative 
predictive value; all diagnostic characteristics are given with their corresponding 
95% confidence intervals in brackets; UTI: complicated urinary tract infections; 
sepsis/meningitis: composite group of sepsis and meningitis cases. For these 
diagnostic categories subgroup analyses the pragmatic CRP-thresholds were 
used. 
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III. Secondary analysis  
 
Newly developed decision tree 
In the specialist setting, we were able to construct a new decision tree 
based on a pre-selected group of clinical features, as described above, to 
be used in paediatric outpatient clinics and the ED in children 1 month to 
16 years of age.  
The decision tree starts with a POC CRP test, using 2 different thresholds 
of 20 mg/L and 74 mg/L.  
 
Children with a CRP level higher than 74 mg/L should be considered at 
high risk of a serious infection and no further splits were attempted (378 
children tested positive with 100 serious infections identified (PPV of 
26.5%)).  
In the group of children having a CRP test result between 20 mg/L and 74 
mg/L, 1065 children tested positive to any of the following seven features 
(different illness, no improvement with antipyretics, age <6 months, fever 
duration <1 day, vomiting, excessive crying, decreased eating or drinking) 
identifying 86 children of the 88 with a serious infection in this group. 
In children testing CRP below 20 mg/L, 2071 children tested positive on 
the vital signs measurements (temperature, respiratory rate, heart rate, 
oxygen saturation and capillary refill time) and seven alarm signs 
(moaning, belly ache, pale skin, neck pain, petechial rash, inconsolable, 
drowsiness) identifying 78 of the 84 children with a serious infection in this 
group. (Figure 5.5) Although other alarm signs (e.g. reduced 
consciousness) could be considered important clinical features, they did 
not contribute to the model, due to interactions with the final decision tree 
predictors. 
 
The decision tree had a sensitivity of 97.1% (95% CI 94.3-98.7%) and a 
negative predictive value of 99.6% (95% CI 99.2-99.8%) at a prevalence 
of 4.9% (95% CI 4.4-5.5%). 
Our new decision tree misclassified 8 cases of serious infection: 6 
children with bronchopneumonia (chest X-ray with peribronchitis and a 
possible pulmonary infiltrate) and 2 children diagnosed with a minor 
complicated urinary tract infection (a DMSA (dimercaptosuccinic acid) 
scan during hospital admission could not confirm pyelonephritis). 
 
Adjusting the high level POC CRP test result threshold to a pragmatic 75 
mg/L (Figure 5.5) did not change the diagnostic characteristics. The 
sensitivity analyses revealed similar sensitivities (96.5-97.1%) and 
negative predictive values (99.5-99.6%) with overlapping confidence 
intervals in the 4595 (83.3%) children in the specialist setting included 
only once during the study period and the 4107 (74.4%) children up to 36 
months of age. 
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DISCUSSION 
 
Main findings 
A threshold of 5 mg/L for the point-of-care (POC) CRP test results as a 
single test in the GP setting had a perfect sensitivity but low specificity. 
Adding CRP to the positive results on the 4-step decision tree resulted in 
a 100% sensitivity, at a specificity of 90% reducing the number of false 
positives by 53% as compared to the original 4-step decision tree 
without CRP testing.  
Adding CRP to the 4-step decision tree resulted in an even higher 
specificity of 92% to diagnose children with a complicated UTI. 
 
In the specialist settings, adding a POC CRP test to the validated 
decision trees was not useful, considering the poor accuracy of the tree 
(see Chapter 3). Instead, we chose to explore and suggest a new 
decision tree, useful in this setting, allowing junior doctors and trained 
triage nurses to efficiently rule out serious infections in 36% of children 
(1 month to 16 years) presenting to the outpatient clinic or emergency 
department, based on two POC CRP thresholds, and adding easy-to-
assess clinical features.  
 
Strengths and limitations 
To our knowledge, this is the first large-scale trial, investigating the 
(added) value of POC CRP in addition to clinical features in identifying 
serious infections in acutely ill children in ambulatory care, including 
general practice, paediatric outpatient clinics and hospital emergency 
departments. 
 
Verification of our target condition relied on the quality of hospital 
records and information obtained during follow-up. Although it is possible 
that not every child with a serious infection was identified, it is 
reasonable to assume that our strategies are robust and this was 
probably avoided.  
 
Measuring the clinical signs and POC CRP (without blinding) might have 
led to additional testing and potentially to a diagnosis of a serious 
infection (verification bias), potentially increasing the sensitivity and 
specificity.[10]  
 
Using a follow up of 5 days for verification of our outcome measure 
might seem arbitrary. If we compared the results of the POC CRP levels 
in our study to the variable “duration of fever” (as a proxy for the duration 
of illness), we observed a clear drop in CRP levels after day 5, 
suggesting CRP can only predict serious infections within a 5-day time 
frame. (Appendix 5.2)  
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Furthermore, there is evidence suggesting that different thresholds for 
CRP values should be applied in relation to duration of fever.[11] 
 
Comparison with existing literature 
Limited evidence on the value of laboratory tests in children in the 
ambulatory setting is available, none of which was obtained in primary 
care.[12] 
A systematic review based on studies from specialist settings suggested 
that CRP levels <20 mg/L provided the best rule out value for serious 
infections in children, which is identical to the threshold identified in our 
analyses.[7] 
 
Implications for clinicians 
None of the suggested algorithms had both perfect sensitivity and 
specificity. Although perfect at ruling out serious infection in the GP 
setting, still 10.5% of all children (n=331) recruited, tested false positive, 
requiring additional testing (urinalysis, chest X-ray) or referral to hospital. 
This was equivalent to the 326 children (10.4%) receiving additional 
testing or a letter of referral from their GP in this study. However, our 
decision tree identified all serious infections at first contact, while 4 of the 
11 children with a serious infection were eventually not referred to 
hospital by their GP. 
 
The decision to refer to hospital should remain in the hands of the 
treating physician. We can only advise which clinical features and tests 
can identify all serious infections at first contact without increasing the 
number of unnecessary referrals or additional testing. 
Although no cases of serious infections were missed in these analyses, 
clinical judgement should still prevail, especially if clinical uncertainty 
remains even after a negative test result on the decision tree. A low CRP 
threshold allows clinicians to reduce the number of children without a 
serious infection deemed at high risk based on symptoms alone. As long 
as appropriate (pro-)active safety netting strategies (e.g. re-consultation, 
telephone follow up) are installed to cope with potentially avoidable 
referrals or additional testing, this decision tree with POC CRP is ready 
for implementation in general practice. 
 
Still 8 out of 272 serious infections, although made up of minor infections 
(peribronchitis and minor complicated urinary tract infection), were 
missed by the newly developed decision tree in the specialist settings. 
An appropriate strategy is required to deal with children scored as 
probably not having a serious infection by this model.  
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In children with a CRP threshold above 75 mg/L, we suggest a 
paediatric consultant or emergency physician should re-assess all of 
these children, applying appropriate ruling in strategies through 
additional testing available at the hospital and reassuring parents if 
further testing remains negative. Children with a CRP test result 
between 20 and 75 mg/L and “yes” to any of the sequential questions in 
the decision tree, should be seen by a consultant, and if “no” to all 
questions, we advise to install a pro-active safety net by having parents 
re-visit the hospital within a desirable time frame, e.g. 24 hours. Children 
with a CRP test result below 20 mg/L can be discharged safely if parents 
are advised when and how to seek further help if certain alarm signs are 
present in their acutely ill child (passive safety net). (Figure 5.5) In 
contrast to the GP setting, this decision tree starts off with two CRP 
thresholds, adding in assessment of clinical features depending on the 
CRP level. This is a deterministic approach and requires appropriate 
safety measures to be put in place to avoid decision-making on the CRP 
level alone. 
 
Our newly developed decision tree focuses on a broad composite 
outcome of serious infections, instead of limiting detection to one 
specific outcome. This is especially relevant in children who initially 
present with generic symptoms potentially leading to different final 
diagnoses.  
Our newly developed decision tree contains several predictors (and 
thresholds) similar to the NICE guideline on feverish illness in 
children.[13] However, we advise future updates should also include 
POC CRP testing, as well as parental concern and effect of antipyretics. 
Our analyses suggest focussing triage in specialist settings on predictors 
measureable by junior doctors or trained triage nurses, optimizing 
consultants’ time allocation. 
 
Future research 
Although our newly developed multivariable triage instrument is one of 
the very few based on existing recent research,[13-17] rather than 
expert consensus, it should be validated prospectively in a new but 
similar specialist paediatric population. Validating and improving a 
clinical prediction rule should prepare the algorithm for impact analysis 
and further dissemination.[18] We believe we have met these 
requirements by means of a pragmatic approach throughout our 
analyses of the 4-step decision tree, ensuring the components of the 
clinical prediction rule to be clinically sensible, comprehensible and 
appropriate for the purpose of the rule.  
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Further research should focus on the implementation of this validated 
model in combination with POC CRP and evaluate the cost-
effectiveness of applying such an algorithm in terms of healthcare 
expenditures (e.g. avoidable admissions, costs per test and quality 
control of the POC devices).  
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Appendix 5.2: Scatter plot of C-reactive protein test result (fingerstick) 
and duration of fever (days). 
C-reactive protein (CRP) test results are depicted in mg/L. After day 5 a clear drop in the 
number of high CRP values can be observed, with only 1 outlier at day 8 above 100 mg/L. 
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GENERAL DISCUSSION 
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Missing a diagnosis of serious infection in acutely ill children troubles 
every physician. Ten years ago, little research was performed on the 
value of signs and symptoms in diagnosing serious infections in acutely 
ill children in primary care. Most research originated from emergency 
department settings,[1-4] often not applicable to general practice, with 
differences in prevalence and patient characteristics. Evidence has 
shown that setting influences the value of different diagnostic tests, 
potentially rendering them useless in primary care.[5]  
 
The Belgian healthcare system allows for unlimited access to paediatric 
outpatient clinics and emergency departments, alongside general 
practice. This provides us with a unique opportunity to examine acutely 
ill children in different urgent-access settings. The distribution of first-
contact consultations in acutely ill children are scattered across these 
three settings, limiting the applicability of clinical prediction rules, which 
were designed in a different specific healthcare system. A recent large 
survey in Flanders by one of the largest mutual health insurance 
companies even claimed that 89% of parents preferred to consult the 
paediatrician directly.[6] This figure however is probably out-dated, as 
availability of outpatient paediatric care and improved collaboration 
between primary care paediatricians and GPs now call for a more 
stepwise and collaborative approach of acutely ill children. 
 
A prospective cohort study in 2006 including over 4000 children in 
primary care resulted in the development of a clinical decision tree 
based on signs and symptoms to diagnose serious infections in acutely 
ill children.[7]  
In a new but similar paediatric population with nearly 9000 inclusions, we 
validated the existing clinical prediction rule, derived in primary care, 
rigorously applying the same criteria as the derivation study for inclusion, 
exclusion and outcome definition. Approximately 0.7% of all children 
within this age range and 1.5% of all children below 5 years of age in 
Flanders were recruited.[8] 
We used a pragmatic approach to facilitate the uptake of a symptom-
based decision tree in further impact analysis and implementation and 
added the results of a point-of-care (POC) C-reactive protein (CRP) test 
to improve the rule’s diagnostic performance, resulting in a stable model. 
Although residual uncertainty was present based on the available 
confidence intervals, we do not believe that future research will be able 
to refute these findings.  
This improved prediction rule can effectively rule out serious infection in 
primary care and reduce the number of children without a serious 
infection deemed at high risk based on symptoms alone by applying a 
low CRP threshold.  
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As long as appropriate safety netting is installed to cope with potentially 
avoidable referrals or additional testing, this decision tree with POC CRP 
is ready to be implemented in general practice. 
A decreasing incidence of serious infections in acutely ill children in 
general practice (section I) and the increasing inability to collect such a 
large sample in a primary care setting might be considered as important 
hurdles to conduct similar research in the future.  
Future research should focus on the implementation of validated clinical 
prediction rules (section II) and POC tests (section III) and evaluate 
their cost-effectiveness when integrated in routine clinical care.  
As no clinical prediction rule is perfect at ruling in serious infections, 
research on the most effective content and methods of delivery of 
appropriate safety netting advice (section IV) in ambulatory care is 
essential. 
 
 
I. INCIDENCE OF SERIOUS INFECTION IN ACUTELY ILL CHILDREN 
 
Serious infections in children are usually defined as sepsis (including 
bacteraemia), meningitis, pneumonia, complicated urinary tract infection, 
bacterial gastroenteritis with dehydration, osteomyelitis, and cellulitis.[9] 
In contrast, acutely illness is one of the most common presentations of 
children to ambulatory care.  
Infections account for 40% of all new episodes in general practice and 
29% of all consultations in all ages in the UK.[10]  
The total incidence of acute illness in primary care in children between 0 
and 14 years of age is approximately 1.1 acute infections per child per 
year in Flanders, with even higher numbers in children below 4 years of 
age.[11]  
The incidence of serious infections has declined over the past 
decade,[12] due to vaccination strategies and improvements in neonatal 
care, amongst other reasons. The immunization against Neisseria 
meningitidis serogroup C (in 2001), Haemophilus influenzae (2002), and 
Streptococcus pneumoniae (2007) has played an important role in this 
decline in Belgium. Observing a similar prevalence of serious infections 
in general practice in our study (0.3%) with a 9-year time interval since 
the 4-step decision tree derivation study (0.4%) assumes this decline to 
be stable.  
However the increase and selection of other bacterial serotypes due to 
vaccination strategies, e.g. serotypes not included in the 13-valent 
pneumococcal vaccine for pneumococcal disease or serotype B for 
meningococcal disease, is still concerning healthcare policy makers 
worldwide. The development of novel vaccines against serotype B might 
substantially change the epidemiology of meningococcal disease in the 
future.[13, 14] 
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In a recent study at a Belgian emergency department, we found an 
incidence of 11%, with most serious infections in children below 4 years 
of age,[15] comparable to data up to 2007 in a study from the 
Netherlands.[16] A lower prevalence was found in two recent 
prospective studies in similar settings in the UK and Australia, with 
numbers comparable to our results in the specialist settings.[17, 18] A 
different definition of the composite outcome of serious infections might 
explain this difference in prevalence, e.g. the inclusion of viral infection 
with hypoxia or dehydration requiring a hospital admission in one 
study.[15]  
 
Serious infections in primary care are dominated by pneumonia, with 
urinary tract infections in second place, and very few cases of sepsis, 
meningitis, or osteomyelitis.[7, 10] This was also the case in our study; 
we even did not observe any sepsis or meningitis cases in the GP 
setting.  
This evolution in diagnostic categories within the serious infections 
spectrum might influence the further development and validation of 
clinical prediction rules: we may need to focus on pneumonia and UTI 
cases as sepsis or meningitis become less and less prevalent or even 
non-existent in this setting, rendering research on these cases almost 
impossible. 
 
Even in the specialist setting (paediatric outpatient clinic and emergency 
department), we found only 1 out of 17 cases of meningitis to be of 
bacterial origin (post-neonatal Group B Streptococcal infection) and only 
1 case of meningococcal sepsis, limiting the validity of clinical prediction 
rules developed to identify meningitis or sepsis based on skin and other 
clinical features, derived in an era that was dominated by meningococcal 
disease.[19, 20] Furthermore, the difficulty to identify serious infections 
will most likely increase at a declining prevalence, especially in the early 
stage of the disease when signs and symptoms are unspecific, even for 
meningococcal disease.[21, 22] A shift to a larger proportion of viral 
causes amongst the few meningitis-cases with often an atypical 
presentation at first-contact might complicate things even further.[22] 
 
Luckily, none of the recruited children died during our study period. 
In the past century, child mortality has fallen to very low rates in all 
developed countries. However, rates between and within countries vary 
widely. In a survey of infection-related deaths of children aged 1 month 
to 14 years of age between 2003 and 2005 before widespread 
immunization against Streptococcus pneumoniae, 1368 infection-related 
deaths were documented in England and Wales, 20% of all deaths in 
this age range.[23]  
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Although declining in prevalence, meningococcal disease is still the most 
common fatal bacterial infection, accounting for 24% of all deaths due to 
infectious diseases in children aged 1 month to 14 years.  
 
Although the incidence has dropped over the past decade as mentioned 
above, the overall incidence in Europe is still 7.37 cases per 100000 per 
year in children younger than 4 years.[24] 
 
In 2012, 44 childhood deaths (0.004% of all children between 0 and 14 
years) in Flanders were caused by a serious infection. Infectious 
diseases are responsible for 13.8% of all deaths in children under the 
age of 1 year, and for 4.6% of deaths in children aged 1 to 14 years in 
Flanders.[25] 
Putting these numbers into a broader perspective of overall childhood 
mortality, allows healthcare policy to be adjusted on a larger scale. 
Considering the high health expenditures in Belgium, the high overall 
mortality (also including road traffic accidents) in infants and children 
aged 1 to 4 years [26] is troublesome and should trigger healthcare 
policy makers to invest in risk modifying strategies to prevent avoidable 
deaths in general in these children. 
To identify the factors that can modify this risk, national child death 
reviews are the first step to bring a broad perspective to the 
understanding why and how children die.[27] Health-system factors (e.g. 
training of paediatric caregivers to meet the needs of a diverse paediatric 
population) and socio-economic factors (e.g. ethnic origin, income 
inequality, access to care) can be considered important starting points to 
influence the risk of future deaths.[28] 
 
 
II. DEVELOPMENT OF CLINICAL PREDICTION RULES 
 
The term clinical prediction rules covers a wide spectrum, but is usually 
defined as a clinical tool that quantifies the contribution of history taking, 
physical examination and (technological) diagnostic tests to stratify 
patients according to the probability of having a target disorder. Although 
other terms, such as “clinical prediction tool” or “clinical decision rule” 
have been suggested, clinical prediction rule is the most widespread 
used expression.  
 
There is a widely accepted methodology for the development of clinical 
prediction rules.[29-31] The derivation of a clinical prediction rule is the 
first of three steps required before it can be disseminated and used in 
practice. This is followed by internal and external validation before finally 
testing the impact of its use on clinical outcomes.  
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These steps require cumulative levels of evidence and the adoption of 
several types of study designs to answer the relevant research and 
clinical questions. The increasing number of clinical prediction rules 
reported in the literature have a tendency to focus on the derivation 
stage with only a minority progressing to validation and very few 
undergoing impact analysis.[32, 33] 
 
In a recent developed international register of clinical prediction rules 
clinical prediction rules for use in primary care, 434 unique clinical 
prediction rules were identified of which only 54.8% had been validated 
and 2.8% had undergone formal impact analysis. Most of these rules 
were developed for cardiovascular disease, respiratory, and 
musculoskeletal conditions.[34] 
 
Clinical prediction rules are commonly derived through development 
techniques available for multivariable algorithms. 
A few scoring systems, however, have been derived from bivariable 
analysis, such as the Alvarado score for acute appendicitis and the 
modified Glasgow score for acute pancreatitis.[35] Others are based on 
expert opinion, such as the APGAR score,[36] which after 50 years still 
remains valid and firmly embedded in routine care.[37]  
A multivariable approach therefore does not guarantee better 
performance in subsequent validation, but has the main advantage (in 
most methods) of taking into account interactions between clinical 
predictors, adjusting for over-fitting and running diagnostics on the final 
model to locate cases with excessive influence on the model, enhancing 
the robustness of the final model. 
 
The methods used to derive a multivariable algorithm are diverse and all 
have their advantages and disadvantages. 
In our analyses, we preferred to use classification and regression tree 
(CART) analysis, a decision tree building method, based on non-
parametric tests. It uses the most discriminative test at every node and 
dichotomizes continuous variables. It allows for multiple cross-validation 
and defining the minimum size split, avoiding over-fitting of the final 
model. It deals with missing values in an intelligent way, through 
surrogate splits and allows users to attribute weights to misclassification 
of cases. It is however prone to variability in the resulting trees and 
usually a large sample size is required, as was the case in our study.[38] 
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Other methods were considered less appropriate for our analyses: 
(1) Simple tree building, although able to account for interactions, 
requires a deliberate choice of variables and their thresholds, which 
is almost impossible in datasets with a large number of tests or tests 
with continuous outcomes. 
(2) Multiple logistic regression is a reasonably fast technique, again 
allowing for interactions and easy handling of continuous variables, 
as well as predicting multiple outcome categories (polytomous 
logistic regression). The main issue is the exclusion of subjects with 
missing values, unless an imputation of missing values technique is 
used, such as multiple imputations (often used inappropriately when 
the assumption of “missing at random” is clearly violated).[39, 40]  
In our analyses, multiple imputation was not feasible, because the 
assumption of “missing at random” was probably violated, i.e. 
clinicians tend to record abnormal findings more often than normal 
findings. As a result, logistic regression was deemed unsuitable for 
our analysis. 
(3) Other methods, originating form machine-learning methods, such as 
neural networks, random forests and Bayesian networks can be 
quite powerful and precise in their predictions, but are not for 
inexperienced researchers and or often considered to create a 
“black box phenomenon”, and also struggle with missing values. We 
tested a number of such strategies on the data by Van den Bruel et 
al.[7] None of them superseded the performance of the initial 
analysis, which was performed using CART.[41] 
 
Very few clinical prediction rules have undergone extensive validation, 
limiting the ability of clinicians or guideline groups to truly evaluate their 
performance and balance benefits and harms.[42] Clinical prediction 
rules tend to perform worse when validated in a new setting.[43] Often 
clinical prediction rules are only internally validated through split-sample 
or cross-validation, simply assessing the precision of a clinical prediction 
rule within its derivation sample. Naturally, this leads to an optimistic 
estimate of performance.[44] Narrow validation with similar conditions as 
the derivation cohort and broad validation in multiple different settings or 
different populations are essential to prepare a rule for further 
dissemination.  
 
In our study we have validated the existing clinical prediction rule in a 
new but similar population at multiple sites (Chapter 3: temporal and 
geographic validation) and examined the diagnostic value in an 
international network of urgent-access ambulatory care settings 
(Chapter 1: broad fully independent validation). Chapter 5 describes 
updating of the clinical prediction rule with a new test, namely POC CRP 
testing. 
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Recently, a statement regarding the reporting of multivariable prediction 
models for individual prognosis or diagnosis (TRIPOD) has been 
developed to improve the transparency of the reporting of prediction 
model studies regardless of the study methods used.[45] It includes a 
checklist recommended to authors of such studies. We believe we have 
met these criteria throughout this thesis and fully support the 
dissemination of the TRIPOD statement. 
 
The integration of a validated clinical prediction rule into routine clinical 
practice presents a number of challenges, including mode of delivery of 
the clinical prediction rule at the point-of-care and the applicability of a 
clinical prediction rule derived in one setting to a new setting.[46]  
 
The components of the clinical prediction rule should be clinically 
sensible, comprehensive and appropriate for the purpose of the rule. 
Preparing the rule for impact analysis and implementation includes 
identifying potential barriers to the use of the clinical prediction rule. For 
instance, an Australian impact analysis study of the Ottawa ankle rule 
considered and addressed barriers at an organizational, individual and 
societal level before conducting their study.[47]  
 
Another important consideration is determining how the clinical 
prediction rule will be integrated into the clinical workflow. This may be 
achieved in different ways, for instance, incorporation of the clinical 
prediction rule as part of a broader guideline implementation and 
embedding the clinical prediction rule into clinical software or a 
computerized clinical decision support system (CDSS), as these have 
shown to modify physicians’ test ordering behaviour.[48, 49] The use of 
digital point-of-care tests for e.g. vital signs or biomarkers 
communicating with the electronic medical record might enhance the 
uptake of the clinical prediction rule. 
 
In the next phase, we need to determine whether the clinical prediction 
rule is effective; does it improve the process of clinical care, patient 
outcomes and increase cost-effectiveness.[30] Other important 
considerations are patient satisfaction and quality of life measures. They 
often require a (clustered) randomized trial. 
If the impact analysis study shows a clinical prediction rule to be 
effective then the focus shifts to the translation of the clinical prediction 
rule from a research setting into everyday clinical practice delivered by 
the wider community of clinicians.[50] Re-evaluation after widespread 
implementation, e.g. through continuous morbidity registration 
networks,[51] can contribute to the success of this process. 
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III. USE OF POINT-OF-CARE TESTING IN GENERAL PRACTICE 
 
Point-of-care (POC) tests are used at or near the site of the patient. 
They usually do not require permanent dedicated space and are 
performed outside the clinical laboratory, although a few exceptions 
occur (e.g. blood gas analyser in intensive care units or B natriuretic 
peptide testing in the core lab).  
 
General practitioners used to pride themselves for being the “low 
technology medicine”, which embodied a human and cheap approach to 
medicine. However, even Hippocrates was an experienced uroscopist, 
examining urine in 400 BC (admittedly only as a prognostic indicator) 
and eventually Theophilus introduced a innovative doctrine to use 
uroscopy for diagnosis of illnesses in 700 AD.[52]  
Dipstick urinalysis is still the most used point-of-care test available in 
primary care to support diagnosis for a wide range of conditions. 
 
There have been some POC devices (ultrasound devices, quick blood 
counts) available for research purposes in the early ‘90s, which were 
abandoned because they were too expensive, too large, and usually a 
combination of the above.  
 
At present, devices are considerably smaller, more affordable, but more 
importantly, due to increasing research performed on biomarkers in 
primary care, more relevant to support clinical decision making. 
 
Likewise, the industry is not missing out, moving devices from the 
professional setting at the lab to more non-traditional scenes as the GP’s 
office and even patient self-monitoring. There are still discrepancies 
between the devices developed by industry and the needs of healthcare 
professionals in the field, but improved communication and interactions 
between industry, academia, and end-users might narrow this gap. 
 
The development of POC tests is driven by many factors, such as testing 
opportunities (e.g. International Normalize Ratio (INR) testing at home, 
blood gas or cardiac enzymes at emergency scenes, Malaria-testing in 
refugee camps) as well as counselling opportunities (e.g. INR testing at 
the GP’s office, HIV testing in STD clinics). 
 
POC testing takes up 31% of the global in-vitro diagnostics market, and 
from 2009 to 2016 the US POCT market is expected to show a 
compound annual growth of 9.2%.[53]  
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EU governments see decentralized testing as a way to control the cost 
of delivering healthcare to their aging populations. They have started 
placing greater emphasis on the prediction and prevention of disease 
through more proactive diagnostics. As a result an increase is expected 
in the number of POC testing conducted as well as the POC testing 
locations, which do not have a legal framework yet.[54] 
 
A recent survey in 5 countries (Australia, Belgium, The Netherlands, UK, 
and USA) examined the current and future use of point-of-care tests by 
primary care doctors.[55] Although differences exist between countries, 
POC tests have not generally been adopted in primary care. Barriers in 
primary care clinicians’ attitudes towards blood POC tests include 
concerns about accuracy, over-reliance on tests and limited usefulness. 
Facilitators include improved diagnostic certainty, targeting of treatment, 
communication and shared decisions.[56]  
Exploring the needs of clinicians can also benefit successful 
development and implementation of new tests. Infections were 
mentioned as one of the top 5 conditions for which Belgian respondents 
would like a POC test.  
Although 75% of Belgian GPs would like to use POC CRP, only 3% 
actually currently used it, probably due to overlap with the participating 
GPs in our validation and added value of CRP study, as compared to 
48% of GPs in the Netherlands (overall 19% in all five countries).  
A POC CRP test was desired by more than half of respondents across 
all countries.[55]  
 
The desired POC tests as well as conditions that clinicians claim POC 
tests would help them diagnose, should be the focus of future research. 
The current evidence-base for test effectiveness in acutely ill children in 
primary care is very mixed, although new projects, such as the Horizon 
Scanning reports by the Monitoring and Diagnosis Workgroup in Oxford 
are trying to bridge that gap as well as other recent work.[57-60] 
 
Based on our experience, we suggest that the perfect POC test should: 
(1) measure (preferably) several relevant tests 
(2) be portable (e.g. fit a doctor’s bag: 6 x 4 x 2 inches) 
(3) be easy to use (e.g. no or few wires) 
(4) have strong batteries 
(5) allow repetitive testing (e.g. for monitoring or re-assessment) 
(6) have a high resolution screen 
(7) provide fast results (ideally less than 2’, maximum 5’) 
(8) be reliable and valid 
(9) be non invasive (except for biomarkers using capillary blood) 
(10) transfer data wirelessly e.g. to a handheld device and the electronic 
medical record of the physician or hospital 
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Several issues should be addressed before widespread use of POC 
testing in primary care can be advocated.  
 
We should: 
(1) examine the cost-effectiveness of a POC test in all applicable target 
conditions in terms of healthcare gain and expenditures. 
(2) involve end-users and patients in the implementation and use of the 
point-of-care tests. 
(3) anticipate the complexity of data management generated by the 
POC tests and maintain a clear oversight. This includes training of 
healthcare professionals (and patients) and regular competency 
assessment, appropriate quality control documentation, planned 
quality performance, scheduled reporting, standardized billing and 
reimbursement strategies, managing multiple testing platforms, and 
interlinking vendor specific versus vendor neutral data management 
systems (interfaces to laboratory and hospital information systems). 
(4) ensure that multiple instruments and multiple cartridges perform 
adequately and produce reliable results. 
(5) establish a framework for verification and monitoring of analytical 
performance, including quality control, calibration verification, 
analytical measurement range verification, and regular check 
method comparability. 
 
To ensure optimal analytical performance and user-friendliness of the 
device, I have conducted a pilot study on the selected POC CRP test, as 
described in Chapter 4.  
 
For internal quality control, control positives provided by the 
manufacturer were measured at regular intervals to confirm the efficacy 
and correct performance of the test according to the manufacturer’s 
instructions during the added value of CRP study (Chapter 5). A Failure 
Modes and Effects Analysis (FMEA) was performed with promising 
results to assess ease-of-use and the risk of measurement failures, 
although with some recommendations concerning error feedback and 
quality control. Collaboration with a centralized clinical laboratory would 
be desirable to avoid such issues. 
 
As this thesis is being written, I am already preparing a first meeting with 
interested stakeholders (clinical biologists, general practitioners, 
academics) to discuss the framework of potential future implementation 
strategies of point-of-care testing in primary care after thoroughly 
investigating cost-effectiveness and acceptability of the proposed tests 
by end-users and patients. 
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Although communication between general practice and other partners in 
the field of POC testing are not yet optimal, contacts with other 
specialties (clinical laboratory, specialists, healthcare policy makers) and 
industry are increasing. Other opportunities, such as the increase of 
miniaturization of POC tests, the experience and network for testing 
accuracy and added value of POC tests, as well as the commercial 
value of deploying POC testing in general practice, might influence 
future development and research in the field of point-of-care testing in 
primary care. 
 
 
IV. SAFETY NETTING IN ACUTELY ILL CHILDREN 
 
A single test will never reach perfect sensitivity and specificity in real life. 
Clinicians need to deal with an ever-present level of clinical uncertainty. 
To tackle this, physicians often put a safety net in place, informing 
parents when to re-contact and which alarm signs are relevant to 
monitor.  
 
GPs have to deal with situations with a very low likelihood of an 
underlying serious disease on a daily basis. They often rely on their gut 
feeling and apply safety netting, however little is known about the 
optimal use of these strategies.[61] Neighbour first introduced the term 
safety netting, and considered it as one of the compounds of a good 
consultation. It is described as creating a contingency plan and 
implementing procedures to ensure that the plan works out and that the 
patient is safe in any (un)-foreseen eventualities.[62]  
Safety netting appears to play an important role in repeated medical help 
seeking for children with fever. A telephone questionnaire revealed that 
parents who were not ‘safety netted’ by their doctor were more likely to 
seek further care.[63]  
 
Almond et al. provided a more detailed explanation of the content of 
safety net advice in relation to illnesses in children seen in general 
practice. Consensus was reached among general practitioners and 
paediatric emergency department consultants on five statements based 
on a modified Delphi approach. It should include: the existence of 
uncertainty, what exactly to look out for, how exactly to seek further help 
and what to expect about time course. The authors found no consensus 
about how this advice should be provided (e.g. verbal, written or other 
formats).[64]  
 
In our prospective study (Chapter 3) as part of the clustered randomized 
controlled trial by Lemiengre et al,[65] a parent leaflet was used, 
depicting which signs to look out for and when to contact their physician. 
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This evidence-based leaflet was in accordance and approved by the 
Flemish agency for the well being of young children and their families 
(Kind en Gezin). The leaflet was adjusted based on suggestions by 
parents of various education levels visiting a health care centre who 
were asked to read the leaflet at their GP’s office. Analyses of these 
interventions are still on-going. 
 
The NICE guideline on feverish children recommends GPs to use safety 
netting by means of a traffic light system, discussed in Chapter 1 and 
2.[66] Though it appears to be an important tool for clinicians, only few 
studies examined the actual use of this safety netting advice. 
 
A recent qualitative study by Jones et al. noticed a range of safety 
netting techniques with many inconsistencies, concerning their relative 
effectiveness on a variety of outcomes such as referrals, admission 
rates, re-attendance to health care and parental understanding, anxiety 
and satisfaction.[67] The participating clinicians were unaware of any 
existing guidelines; neither did they receive any specific training on the 
subject. 
 
In another recent qualitative study, interviewing 37 GPs, we found that, 
although GPs are unfamiliar with the term safety netting, they frequently 
apply such advice applying gut feeling and intuition. What’s more, they 
do not feel a need for guidelines or any other formal form of support. 
The content of their advice remains the same when dealing with different 
types of patients, but they adjust the wording to patient’s characteristics 
and the illness in question. Checking whether parents understood the 
given advice proved to be rather difficult.[68] 
Safety netting offers a useful framework for the patient's parents and 
improves the doctor patient relationship. Furthermore, safety netting can 
avoid legal issues. It fulfils an educational role and probably aids in 
reducing overconsumption of investigations, doctor visits and antibiotics.  
 
Whether it is verbal advice, patient leaflets, or new forms of 
communication through social media, it is certain that physicians need to 
adopt these instruments to deal with the ever-present clinical 
uncertainty. 
 
Serious infections are rare. To avoid serious complications or death, 
early recognition is crucial. Our analyses have improved detection of 
serious infections in general practice, without increasing the number of 
avoidable referrals or additional testing. In specialist settings POC CRP 
can help triage children. Future research should focus on the 
implementation of this decision tree, as well as defining the content of 
the advice given to parents of acutely ill children. 
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Background: Acute infection is the most common presentation of children to 
ambulatory care. In contrast, serious infections are rare and often present at an 
early stage. To avoid complications or death, early recognition and adequate 
referral are essential. In a recent large study children were included prospectively 
to construct a symptom-based decision tree with a sensitivity and negative 
predictive value of nearly 100%. To reduce the number of false positives, point-
of-care (POC) tests might be useful, providing an immediate result at the bedside. 
The most probable candidate is C-reactive protein. Every clinician should 
reassure anxious parents of children with self-limiting illnesses. The improvement 
of diagnostic algorithms, the addition of technological devices and the sensible 
use of safety netting procedures could improve prognosis of seriously ill children. 
 
Methods: First, we externally validated clinical prediction rules, identified by a 
systematic review, in 7 urgent-access datasets, as well as comparing these 
results to recent findings in other studies. After zooming in on the diagnostic 
value of the clinical prediction rules based on vital signs with potential to 
differentiate serious infections from the majority of self-limiting illnesses in an 
inpatient paediatric setting in the UK, we focused our analyses on the temporal & 
geographic validation of the decision tree based on signs and symptoms in a new 
but similar population in Flanders. We examined the analytical accuracy and 
user-friendliness of a POC test after careful selection of a device that meets all 
our requirements. Finally we explored the added value of the selected POC CRP 
test in a prospective diagnostic accuracy study in three different ambulatory care 
settings: general practice, outpatient paediatric clinic, and the emergency 
department. 
 
Results: In low to intermediate prevalence settings the 4-step decision tree and 
evidence-based guidelines had high sensitivity, providing promising rule-out value 
for serious infections in 7 datasets. The paediatrician’s overall illness assessment 
was the most useful feature to rule in sepsis or meningitis in a study of 
hospitalized children. Temporal validation of the 4-step decision tree indicated 
that this practical tool for diagnostic triage of acutely ill children in primary care is 
valid and ready to be implemented in routine care, if appropriate safety netting or 
additional testing is applied. The selected POC CRP test was accurate in children 
and should be considered reliable and user-friendly. Adding point-of-care CRP 
test results to the 4-step decision tree helped identifying serious infections in the 
GP setting and can potentially reduce the number of investigations and 
admissions in children with non-serious infections. I propose a new decision tree 
to be used in specialist settings as a triage instrument to safely rule out serious 
infections. 
 
Discussion: The incidence of serious infections has declined over the past few 
years, amongst other reasons, due to vaccination strategies and improvements in 
neonatal care. Before a clinical prediction rule can be implemented in routine 
care, it has to go through several stages of development and testing. A single test 
will never reach perfect sensitivity and specificity in real life. To tackle the ever-
present clinical uncertainty, physicians often put a safety net in place, informing 
parents when to re-contact and which alarm signs are relevant to monitor. I put 
an emphasis on these issues and offer a perspective for future developments in 
the field of point-of-care testing in serious infections in paediatric primary care.
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Appendix IV: samenvatting. 
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Acute infectie is één van de meest voorkomende ziektebeelden bij 
kinderen in de eerste lijn. 
Daarentegen zijn ernstige infecties zeldzaam bij kinderen in de westerse 
wereld, maar geassocieerd met aanzienlijke morbiditeit en mortaliteit. 
In Vlaanderen zijn infectieziekten verantwoordelijk voor 13.8% van alle 
overlijdens in kinderen onder 1 jaar, en 4.6% van alle kinderen tussen 1 
en 14 jaar. Ernstige infecties bij kinderen worden meestal gedefinieerd 
als sepsis (inclusief bacteriëmie), meningitis, pneumonie, 
gecompliceerde urineweginfectie, bacteriële gastro-enteritis met 
dehydratatie, osteomyelitis en cellulitis. 
 
Zaak is deze ernstige infecties te onderscheiden van de grote groep van 
zelflimiterende infecties bij kinderen. In de eerste lijn, zal minder dan 1% 
van de acuut zieke kinderen evalueren naar een ernstige infectie.  
De incidentie van ernstige infecties bij kinderen is 5 tot 10 maal hoger op 
de pediatrische spoedafdeling.  
 
In een recente studie werden meer dan 4000 kinderen prospectief 
gerekruteerd om een beslisboom te ontwikkelen op basis van tekens en 
symptomen. De beslisboom had een sensitiviteit en negatief 
voorspellende waarde van bijna 100%. Echter de kans van een ernstige 
infectie bij kinderen die positief testen was ongeveer 6%. In dit 
proefschrift hebben we deze beslisboom gevalideerd in een nieuwe 
populatie en de toegevoegde waarde van point-of-care (POC) testen 
onderzocht in de diagnose van ernstige infecties bij acuut zieke kinderen 
in de eerste lijn. 
 
POC testen zijn laboratorium- en andere testen die men kan uitvoeren 
en analyseren nabij de patiënt. De arts heeft dadelijk resultaat en kan 
het beleid onmiddellijk aanpassen. Deze testen zijn vooral interessant 
wanneer een snelle beslissing nodig is, zoals bij een spoedgeval. Ze zijn 
minimaal invasief en dus relevant in de pediatrische eerstelijnszorg. 
 
Een systematische review identificeerde de laboratoriumtesten die 
bruikbaar zijn bij ernstige infecties bij kinderen met koorts in de 
ambulante praktijk. C-reactief proteïne (CRP) werd weerhouden als één 
van de beste kandidaten. 
De huisarts gebruikt vaak vangnet-advies om het ziekte-inzicht van de 
patiënt (en ouders) te toetsen en advies te geven over alarmsignalen en 
wanneer opnieuw contact op te nemen.  
De verbetering van diagnostische algoritmen, de toevoeging van point-
of-care testen en het correct gebruik van vangnet-advies kan de 
prognose van ernstig zieke kinderen verbeteren. 
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DOELSTELLINGEN 
De onderzoeksvraag van dit proefschrift was: 
"Naast het meten van de klinische tekens en symptomen, kan nieuwe 
of bestaande technologie de vroegtijdige herkenning van ernstige zieke 
kinderen in de eerste lijn verbeteren?" 
 
In hoofdstuk 1 zijn we dieper ingegaan op de klinische beslisregels 
geïdentificeerd door een recente systematische review gebaseerd op 
vitale tekens en symptomen. We hebben deze proberen valideren in 7 
datasets van acuut zieke kinderen en heb de resultaten vergeleken 
met recente bevindingen uit andere studies. 
Hoofdstuk 2 zoomde in op de waarde van de klinische beslisregels 
bestaande uit vitale tekens om ernstige infecties te onderscheiden van 
niet-ernstige infecties in een pediatrische ziekenhuisafdeling in het 
Verenigd Koninkrijk. 
Hoofdstuk 3 beschreef de resultaten van onze validatie van een 
beslisboom op basis van tekens en symptomen in een nieuwe, maar 
vergelijkbare populatie in Vlaanderen.  
Hoofdstuk 4, in voorbereiding van de grote prospectieve studie, betrof 
een haalbaarheidsstudie over het gebruik van de gekozen POC test in 
de pediatrische zorg. We bestudeerden de analytische nauwkeurigheid 
en gebruiksvriendelijkheid van een geselecteerde POC test na 
zorgvuldige selectie van een POC test die voldeed aan al onze 
voorwaarden. 
Hoofdstuk 5 beschreef de resultaten van de prospectieve 
diagnostische accuraatheidsstudie, met tot doel de toegevoegde 
waarde van de POC CRP test in de eerstelijnsgezondheidszorg te 
verkennen. We richtten ons op de klinische bruikbaarheid van deze 
POC test in drie verschillende settings: de huisartspraktijk, de 
poliklinische kinderartspraktijk en de spoedafdeling. 
 
De incidentie van ernstige infecties is afgenomen in de afgelopen 
jaren, onder andere als gevolg van vaccinatiecampagnes en 
verbeteringen in de neonatale zorg. 
Alvorens een klinische beslisregel te implementeren in routinezorg, 
moet men verschillende stadia van ontwikkeling doorlopen. 
Een enkele test kan nooit perfect gevoelig en specifiek zijn. Clinici 
moeten omgaan met een altijd aanwezige klinische onzekerheid. 
Artsen gebruiken vangnet-advies door ouders te informeren wanneer 
opnieuw contact te nemen en welke alarmtekens in het oog te houden. 
De discussie beschreef deze vraagstukken, en trachtte een perspectief 
te bieden voor toekomstige ontwikkelingen op het gebied van POC 
testen in de diagnose van ernstige infecties bij kinderen in de eerste 
lijn. 
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KLINISCHE BESLISREGELS IN VERSCHILLENDE AMBULANTE SETTINGS 
Beslisregels worden gepropageerd als hulpmiddel om herkenning van 
ernstige infecties te verbeteren. Een recente systematische review 
identificeerde zeven klinische beslisregels, waarvan er slechts één 
prospectief werd gevalideerd. Ons doel was de diagnostische waarde 
van deze regels in verschillende ambulante zorg populaties verspreid 
over West-Europa te onderzoeken. 
Vier klinische beslisregels en twee nationale richtlijnen, op basis van 
klinische tekens en symptomen, werden retrospectief gevalideerd in 
zeven datasets, bestaande uit 11023 kinderen uit het Verenigd 
Koninkrijk, Nederland en België. In laag prevalente (LP) settings, 
hadden een 4-staps beslisboom en pneumonie-regel sensitiviteiten van 
>90% voor het uitsluiten van ernstige infecties. In intermediair 
prevalente (IP) settings, hadden de 4-staps beslisboom, pneumonie-
regel, en Yale Observation Scale sensitiviteiten tussen de 22 en 88%. 
In een hoog prevalente (HP) setting, leverde de 4-staps beslisboom 
een sensitiviteit van 23%. In LP of IP-settings varieerde de sensitiviteit 
van de “National Institute for Clinical Excellence (NICE)”-richtlijn voor 
kinderen met koorts en de alarmtekens van het Nederlands Huisartsen 
Genootschap van 81 tot 100%. 
Geen van de klinische beslisregels in deze studie leverde perfecte 
diagnostische nauwkeurigheid. In LP of IP-settings, had de 4-staps 
beslisboom en de evidence-based richtlijnen de hoogste sensitiviteit 
om  ernstige infecties uit te sluiten, steeds met een bepaalde 
hoeveelheid onzekerheid. Geen van de beslisregels geïdentificeerd 
leek nuttig voor HP-settings, zoals spoedafdelingen.  
 
KLINISCHE BESLISREGELS IN EEN PEDIATRISCHE ZIEKENHUISAFDELING 
Kinderartsen worden dagelijks geconfronteerd met de uitdaging om de 
enkele kinderen met meningitis of sepsis te onderscheiden van de 
grote groep met zelflimiterende ziekte. Ons doel was de diagnostische 
waarde van de klinische kenmerken en hun beslisregels te 
onderzoeken om kinderen met sepsis of meningitis te identificeren bij 
acuut zieke kinderen opgenomen in een regionaal ziekenhuis in het 
Verenigd Koninkrijk. 
Deze case-control studie liep tussen 2000 en 2005. We onderzochten 
de diagnostische accuraatheid van de individuele klinische tekens en 6 
beslisregels, waaronder het NICE stoplicht-systeem, om de klinische 
bruikbaarheid te bepalen bij het identificeren van kinderen met een 
diagnose van sepsis of meningitis. 
Verlies van bewustzijn, verlengde capillaire refill, verminderde 
alertheid, bemoeilijkt ademen, het oordeel van de arts dat het kind 
ernstig ziek was, hadden hoge positieve likelihood ratio’s (9-114) met 
brede betrouwbaarheidsintervallen, om sepsis of meningitis aan te 
tonen.  
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Het NICE stoplicht-systeem, de gewijzigde Yale Observation Scale, en 
de Paediatric Advance Warning Score deden het slecht met positieve 
likelihood ratio's, variërend van 1 tot 3. 
De beoordeling van de algemene ziekte-indruk door de kinderarts 
bleek de beste voorspeller van sepsis of meningitis bij deze 
gehospitaliseerde kinderen. Klinische beslisregels konden sepsis of 
meningitis niet effectief aantonen. Enkele klinische symptomen kunnen 
deze scores aanvullen om sepsis of meningitis aan te tonen. Verder 
onderzoek is nodig om deze beslisregels te valideren. 
 
VALIDATIE VAN DE 4-STAPS BESLISBOOM 
We valideerden de 4-staps beslisboom in een prospectieve 
diagnostische accuraatheidsstudie. Acuut zieke kinderen die zich 
aanmeldden bij een huisarts of kinderarts werden consecutief 
gerekruteerd in Vlaanderen. Artsen werd gevraagd de 4-staps 
beslisboom te scoren, naast een grondige klinische evaluatie en 
gebruikelijke zorg. De bestudeerde uitkomst was ziekenhuisopname 
meer dan 24 uur met een ernstige infectie binnen 5 dagen na eerste 
contact. We rapporteerden de diagnostische accuraatheid van de 
beslisboom in sensitiviteit, specificiteit en positief en negatief 
voorspellende waarden. 
We vonden een sensitiviteit en negatief voorspellende waarde van 
100% in de huisartsensetting, perfect dus om ernstige infecties uit te 
sluiten. 
Dit praktisch hulpmiddel voor diagnostische triage van acuut zieke 
kinderen in de eerste lijn bleek valabel en is klaar voor implementatie 
in routinezorg, op voorwaarde dat vangnet-advies en bijkomende 
testen worden aangewend. 
 
ANALYTISCHE ACCURAATHEID VAN EEN POC CRP TEST 
CRP is een acute-fase eiwit, gesynthetiseerd in reactie op een infectie 
of ontsteking. Veneuze bloedafname is niet evident bij kinderen in de 
ambulante praktijk. Een POC test op een druppel bloed geef dadelijk 
resultaat en is vooral nuttig bij kinderen. 
Vorige generaties van POC CRP testen bleken goede correlatie met 
standaard laboratoriumtesten te hebben in studies in de eerste lijn en 
spoedgevallen. Het meten van CRP zou kunnen bijdragen aan de 
klinische besluitvorming in de diagnose van een ernstige infectie. 
We konden de analytische accuraatheid van de Afinion POC CRP-test 
bevestigen in vergelijking met een immunoturbidimetrische CRP-test 
op een Cobas c702 toestel, zowel bij kinderen als volwassenen. Zelfs 
bij hoge CRP-concentraties, bleek de test nauwkeurig. De weinige 
verschillen tussen beide methoden bij lage CRP niveaus bleken 
klinisch niet significant. Alle deelnemende artsen en de 
hoofdonderzoekers achtten de test gebruiksvriendelijk. 
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TOEGEVOEGDE WAARDE VAN EEN POC CRP TEST IN DE AMBULANTE 
PRAKTIJK 
Om het aantal vals-positieve testresultaten op de gevalideerde 4-staps 
beslisboom in de eerste lijn te verminderen, zou de POC CRP-test een 
belangrijke rol kunnen spelen. 
In de diagnostische accuraatheidsstudie, hierboven vermeld, kregen 
kinderen die positief testten op de beslisboom een POC CRP-test. We 
rapporteerden de diagnostische accuraatheid van de beslisboom in 
combinatie met de POC CRP-testresultaten in sensitiviteit, specificiteit, 
positieve en negatieve likelihood ratio’s en positieve en negatieve 
voorspellende waarden. 
Het toevoegen van de resultaten van het POC CRP-test aan de 
beslisboom verhoogde de specificiteit naar 89.5% (95% CI 88.3-
90.5%), met een sensitiviteit van 100% (95% CI 71.5-100%) in de 
huisartsensetting. Een nieuw ontwikkelde beslisboom gebaseerd op 
eenvoudig-te-beoordelen klinische tekens werd ontwikkeld in de 
ziekenhuissetting, met een sensitiviteit van 97.1% (95% CI 94.3-
98.7%) en een negatief voorspellende waarde van 99.6% (95% CI 
99.2-99.8%). 
Het toevoegen van POC CRP-testresultaten aan een gevalideerde 
beslisboom hielp ernstige infecties te identificeren in de 
huisartsensetting en kan het aantal onderzoeken en opnames bij 
kinderen met niet-ernstige infecties mogelijk verminderen. Dit model is 
klaar voor implementatie in de huisartspraktijk. We stellen een nieuwe 
beslisboom voor als triage instrument om ernstige infecties uit te 
sluiten in de ziekenhuis setting. 
 
DISCUSSIE 
We hebben een bestaande klinische beslisregel, afgeleid in de eerste 
lijn, gevalideerd in een nieuwe maar vergelijkbare populatie van bijna 
9000 inclusies bij acuut zieke kinderen. We gebruikten een 
pragmatische aanpak om de disseminatie van de klinische beslisregel 
in de dagelijkse praktijk te vergemakkelijken en voegden de resultaten 
van een POC CRP test toe om de diagnostische waarde van de regel 
te verbeteren. Dit leidde tot een stabiel model effectief in het uitsluiten 
van ernstige infecties in de eerste lijn met het potentieel om het aantal 
vermijdbare verwijzingen en onderzoeken te reduceren.   
Toekomstig onderzoek moet zich richten op de implementatie van 
gevalideerde klinische beslisregels en POC testen en hun kosten-
baten evalueren. Aangezien geen enkele klinische beslisregel perfect 
is om ernstige infecties aan te tonen, is er onderzoek nodig naar de 
meest effectieve inhoud en toepassing van vangnet-advies in de 
ambulante praktijk. 
  
173 
A
P
P
E
N
D
IX
 V
 
Appendix V: summary. 
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Acute infection is one of the most common problems of children 
attending primary care. In contrast, serious infections are rare in children 
in developed countries, but associated with considerable morbidity and 
mortality. In Flanders, infectious diseases are responsible for 13.8% of 
all deaths in children under the age of one year, and for 4.6% of deaths 
in children aged 1 to 14 years. Serious infections in children are usually 
defined as sepsis (including bacteraemia), meningitis, pneumonia, 
complicated urinary tract infection, bacterial gastroenteritis with 
dehydration, osteomyelitis, and cellulitis.  
 
These serious infections need to be distinguished from the vast majority 
of self-limiting infections in children. In a primary care setting, less than 
1% of children assessed will have a serious infection. The incidence of 
serious infections in children is assumed to be 5 to 10 times higher at 
the paediatric emergency department, as seen in one of our recent 
studies. 
 
In a recent study, over 4000 children were included prospectively to 
construct a decision tree based on signs and symptoms. The decision 
tree had a sensitivity and negative predictive value of nearly 100%. The 
probability, however, of having a serious infection in children testing 
positive, was approximately 6%. In this thesis, I aimed to validate this 
decision tree in a new population and explore the added value of 
technological tests, such as point-of-care (POC) tests in diagnosing 
serious infection in acutely ill children in primary care. 
 
POC tests are defined as laboratory and other services provided to 
patients at the bedside. The physician has an immediate result and 
management can be adjusted accordingly. This makes them especially 
attractive in situations where a fast decision is warranted, such as 
urgent-access primary care. They are minimally invasive, and thus 
relevant in paediatric care.  
A systematic review identified the laboratory tests used to detect serious 
infections in febrile children in ambulatory settings. C-reactive protein 
(CRP) is one of the most probable candidates for this purpose.  
 
The general practitioner often puts a safety net procedure in place in 
order to clarify the patient’s knowledge of the current illness and to 
advice on alarming signs and when to re-consult in specific situations. 
The improvement of diagnostic algorithms, the addition of technological 
tests and the sensible use of safety netting procedures could improve 
prognosis of seriously ill children. 
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OBJECTIVES 
Vital signs and clinical features can play an important role in confirming 
or excluding the possibility of serious infection in children presenting to 
an ambulatory care setting. Van den Bruel et al. demonstrated that a 
decision tree based on signs and symptoms could be constructed with a 
negative predictive value of nearly 100%. If applied in clinical practice 
without caution, this decision tree could cause far too many children to 
be referred to specialist. 
 
The research question of this thesis was: 
“In addition to measuring clinical signs and symptoms, can new or 
existing technology improve the early identification of seriously ill 
children in primary care?”  
 
In chapter 1 we focused on the clinical prediction rules identified by a 
recent systematic review based on vital signs and symptoms only and 
try to validate these rules in an 7 urgent-access datasets, as well as 
comparing these results to recent findings in other studies. 
Chapter 2 zoomed in on the value of the clinical prediction rules based 
on vital signs with potential to differentiate serious infections from the 
majority of self-limiting illnesses in an inpatient paediatric setting in the 
UK. 
Chapter 3 described the results of a temporal & geographic validation of 
the decision tree based on signs and symptoms in a new but similar 
population in Flanders. 
Chapter 4 set the scene for a large prospective trial with a feasibility 
study on the use of the POC test in the intended setting, namely 
ambulatory primary care. We examined the analytical accuracy and 
user-friendliness of a selected POC test after careful selection of a 
device that meets all our preliminary requirements. 
Chapter 5 described the results of the prospective diagnostic accuracy 
study, aiming to explore the added value of selected POC tests in 
primary care. We focused on the clinical utility of these POC tests in 
three different ambulatory care settings: general practice, outpatient 
paediatric clinic, and the emergency department. 
The incidence of serious infections has declined over the past few years, 
amongst other reasons, due to vaccination strategies and improvements 
in neonatal care. 
Before a clinical prediction rule can be implemented in routine care, it 
has to go through several stages of development and testing. 
A single test will never reach perfect sensitivity and specificity in real life. 
Clinicians need to deal with an ever-present level of clinical uncertainty. 
To tackle this, physicians often put a safety net in place, informing 
parents when to re-contact and which alarm signs are relevant to 
monitor.  
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The final discussion put an emphasis on these issues and offered a 
perspective for future developments in the field of POC testing in serious 
infections in paediatric primary care. 
 
 
CLINICAL PREDICTION RULES IN DIFFERENT AMBULATORY CARE SETTINGS 
Prediction rules are promoted as a means to improve recognition of 
serious infections. A recent systematic review identified seven clinical 
prediction rules, of which only one had been prospectively validated, 
calling into question their appropriateness for clinical practice. We aimed 
to examine the diagnostic accuracy of these rules in different ambulatory 
care populations in Europe.  
Four clinical prediction rules and two national guidelines, based on signs 
and symptoms, were validated retrospectively in seven individual patient 
datasets from primary care and emergency departments, comprising 
11,023 children from the UK, the Netherlands, and Belgium. In low 
prevalence (LP) settings, a 4-step decision tree and a pneumonia rule 
had sensitivities of >90% (at a negative likelihood ratio (NLR) of < 0.2) 
for ruling out serious infections. In intermediate prevalence (IP) settings, 
the 4-step decision tree, the pneumonia rule, and YOS had sensitivities 
between 22 and 88%, with NLR ranging from 0.3 to 0.8. In a high 
prevalence (HP) setting, the 4-step decision tree provided a sensitivity of 
23%. In LP or IP settings, the sensitivities of the National Institute for 
Clinical Excellence guideline for feverish illness and the Dutch College of 
General Practitioners alarm symptoms ranged from 81 to 100%.  
None of the clinical prediction rules examined in this study provided 
perfect diagnostic accuracy. In LP or IP settings, the 4-step decision tree 
and evidence-based guidelines had high sensitivity, providing promising 
rule-out value for serious infections in these datasets, although all had a 
percentage of residual uncertainty. None of the prediction rules identified 
seemed to be valuable for HP settings such as emergency departments.  
 
 
CLINICAL PREDICTION RULES IN INPATIENT PAEDIATRIC SETTING 
Clinical staff at acute paediatric services faces the challenge of 
differentiating the few children with meningitis or sepsis from the majority 
with self-limiting illness. We aimed to determine the diagnostic value of 
clinical features and their prediction rules for identifying children with 
sepsis or meningitis among those children admitted to a District General 
Specialist (DGH) with acute febrile illness. 
Acutely ill children admitted to a DGH in England were included in this 
case-control study between 2000 and 2005. We examined the 
diagnostic accuracy of individual clinical signs and 6 clinical prediction 
rules, including the National Institute for Clinical Excellence ‘‘traffic light’’ 
system, to determine clinical utility in identifying children with a diagnosis 
of sepsis or meningitis.  
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Loss of consciousness, prolonged capillary refill, decreased alert- ness, 
respiratory effort, and the physician’s illness assessment had high 
positive likelihood ratios (9-114), although with wide confidence 
intervals, to rule in sepsis or meningitis. The National Institute for Clinical 
Excellence traffic light system, the modified Yale Observation Scale, and 
the Paediatric Advanced Warning Score performed poorly with positive 
likelihood ratios ranging from 1 to 3.  
The paediatrician’s overall illness assessment was the most useful 
feature to rule in sepsis or meningitis in these hospitalized children. 
Clinical prediction rules did not effectively rule in sepsis or meningitis. 
The modified Yale Observation Scale should be used with caution. 
Single clinical signs could complement these scores to rule in sepsis or 
meningitis. Further research is needed to validate these clinical 
prediction rules.  
 
 
TEMPORAL & GEOGRAPHIC VALIDATION OF THE 4-STEP DECISION TREE 
In a prospective diagnostic accuracy study we validated the 4-step 
decision tree for serious infections. Acutely ill children presenting to a 
general practitioner or paediatrician were included consecutively in 
Flanders, Belgium. Physicians were asked to score the 4-step decision 
tree, in addition to a thorough clinical assessment and their usual care. 
The outcome of interest was specialist admission more than 24 hours 
with a serious infection within 5 days. We reported the diagnostic 
accuracy of the decision tree in sensitivity, specificity, and positive and 
negative predictive values. 
Reaching both sensitivity and negative predictive value of 100% in the 
GP setting, the 4-step decision tree performed as intended, to rule out 
serious infections.  
This practical tool for diagnostic triage of acutely ill children in primary 
care has shown to be valid and is ready to be implemented in routine 
care, if appropriate safety netting or additional testing is applied. 
 
 
ANALYTICAL ACCURACY OF A POC CRP TEST 
CRP is an acute-phase protein, secreted in response to any infection or 
inflammation. Venous blood sampling can be difficult in children in 
ambulatory care. A POC test, provided at the bedside, presents an 
immediate result from a droplet of blood and is especially useful in 
children.  
Previous generations of POC CRP tests have shown good correlation 
with standard laboratory tests in studies in primary care and emergency 
departments. Measuring CRP could contribute to clinical decision-
making in diagnosing serious infection.  
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We were able to confirm the analytical accuracy of the Afinion POC CRP 
test in comparison with an immunoturbidimetric CRP test on a Cobas 
c702 device in children as well as in adults. Even at high CRP 
concentrations, the test demonstrated high agreement and precise 
measurements. The few differences between both methods in cases 
with low CRP levels were not found to be clinically significant, as they 
would not change decisions on further treatment or testing.  
All participating physicians and the principal investigators deemed the 
device user-friendly. 
 
 
ADDED VALUE OF A POC CRP TEST IN AMBULATORY CARE 
To reduce the number of false positive test results on the validated 4-
step decision tree in primary care, the POC CRP test might be useful, 
providing an immediate result at the bedside. 
 
In the diagnostic accuracy study, mentioned above, children testing 
positive on the decision tree got a POC CRP test. We reported the 
diagnostic accuracy of the decision tree in combination with the POC 
CRP test result in sensitivity, specificity, positive and negative likelihood 
ratios and positive and negative predictive values. 
 
Adding the results of the POC CRP test to the decision tree increased 
the specificity to 89.5% (95%CI 88.3 - 90.5%) while maintaining a 
sensitivity of 100% (95% CI 71.5 - 100%) in the GP setting. A newly 
developed decision tree, based on objective easy-to-assess clinical 
features was developed in the specialist setting, reaching a sensitivity of 
97.1% (95% CI 94.3-98.7%) and a negative predictive value of 99.6% 
(95% CI 99.2-99.8%). 
 
Adding POC CRP test results to a validated signs and symptoms-based 
decision tree helped identifying serious infections in the GP setting and 
can potentially reduce the number of investigations and admissions in 
children with non-serious infections. This model is ready for impact 
analysis and implementation in general practice. We propose a new 
decision tree to be used in specialist settings as a triage instrument to 
safely rule out serious infections. 
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DISCUSSION 
The Belgian healthcare system allows for unlimited access to paediatric 
outpatient clinics and emergency departments, alongside general 
practice.  
We have validated an existing clinical prediction rule, derived in primary 
care, in a new but similar paediatric population of nearly 9000 inclusions, 
rigorously applying the same criteria as the derivation study for inclusion, 
exclusion and outcome definition. We recruited approximately 0.7% of all 
children within this age range in Flanders and 1.5% of all children below 
5 years of age. 
We have used a pragmatic approach to facilitate the uptake of the 
clinical prediction rule in routine care and added the results of a POC 
test to improve the rule’s diagnostic performance, resulting in a stable 
model effective at ruling out serious infections in primary care, leaving a 
certain amount of potentially avoidable referrals or additional testing, 
where safety netting plays an important role. Although residual 
uncertainty was present based on the available confidence intervals, we 
do not believe that future research will be able to refute these findings.  
A decreasing incidence of serious infections in acutely ill children in 
general practice and the inability to collect such a large sample in a 
primary care setting might be considered as important hurdles to 
conduct similar research.  
Future research should focus on the implementation of validated clinical 
prediction rules and POC tests and evaluate their cost-effectiveness 
when integrated in routine clinical care.  
As no clinical prediction rule is perfect at ruling in serious infections, 
research on the most effective content and methods of delivery of 
appropriate safety netting advice in ambulatory care is essential. 
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Appendix VI: thanks to … 
 
 
 
 
 
 
    
 
182 
A
P
P
E
N
D
IX
 V
I 
Silent gratitude isn’t much use to anyone - G.B. Stern 
 
 
Writing up this thesis, I realised I have a lot to be thankful for. 
Above all for the people who surround me and support me. 
 
Frank, u heeft mij deze kans geboden en ik ben u enorm dankbaar om vanaf 
dag een in mij te geloven. Uw betrokkenheid is zeldzaam bij een promotor en 
uw kalmte heeft mij altijd weten geruststellen. Ik vergeet vaak context te geven 
bij een onderwerp, maar iedereen die Frank kent, weet dat dit niet nodig is, 
gezien u binnen 5 minuten de pijnpunten weet bloot te leggen. Ik ga ervan uit 
dat ik niet uw laatste doctoraatsstudent zal zijn en hoop nog veel met u te 
mogen samenwerken. 
 
Bert, als mijn adoptie-co-promotor, heeft u mij vanaf het begin geleerd in klare 
taal te spreken en niet te gaan zweven. Ik ben dankbaar voor uw oprechtheid 
en uw relativeringszin en ben trots met u als hoofd aan onze afdeling 
huisartsgeneeskunde. 
 
An, als copromotor vanuit UGent wist u altijd probleemloos de afstand te 
overbruggen, zij het fysiek dan wel via Skype. Uw aanmoedigende woorden 
hebben mij doorheen dit project tot in de laatste fase steeds weten motiveren 
om de lat hoger te leggen. 
 
Ann, een parabool snijdt een rechte in twee punten en ook zo was jij bij het 
begin en het einde van dit project betrokken. Het was even slikken toen jij naar 
Oxford trok, maar gezien mijn huidige affiliatie kan ik moeilijk zeggen dat ik daar 
spijt van heb. Ik wil u danken om nooit half werk te doen bij het 
becommentariëren van mijn teksten en het vertrouwen. Je kan op mijn 
enthousiasme rekenen voor verdere samenwerking. 
 
Marieke, toen we in 2009 voor de eerste keer samenzaten in Gent, droomden 
we beiden van een grote dataset van zieke kinderen. We hebben de nodige 
tegenslagen gehad bij de zoektocht naar financiering, maar dankzij onze 
gebundelde krachten zijn we er toch geraakt. Uw twee flinke zonen en onze 
Jonas kunnen getuigen dat we hard gewerkt hebben met toch de nodige balans 
tussen werk en privé. 
 
Tine, je hebt dit project ter harte genomen en mij in elke fase bijgestaan, van de 
torens registratieformulieren tot de jobstudenten-sweatshop tijdens de 
database-invoer. Zoals Bert zo eloquent bevroeg tijdens uw sollicitatie “Waarom 
komt een postdoc onderzoeker werken voor een snotneus zoals Jan?” Was het 
misschien onze bureau op de belle-vue van de afdeling of de ERNIE2-taarten 
met mascarponevulling? Ik denk dat het de werkethos en visie waren die we 
delen. 
 
Rafael, you made me feel welcome at the Department of Primary Care Health 
Sciences in Oxford. You are an inspiration for every clinician interested in 
biostatistics and have such a naturel when discussing clinical subjects; one 
would almost assume you are a general practitioner, disguised as a statistician. 
  
183 
A
P
P
E
N
D
IX
 V
I 
Thank you for your support and your willingness to travel to my hometown to 
jury my thesis. 
  
Professor Hobbs, dear Richard, thank you for hosting my visiting research 
fellowship in Oxford and I hope to continue our collaboration in the future. 
 
Matthew, I am grateful for your help and input throughout my PhD project. Your 
standing invitations to work with you in Oxford were greatly appreciated and 
kept me motivated while resulting in several collaborative publications. 
 
David, much obliged for your guidance and input from day 1 and in preparing 
this presentation. 
 
Richard, thank you for teaching me to think like a (bio)-statistician, always 
making sure the statistics are appropriate for the purpose of the analysis. 
 
Dear Beth, thank you for listening and helping me out at a crucial point in my 
analysis. Your input is greatly appreciated. 
 
Monica, it was an honour to work with you and I would very much like to 
continue our fruitful collaboration to further bridge the gap between GP- and 
hospital-based research. 
I would like to thank the other members of the European Network for 
Recognising Serious Infections (ERNIE) for their views and support. 
 
Roddy, thank you for your impressive work ethic collecting data on acutely ill 
children at Pinderfields hospital, registering all clinically relevant predictors. 
 
Sta me toe de andere leden van de jury te bedanken: Isabelle, dank voor uw 
begeleiding en om samen de MCH bijscholing te verzorgen, Lars, dank voor uw 
rondleiding op de pediatrisch intensieve zorgen, de enige manier om voeling te 
krijgen met ernstig zieke kinderen, Jean-Bernard, u heeft steeds tijd gemaakt 
voor mij; uw visie op urgentiegeneeskunde is inspirerend, Andre, dank voor uw 
input halverwege mijn PhD project in aansluiting op uw lezing in Leuven. 
 
Dominique, bedankt voor uw kritische blik vanaf dag 1 en uw hulp bij de 
zoektocht naar partners in de kindergeneeskunde in heel Vlaanderen. Chris, als 
diensthoofd heeft u steeds deze studie gesteund waarvoor ik u dankbaar ben. 
 
Marc en Luc, dank om uw collega’s te overtuigen en bij te dragen aan de 
datacollectie. Marie-Paule, Heidi, Alex, uw bijdrage aan de studie was van vitaal 
belang. 
Dank ook aan Frederick (voor de omwegen door het Vlaamse land), Greet en 
Annelien die Oost- en West-Vlaanderen doorkruisten voor de studie. 
 
Peter, sinds ons eerste telefoontje ontbrak het u, evenals de mensen van Alere, 
niet aan visie, waarvoor dank. 
 
    
 
184 
A
P
P
E
N
D
IX
 V
I 
Beste Mr. Thijs, beste Fons, ik wil u danken voor de selectie van dit project uit 
velen en de ondersteuning vanuit het RIZIV. Uw visie heeft geholpen dit project 
waar te maken, waarvoor we Dr. Ri De Ridder eveneens dankbaar zijn. 
 
Marina, dank voor uw steun doorheen dit project. Zonder u zou er zoveel meer 
mislopen dan we zelf durven toegeven. Dank ook aan Katrien voor het talloze 
rekenwerk en leuke babbels, Martine, Monique, Elizabeth voor uw steun op alle 
vlak.  
 
Alle collega’s van het ACHG die me deze kans geboden hebben, wens ik 
bijzonder te bedanken. 
 
Mijn collega’s op de praktijk, in het bijzonder Jo en Lucia, dank voor het 
vertrouwen en de bereidheid mij als halftijds HAIO aan te werven en mij te 
verwelkomen in de associatie. Ook mijn patiënten ben ik dankbaar voor het 
begrip tijdens mijn afwezigheid. 
 
Aan alle vrienden die voor de welkome afleidingen zorgden: niets zo 
ontspannend als een Ardennen-weekend met blauwe jello of een tuinfeest met 
plons in de moerasvijver om alles te relativeren: Gust, Michiel, Arnout, 
Pieterjan, Vincent, Marin, Serge, Tom, Kris, Julie, Anneke, Marjan, Lore, Lore, 
Annelies, Isabelle, An, Lien, Bart, Hendrik, Lieven: merci! 
Ook de jaargenoten voor hun oprechte interesse in mijn onderzoek en de 
winter-barbecues in Saint-Hubert: Evelien, Evelien, Alix, Lien, Katleen, Jasmien, 
Inneke, Christine, Lotte, Laura, Julie, Anne-Sophie, Klaar, en hun partners, en 
vooral aan Pol en Maarten om toch wat mannelijk tegengewicht te bieden in ons 
jaar. 
 
Lieve ouders, ik ben jullie dankbaar om ons op te voeden met een gezonde 
nieuwsgierigheid voor wetenschap en ons aan te moedigen om ons best te 
doen in wat we ook doen. Maar ik ben eigenlijk vooral dankbaar en trots op wie 
jullie zijn: hartelijk, liefdevol en fantastische (groot)ouders voor ons gezin. 
 
Ward, uw substantiële inbreng aan de cover en uitnodiging is niet te 
onderschatten, maar vooral bedankt voor uw ongezouten mening en eerlijkheid. 
Als recordhouder bezoekjes-in-London slaag je erin onze Jonas te verwennen 
en ons huis weg van huis te weren van heimwee. 
 
Els, of Elsje zoals Jonas zegt, jij weet maar al te goed wat een thesis met zich 
meebrengt en deze kan nu met een grote rode strik naast die van u in ons 
familiearchief. Bedankt voor uw energie om de afstand die vaak groot lijkt te 
overbruggen, met bezoekjes, Skype-sessies en uw twee schatten van kinderen. 
 
Dominique, mijn vrouw, dank u voor uw ongelooflijke geduld, zowel met mij 
tijdens dit project als met onze lieve zoon. Ik heb u beloofd deel 2 en 3 van 
onze trilogie samen te beleven. Nu sluit dit boekje: beschouw het als een 
proloog op deel 2 van ons leven.  
Jonas, het zonnetje in mijn leven, papa is nu klaar met zijn boekje, nu kunnen 
we weer verder lezen in jouw favoriete boekje “we’re going on a bear hunt”. 
Lieve schatten, ik hou van jullie! 
  
185 
A
P
P
E
N
D
IX
 V
I 
Deze thesis werd financieel ondersteund door het Rijksinstituut voor Ziekte- en 
Invaliditeitsverzekering (RIZIV, BE) onder referentie CGV 2012/235, het FWO 
onder referentie G067509N, het Health Technology Assessment Programme 
(HTA, UK) onder projectreferentie 07/37/05 en de National Institute for Health 
Research (NIHR, UK) onder referentie RP-PG-0407-10347. De meningen in 
deze publicatie zijn deze van de auteurs en niet noodzakelijk van de NHS, 
NIHR, FWO of RIZIV. 
 
Dank aan Mevr. Sabrina Requejo van IKEA Belgium voor de vingerpopjes 
tijdens onze veldstudie. 
 
Ik wil graag alle artsen bedanken voor hun deelname aan dit project en het 
includeren van acuut zieke kinderen: 
dr. Aagje Pareyn, dr. Agnes Coenegrachts, dr. Agnes Liebert, dr. Alain De 
Mûelenaere, dr. Alexander Baekelandt, dr. Alja Lammens, dr. An Ramon, dr. An 
Weerts, dr. An-Sophie Vandenbulcke, dr. Anaïs Vandendriessche, dr. Ann 
Heyneman, dr. Ann Mandervelt, dr. Anne Desot, dr. Anneleen Cloots, dr. 
Anneleen De Bonte, dr. Anneleen Notebaert, dr. Annelies Raes, dr. Annelies 
Van Raemdonck, dr. Annemie Janssens, dr. Annemie Wijnants, dr. Areski 
Boumendil, dr. Barbara De Wilde, dr. Bea Vanheule, dr. Ben Hören, dr. 
Benedicte Lambrechts, dr. Berthold Aman, dr. Carolin Van Rossem, dr. 
Caroline Buyck, dr. Caroline Elsing, dr. Caroline Vanwelden, dr. Christine 
Balcaen, dr. Claudia Golen, dr. Daan Witdouck, dr. Daisy Rymen, dr. Danielle 
Van Bruggen, dr. Deepanjali Custers, dr. Delphine Magniette, dr. Didier Baert, 
dr. Diederik Van Sassenbroeck, dr. Diëgo Schrans, dr. Dirk Anseeuw, dr. Dirk 
Hofkens, dr. Dirk Peeters, dr. Dirk Vermandere, dr. Eddy Van Hollebeke, dr. 
Elisabeth Rundfeldt, dr. Elke Janssens, dr. Elke Van Hoyweghen, dr. Ellen De 
Ceunynck, dr. Els Deroose, dr. Els Ide, dr. Els Pieters, dr. Emilie Beke, dr. 
Emmylou Nelen, dr. Eric Van Tilborg, dr. Erik Schreurs, dr. Erika Flo, dr. Eva 
Cosyn, dr. Eva Decat, dr. Eva ter Haar, dr. Evelien Byloos, dr. Evelien Lenaerts, 
dr. Filip Roelens, dr. Fleur Helewout, dr. Franky D'Argent, dr. Frans Baccarne, 
dr. Frédéric Van Tongel, dr. Frederik Huysentruyt, dr. Geert Potloot, dr. Geert 
Van Moer, dr. Geoffry Lemeure, dr. Gerda Ottenbourg, dr. Gerda 
Vanderhaegen, dr. Godelieve Vaes, dr. Goele Nys, dr. Goele Smeets, dr. Griet 
Callens, dr. Griet De Cock, dr. Hanh Nguyen, dr. Hannah Govaert, dr. Hanne 
Beinsberger, dr. Hanne Vanhee, dr. Hanneke Vandenberghe, dr. Hannes 
Blockeel, dr. Hans Bogaert, dr. Hans Van den Abbeele, dr. Heidi Schaballie, dr. 
Heleen Debrabandere, dr. Herman Depoortere, dr. Hilde Tack, dr. Hilde Van 
Marcke, dr. Hilde Van Watermeulen, dr. Hilde Vandamme, dr. Ines Somers, dr. 
Inez Renders, dr. Inge De Gussem, dr. Inge Lampens, dr. Inge Matthijs, dr. Inge 
Vanlommel, dr. Ingeborg Van Eynde, dr. Jacob Merckx, dr. Jan De Lepeleire, 
dr. Jan Joris, dr. Jannaert, dr. Janssen, dr. Jasmine Leus, dr. Jasper Naert, dr. 
Jean Pierre Hoengenaert, dr. Jelle De Graeuwe, dr. Jeroen Stubbe, dr. Jessie 
De Ridder, dr. Jessie Errico, dr. Jo Borremans, dr. Jo Lisaerde, dr. Joachim 
Depaepe, dr. Johan Bourdeaud'huy, dr. Johan Van Acoleyen, dr. Johan Vliers, 
dr. Johan Wuyts, dr. Jonnaert, dr. Jos Truyen, dr. Julie De Meulemeester, dr. 
Julie Lefevere, dr. Justin Gouhie, dr. Kaatje Van Aerschot, dr. Karen Bertheloot, 
dr. Karen Sinnesael, dr. Karen Van Massehove, dr. Karen Van Roy, dr. Karin 
Decaestecker, dr. Karl Deleu, dr. Karl Logghe, dr. Karolien De Ceulaer, dr. 
Kathleen Hunninck, dr. Katja Clohse, dr. Katrien Butaye, dr. Katrien De 
    
 
186 
A
P
P
E
N
D
IX
 V
I 
Schynkel, dr. Katrien Tilleman, dr. Katty Govers, dr. Kim Hermans, dr. Klaar 
Charlier, dr. Klaartje Antonissen, dr. Kris Van Haver, dr. Kristel Delanghe, dr. 
Kristel Van Tichelt, dr. Kristien Boel, dr. Kristien Kamoen, dr. Kristof Hillemans, 
dr. Laurent Mestdagh, dr. Leen Bouzen, dr. Leen Geyskens, dr. Leen 
Thienpont, dr. Lien Cruys, dr. Lien Lepère, dr. Lien Willems, dr. Lies De Sutter, 
dr. Lies Vanderperre, dr. Liesbet Vercammen, dr. Liesbeth Aeyels, dr. Liesbeth 
Christiaens, dr. Liesbeth Eggermont, dr. Liesbeth Schuermans, dr. Lieve 
Deruyter, dr. Linde Van Schelvergem, dr. Line Dalemans, dr. Lise Cornelis, dr. 
Lore De Greef, dr. Lore Vallaeys, dr. Lore Winters, dr. Lotte Maes, dr. Luc 
Debaere, dr. Luc Foucart, dr. Luc Pattyn, dr. Luc Seuntjens, dr. Lucas 
Ceulemans, dr. Lucia De Smet, dr. Lut Van Den Berghe, dr. Maes, dr. Maike 
Kuppens, dr. Marc Geeraert, dr. Marc Raes, dr. Maria Sophia Feytons, dr. 
Marie Coenen, dr. Marleen Devriese, dr. Marlien Buyssens, dr. Marlies Potoms, 
dr. Martien Humblet, dr. Martine Besouw, dr. Martine Debyser, dr. Meerschaut, 
dr. Michael Erkens, dr. Michel Creemers, dr. Michel Pôlet, dr. Mieke Bouvry, dr. 
Mieke Latruwe, dr. Mieke Martens, dr. Nele De Boer, dr. Nele Reynaert, dr. 
Nele Van Pee, dr. Nelly Aerts, dr. Nicky Huybrechts, dr. Nicola De Cono, dr. 
Norbert Van Mulders, dr. Olivia Vandeput, dr. Olivier Gernay, dr. Patrick 
Coursier, dr. Patrick Vanbelle, dr. Paul Lemay, dr. Peter Aerssens, dr. Peter De 
Sutter, dr. Philippe Alliet, dr. Philippe Gillis, dr. Piet Debackere, dr. Piet Van de 
Sype, dr. Piet Vanden Bussche, dr. Pieter Nevejan, dr. Pieter Op de Beeck, dr. 
Pieterjan Deraeve, dr. Quaegebeur, dr. Raaijmakers, dr. Rik Huybrechts, dr. 
Rita Stegen, dr. Rousseff, dr. Ruben Ryckeboer, dr. Sabine Fevery, dr. Sabine 
Van Baelen, dr. Sam Van Alphen, dr. Sanne Boonen, dr. Sandra Pollers, dr. 
Sara Lecoutere, dr. Sarah Haelewyn, dr. Sarah Maesen, dr. Saskia Wille, dr. 
Schamp, dr. Sofie Delameilleure, dr. Sofie Gadeyne, dr. Sophie Maes, dr. 
Staels, dr. Stefanie Matthé, dr. Stefanie Vermandere, dr. Stéphanie Biot, dr. 
Stephanie Bracke, dr. Stijn Allard, dr. Stijn Tiberghien, dr. Suzan De Wilde, dr. 
Swaegers, dr. Tania Claeys, dr. Thomas Eeckhout, dr. Tine Van Peer, dr. Tine 
Ysenbaert, dr. Tinneke Stals, dr. Tom Deputter, dr. Tom Lambrechts, dr. Tom 
Poelman, dr. Tom Seijnhaeve, dr. Valentin Degryse, dr. Van Hulle, dr. 
Vangheluwe, dr. Veerle Van Riet, dr. Vera De Vleesschauwer, dr. Wardenier, 
dr. Wendy Werckx, dr. Willem Van Nuffel, dr. Willieme, dr. Wouter De Rouck en 
dr. Wouter Van Mechelen, en hun collega’s. 
 
Last but not least, dank aan alle ouders en kinderen voor deelname aan de 
studie. Zonder uw goedkeuring, medewerking en prikjes in uw vinger was deze 
studie niet mogelijk geweest! 
SERIOUS INFECTION IN ACUTELY ILL CHILDREN 
IN PRIMARY CARE
Validating clinical prediction rules and the added value 
of vital signs and point-of-care tests.
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